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Chapter 1 
 
Treatment of Lone Atrial Fibrillation: A Look at the Past, a View of the 
Present and a Glance at the Future. 
 
Sandro Gelsomino, Mark La Meir, Fabiana Lucà, Laurent Pison, MD, Roberto Lorusso, 
Rocco Carella, Carlo Rostagno, Giuseppe Billè, Elena Crudeli, Luigi Padeletti, Gian 
Franco Gensini and Jos Maessen. 
Eur J Cardiothorac Surg. 2012 Jan 10. 
 
Abstract 
Background. Despite its proven efficacy, the Cox-Maze III procedure did 
not gain widespread acceptance for the treatment of lone atrial fibrillation 
(LAF) because of its complexity and technical difficulty. Surgical ablation 
for LAF can now be successfully performed utilizing minimally invasive 
techniques. This article provides an overview of the current state of the art 
in the surgical treatment of LAF.  
Methods. Papers selected for this review were identified on PUBMED 
using the search terms “lone atrial fibrillation” and “lone atrial fibrillation 
surgery”. All articles were reviewed and references were selected on the 
basis of historical contribution, number of patients and new contributions to 
the field.  
Results. The most widely employed minimally invasive approach to LAF 
has been the video-assisted bilateral mini-thoracotomy or thoracoscopic 
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pulmonary vein island creation and left atrial appendage removal or 
exclusion, usually with ganglionic plexi evaluation and destruction.  
Recently, a hybrid approach has been introduced, which combines a mono 
or bilateral epicardial approach with a percutaneous endocardial ablation in 
a single-step procedure to limit the shortcomings of both techniques. 
Conclusions. The ideal approach should be patient-tailored, employing a 
procedure which is adapted to the origin of the patient’s AF and takes into 
consideration triggers and substrate. This can only be achieved through a 
close collaboration between the surgeon and the electrophysiologist. 
 
Introduction 
Atrial fibrillation (AF) is the commonest sustained cardiac arrhythmias1 and 
it is associated with increased morbidity and mortality2.  AF is the cause of 
one-third of all hospitalizations associated with cardiac rhythm 
disturbances and it has been estimated that it affects more than 2.2 million 
people in the US, and that 4.5 million people in the European Union have 
paroxysmal or persistent AF3,4. AF is commonly associated with a number 
of cardiac and non-cardiac risk factors including ischemic heart disease, 
cardiac failure, valvular heart disease, hypertension, diabetes, alcohol 
abuse, thyroid disorders, and pulmonary disease5. It has been estimated that 
up to 80% of people presenting with AF have structural or organic heart 
disease6 and such cases have been referred to as “pathological AF”7. 
Nonetheless, in a not negligible percentage of people presenting with AF, 
there is no identifiable etiology and this subset of patients is often referred 
to as “lone AF” (LAF)8. 
This review focuses on the state-of-the art of the surgical treatment of LAF. 
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Review criteria 
Papers selected for this review were identified on PUBMED using the 
search terms “lone atrial fibrillation” and “lone atrial fibrillation surgery”. 
Up to March 2010, 516 published articles contained both “lone atrial 
fibrillation” and “surgery”; 
All articles were reviewed and references were selected on the basis of 
historical contribution, number of patients and new contributions to the 
field. 
 
A Brief History 
Atrial fibrillation was not known until 1874, when Edmé Félix Alfred 
Vulpian observed the irregular atrial electrical behavior that he termed 
"fremissement fibrillaire" in dog hearts9. In the mid-eighteenth century, 
Jean-Baptiste de Sénac took note of dilated, irritated atria in people with 
mitral stenosis10. The irregular pulse associated with AF was first recorded 
in 1876 by Carl Wilhelm Hermann Nothnagel and termed "delirium 
cordis", stating that in this form of arrhythmia “the heartbeats follow each 
other in complete irregularity… the height and tension of the individual 
pulse waves are continuously changing"11. Correlation of delirium cordis 
with the loss of atrial contraction as reflected in the loss of a wave in the 
jugular venous pulse was made by Sir James MacKenzie in190412. In 1906, 
Arthur Cushny and Charles Edmunds, pharmacologists at the University of 
Michigan, published an article on "paroxysmal irregularity of the heart and 
auricular fibrillation"13. They concluded that atrial fibrillation, known to 
develop acutely in dogs under certain (open-chest) experimental conditions, 
could occur in humans. 
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Willem Einthoven had first reported his invention of the electrocardiograph 
in 1902 but it was not until 1906 with the article "Le Télécardiogramme" 
that he demonstrated the clinical value of the technique14.This article 
included a tracing depicting what we now recognize as atrial fibrillation, 
which he termed "pulsus inaequalis et irregularis"15,16. 
The connection between the anatomical and electrical manifestations of AF 
and the irregular pulse of “delirium cordis” was made in 1909 by Carl 
Julius Rothberger, Heinrich Winterberg, and Sir Thomas Lewis17-19. 
The term “lone auricular fibrillation” was introduced by Evans and Swann 
in 195320. More recently, Kopecky21 reported ninety-seven patients aged 60 
years or younger at diagnosis, with lone atrial fibrillation defined as “atrial 
fibrillation in the absence of overt cardiovascular disease or precipitating 
illness” and concluded that it was associated with a very low risk of stroke. 
 
Definition of Lone Atrial Fibrillation 
Lone atrial fibrillation was initially defined in the era before modern 
echocardiography to identify a cohort of young patients with AF who had 
no clinical evidence of cardiovascular disease and were at low risk for 
thromboembolism20-22,23. Patients could have paroxysmal, persistent, or 
chronic AF21. With the availability of echocardiography, the definition now 
also includes no echocardiographic evidence of cardiac or pulmonary 
disease1,21. It is still unclear whether LAF and pathological AF are two 
distinct disorders requiring different approaches and management 
strategies. In recent years, it has even been hypothesized that LAF and 
pathological AF are different disease processes with contrasting risk 
predictors6. However, certain questions remain unanswered, including 
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patient age, other comorbid conditions, and the importance of mild 
echocardiographic abnormalities. 
Indeed, LAF has generally been applied to patients under 60 years of 
age1,21.  However, some studies have included those up to age 65 or even 
older who appear to be at increased thromboembolic risk compared to 
younger patients24,25. Furthermore, in some risk models of patients with AF, 
the presence of diabetes is considered a risk factor for 
thromboembolism1,26-29. By conventional definitions, such patients could 
still have LAF. 
Finally, there are no data concerning whether or how the presence of mild 
echocardiographic abnormalities (e.g., mild mitral regurgitation, left atrial 
enlargement, or increased left ventricular mass) alters the natural history of 
lone AF. 
Based upon these unresolved issues, the 2006 ACC/AHA/ESC guidelines 
concluded that there was no standard definition for lone AF1. The 
guidelines applied the term to  
“Young individuals younger than 60 years without clinical or 
echocardiographic evidence of cardiopulmonary disease, including 
hypertension”1,21 . 
However, although these patients have a favorable prognosis with respect 
to thromboembolism and mortality, over time they move out of the LAF 
category owing to aging or to the development of cardiac abnormalities, 
and their risks of thromboembolism and mortality rise1,2,30.  
By convention, the term “non-valvular AF” is restricted to cases in which 
the rhythm disturbance occurs in the absence of rheumatic mitral valve 
disease, a prosthetic heart valve, or mitral valve repair1. A recent 
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international consensus on nomenclature and classification of AF mentions 
that only AF in the absence of heart disease is termed ‘lone’ while in the 
absence of any disease is termed “idiopathic”31. 
Indeed, lone AF does not necessarily mean “idiopathic”. In addition, in 
recent years an increasing body of evidence has indicated several novel 
epidemiological and pathophysiological associations of AF32-34. It could 
therefore be hypothesized that many of the recorded lone or idiopathic AF 
cases are linked to other not well-known factors35.   
However,  the diagnosis of lone AF is essentially a diagnosis of exclusion, 
and should be preceded by careful evaluation, including thorough 
collection of the patient’s medical history, physical examination, blood 
pressure measurement, laboratory tests, ECG, echocardiography and, 
according to some experts, chest x-ray and exercise testing1. 
 
Incidence, Prevalence and Natural History 
The overall prevalence of AF is 0.4% to 1% in the general population36-38.  
Among that Group, LAF occurs in 1.6 to 11.4% of all cases of AF21,24,38. 
However, the ALFA study (Etude en Activité Libérale de la Fibrillation 
Auriculaire) report the proportion of lone AF among all cases of AF to be 
over 30%39. In other epidemiological studies lone AF was reported to occur 
in a percentage ranging between 1.9% and 32%40-42. 
Epidemiological data show a male predominance in patients with lone AF, 
since men constitute 78% of this patient population43. In a recent study, this 
sex difference was further investigated, showing that the proportion of 
males was greater among sporadic lone AF. Sporadic lone AF is also more 
common in men than in women44 .The natural history of lone AF has not 
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been well-studied. However, accumulated data suggest that it is associated 
with a low risk of progression to permanent AF, mortality, congestive heart 
failure, and stroke/transient ischemic attack43,45. 
The clinical course of lone AF also suggests that many of these patients 
have a paroxysmal form of the arrhythmia, with an estimated risk of 
progression to permanent AF of 29% over 30 years43. Patton and 
coworkers46confirmed the prevalence of a paroxysmal form of lone AF 
(94% of patients) with a lower progression rate (7.8%), but this was 
evaluated on the basis of a shorter follow-up period. 
The course of LAF may be influenced by several factors such as the left 
atrial volume. Indeed, Osranek and coworkers47 demonstrated that patients 
with LAF and increased left atrial volume at diagnosis or later during the 
follow-up experienced more adverse events, such as cerebral infarction, 
myocardial infarction and congestive heart failure. Furthermore, increasing 
age and the development of hypertension may increase the risk of 
cerebrovascular events43. Finally, approximately 44% of patients with an 
initial diagnosis of lone AF may represent occult cases of arterial 
hypertension. In these patients, hypertension may affect AF recurrence and 
treatment outcomes48. 
 
Pathophysiology 
The onset and the maintenance of LAF require an event (trigger) that 
initiates the arrhythmia and the presence of a predisposing substrate and 
genetic factors that perpetuate it. Additional factors may also cooperate as 
modulators in facilitating initiation or continuation of AF (Figure 1). 
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Substrate 
Several recent studies have focused on the underlying substrate in patients 
with LAF49. For instance, patients with lone AF have an abnormal atrial 
substrate and these abnormalities are essential contributors to the “second 
factor” that promotes progression of AF. Studies employing 
electrophysiological and electro-anatomic mapping gave new insights into 
the nature of abnormalities within the atria of patients with LAF: a) 
structural abnormalities characterized by atrial dilation and lower mean 
atrial voltage, suggesting the loss of atrial myocardium b) conduction 
abnormalities, characterized by prolongation of conduction times, longer P-
wave duration and slower conduction. c) Impaired sinus node function. d) 
Increase in effective refractory period consistent with prior studies 
evaluating clinical substrates for AF but in contrast to the remodeling 
attributed to AF itself. 
Furthermore, it has been demonstrated that left ventricular diastolic 
dysfunction relates to left atrial dilatation and stretch as well as to the 
development of AF50. In addition, a recent echocardiographic case-control 
study demonstrated that in patients with lone paroxysmal AF, LA area and 
volume were larger than in healthy volunteers, despite there being similar 
LV dimensions, ejection fraction, and diastolic function and regardless of 
the recurrence of the arrhythmia51. Thus, 2-dimensional echocardiography 
in the antero-posterior dimension underestimates the true LA size in 
patients with lone paroxysmal AF52. Even in the presence of normal LV 
systolic and diastolic functions, LA diameter, and LA systolic activity, the 
LA diastolic performance may be compromised in patients with lone AF, 
as evidenced by abnormalities of the systolic phase of pulmonary vein (PV) 
flow 53. Collectively, it appears that LV diastolic and LA abnormalities are 
19
 
  
prevalent in apparently lone AF but it is still unclear whether they represent 
a cause and/or consequence of the arrhythmia.  
Genetic Factors 
Evidence of a genetic contribution in the development of AF was first 
provided in 1943 by Wolff54 who documented transmission of lone AF in a 
family with an autosomal dominant pattern of inheritance. Since that time, 
large epidemiological studies have documented evidence of heritability in 
AF, in particular in the context of lone AF55-57. 
It is now evident that LAF may be caused by mutations of different genes 
controlling cardiac excitability such as the potassium channel genes 
KCNQ1, KCNE2, KCNJ2 KCNE5, KCNA5 and KCNH2 or the SCN5A 
sodium channel gene58-63. The final effect of ion channel mutations is 
reduced action potential duration. Consequently, carriers of genetic 
channelopathies have a short atrial refractory period that creates a 
vulnerable substrate for the development of AF. The mechanism translating 
cellular hyper excitability secondary to SCN5A gain-of-function mutations 
into the phenotype of AF potentially relates to enhanced automaticity of 
atrial cardiomyocytes. The resultant triggers, in the setting of an ideal 
substrate such as the pulmonary veins, may be sufficient to both induce and 
maintain AF. Subsequent screening of lone AF cohorts suggested that these 
channels were a rare cause of the arrhythmia64,65. However, the association 
between Brugada’s syndrome and AF supports the pathogenic rule of 
SCN5A66 
These findings implied that there were likely other classes of genes that 
played an important role in the development of the more common sporadic 
form of AF. Attractive candidate genes included connexins, trans-
membrane-spanning proteins that form gap junctions, which serve as 
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intercellular pores, providing low-resistance pathways for the passage of 
current between adjacent cells67. Of the 5 connexin isoforms expressed in 
the heart, connexin 40 (Cx40) seemed the most intriguing in the context of 
AF given its high level of expression within the atria and absence from 
ventricular myocardium68. Defects in connexin 40 are expected to lead to 
increased propensity to AF through an impaired electrical coupling 
between cells and decreased atrial conduction velocity. Another study69 has 
highlighted the role of age-related accumulation of mitochondrial DNA 
mutations. 
The most recent culprit gene identified (NPPA) encodes a circulating 
hormone, the atrial natriuretic peptide (ANP)70 . Before this work, ANP had 
generally been viewed as a cardio protective hormone with an important 
role in sodium balance and blood pressure regulation71. There was 
evidence, however, that ANP was capable of modulating the activity of 
various ion channels within the heart72,73. Although the potential role of 
ANP in directly modulating atrial electrophysiology and promoting an AF 
substrate is intriguing, other pro-arrhythmic actions of ANP are also 
conceivable, an example being inflammation that could stem from the 
important role of ANP in the regulation of the innate immune system74,75. 
Given that ANP is a known mediator of inflammation, long-term exposure 
to altered levels of ANP might induce structural changes related to 
inflammation that ultimately result in atrial fibrosis and subsequent 
development of an AF substrate. 
Other peptides that have been investigated are the serum B-natriuretic 
peptide (BNP), whose concentration in LAF is significantly higher than in 
age- and sex- matched healthy subjects76and the Apelin, an endogenous 
peptide hormone that appears to have a physiological role in counter-
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regulation of the angiotensin and vasopressin systems ,whose levels where 
significantly lower in patients with LAF compared with control subjects 
with sinus rhythm77.It has been demonstrated that activation of the renin-
angiotensin system (RAS) with increase in Angiotensin II levels promotes 
formation of collagen. Therefore, pharmacological inhibition of this system 
could represent a novel approach to counteract the development of fibrosis 
and recurrence of AF78. Finally, it has been suggested that a specific 
polymorphism of matrix metalloproteinase-2 gene is a risk factor for 
chronic LAF, while C allele of the interleukin-10 (IL-10) polymorphism 
represents a protective factor79 
Triggers 
There is general agreement that AF requires a trigger usually located in the 
pulmonary veins and left atrium80-84. Haissaguerre and colleagues85 
demonstrated that paroxysmal AF originates from ectopic beats in the 
pulmonary veins in 94% of cases. This likely relates to the anatomical 
transition from pulmonary vein endothelium to left atrial endocardium; at 
this juncture, two types of tissue with different electric properties are 
juxtaposed, and this may potentiate development of AF85,86. Catheter 
ablation of the posterior left atrium, including the antra surrounding the 
pulmonary veins, has proven effective at ablating both paroxysmal and 
permanent AF85,87,88. 
Other anatomical structures that may also provide ectopic beats causing 
LAF are the superior vena cava, the vein of Marshall, the musculature of 
coronary sinus and the posterior wall of the left atrium (LA). However, for 
LAF to become sustained the presence of an atrial substrate of sufficient 
mass capable of maintaining re-entrant circuits is necessary. The LA-PV 
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junction and the posterior wall of the LA are critical structures in this 
regard89. 
Finally, increasing evidence suggests that sustained AF is the result of a 
combination of PV vein focal discharge and PV-LA re-entrant activity90. 
Modulating Factors 
Currently, there is an intense research interest in the role of inflammation in 
the pathophysiology of AF91,92. Inflammatory indexes, mainly C-reactive 
protein (CRP) have been related to future AF development, AF recurrences 
after cardioversion, and to the persistence of the arrhythmia93. The role of 
inflammation in the pathogenesis of lone AF remains equivocal and 
limited. Indeed, only the study by Frustaci et al94. demonstrated abnormal 
atrial histology in most of the patients with paroxysmal lone AF refractory 
to conventional anti-arrhythmic therapy (inflammatory infiltrates in 66% of 
patients). 
Conversely, other investigators failed to show inflammatory changes in LA 
histological specimens from lone AF patients95. Furthermore, Ellinor et 
al.96 failed to demonstrate increased CRP levels in patients with lone AF 
compared to controls while the opposite was observed in patients with AF 
and hypertension. It has therefore been postulated that markers of 
inflammation are associated with the presence of other concomitant 
diseases94. Another case-control study showed elevated CRP levels in lone 
AF patients; however, subjects with hypertension had not been excluded97. 
An imbalance of autonomic nerve activity has been implicated in the 
initiation of AF98. 
Parasympathetic nerves (which slow heart rate) and sympathetic nerves 
(which increase heart rate) can both initiate AF, due to shortening of the 
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atrial effective refractory period and to changes in intracellular calcium 
cycling99,100. The pulmonary veins are a primary location for entry of vagal 
nerves into the left atrium101,102. Depending on the branches stimulated, 
vagal activity can cause slowing of heart rate, slowing of atrio-ventricular 
nodal conduction, or heterogeneous shortening of atrial action potentials; 
these effects result from activation of the potassium channels coupled to 
muscarinic (M2) receptors that are present at high density in atrial and 
nodal myocytes103. 
Results from experimental studies on isolated canine pulmonary vein 
preparations suggest that simultaneous sympathetic and parasympathetic 
(adrenergic and cholinergic) stimulation is most effective at promoting PV 
ectopy, by simultaneously stimulating calcium overload while abbreviating 
the effective refractory period.104. In addition, Armour and colleagues105 
were the first to document the presence of an intrinsic cardiac nervous 
system, consisting of bundles of neurons (ganglionic plexuses, GP) located 
in multiple atrial and ventricular locations104. They noted that activity of 
these GP neurons could modify cardiac activity. Ganglionic plexuses are 
embedded in fat pads on the epicardium of the heart. Stimulation of GP 
located at the PV–atrial junction has been reported to convert PV focal 
activity into AF106. 
On this basis, it has been suggested that selective elimination of ganglionic 
plexuses might attenuate the occurrence of AF. Other modulating factors107-
116 are shown in Figure 1. 
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Types of AF 
Following the recently updated guidelines five types of AF are 
distinguished117:  
1) First diagnosed AF, irrespective of the duration of the arrhythmia or the 
presence and severity of AF-related symptoms.2) Paroxysmal AF is self-
terminating, usually within 48 h. 
3) Persistent AF is present when an AF episode either lasts longer than 7 
days or requires termination by cardioversion, either with drugs or by direct 
current cardioversion (DCC). 
4) Long-standing persistent AF has lasted for ≥1 year when it is decided to 
adopt a rhythm control strategy. 5) Permanent AF is said to exist when the 
presence of the arrhythmia is accepted by the patient (and physician). 
 
Medical Treatment: An Overview and the Latest Updates 
Medical therapy for AF in restoring sinus rhythm showed poor results. 
Indeed, antiarrhythmic drugs have low therapeutic indices and limited 
long-term efficacy118and attainment and maintenance of sinus rhythm have 
been suboptimal in comparative studies such as AFFIRM119, HOT 
CAFÈ120,PIAF121,RACE122, STAF123 and AF-CHF124. 
According to current guidelines amiodarone, dronedarone, flecainide, 
propafenone and I-sotalol are recommended for rhythm control117.  
Vernakalant is a is a relatively atrial-selective antiarrhythmic agent125 
recently recommended for approval by the European Medicines Agency for 
rapid cardioversion of recent-onset AF to sinus rhythm in adults (≤7 days 
for non-surgical patients; ≤3 days for surgical patients)126,127. Atrial-
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selectivity of Vernakalant is achieved by targeting atrial specific channels: 
the Kv1.5 channel which carries K+ current (IKur) and the Kir3.1/3.4 
channel which carries muscarinic K+ current ( IKAch). Vernakalant can 
also work to block Ito, late Ina, with minor blockade of IKr currents 
A direct comparison with amiodarone in the AVRO trial128 showed that 
Vernakalant was more effective than amiodarone for the rapid conversion 
of AF to sinus rhythm 
In selected highly symptomatic patients with occasional recurrences of AF 
(i.e. between once per month and once per year), the ‘pill-in-the-pocket’ 
approach consisting in oral propafenone (450–600 mg) or flecainide (200–
300 mg) may be used.129. 
Rate reduction, allowing adequate time for ventricular filling and avoiding 
rate-related ischemia, may result in improved hemodynamics. However, the 
RACE II study shows that lenient-rate control < 110 bpm is not inferior to 
strict-rate control <80 bpm130. As lenient-rate control is generally more 
convenient, requiring fewer outpatient visits and examinations, it may be 
adopted as a reasonable strategy in patients with permanent AF. 
Drugs commonly used for rate control are b-blockers, non-dihydropyridine 
calcium channel antagonists, and digitalis. Amiodarone may be suitable for 
some patients with otherwise refractory rate control117. Dronedarone is 
similar to amiodarone but lacks an iodine moiety. Possessing both rate- and 
rhythm-control properties, Dronedarone has proved safe and effective in 
preventing recurrence of AF in patients with persistent AF in the DAFNE 
(Dronedarone Atrial Fibrillation Study After Electrical Cardioversion) trial, 
the first prospective randomized trial to evaluate its efficacy and safety131.. 
Nonetheless, the DIONYSOS study132 (Efficacy & Safety of Dronedarone 
Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With 
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Persistent Atrial Fibrillation) suggests higher tolerability but less efficacy 
for Dronedarone than for amiodarone. In the ATHENA trial133 
Dronedarone improved the composite endpoint of cardiovascular 
hospitalizations and all-cause mortality in a carefully selected, high-risk, 
nonpermanent AF population. The new ESC 2010 AF guidelines 
incorporate Dronedarone into the algorithm previously recommended for 
therapy to maintain sinus rhythm in patients with recurrent paroxysmal or 
persistent AF 117. 
Recommendations for antithrombotic therapy should be based on the 
presence (or absence) of risk factors for stroke and thrombo-embolism. 
Unless contraindicated, chronic oral anticoagulation therapy (OAC) is 
recommended in patients with a CHADS2 [cardiac failure, hypertension, 
age, diabetes, stroke (doubled)] score ≥2 to achieve an International 
Normalized Ratio (INR) value of 2.0-3.0. In patients with CHADS2 0-1  the  
CHA2DS2-VASc [congestive heart failure, hypertension, age ≥75 (doubled), 
diabetes, stroke (doubled), vascular disease, age 65–74, and sex category 
(female)]score is recommended and OAC therapy is suggested if the 
CHA2DS2-VASc score >2 117. 
Moreover, the new AF guidelines emphasize the importance of bleeding 
risk assessment before starting anticoagulation. In this case the HAS-BLE 
[Hypertension, Abnormal renal and liver function, stroke, bleeding, labile 
INRs, elderly] bleeding risk score is recommended. A score of ≥3 is 
considered indicative of ‘high-risk’ patients who require caution and 
regular review after starting antithrombotic therapy117. 
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Catheter Ablation, Present and Future: Ready for first-line 
therapy? 
Multiple approaches have been developed for catheter ablation, all aimed at 
eliminating mechanisms in the initiation and maintenance of AF. A 
complete isolation of the PVs and application of the lesion set proximal to 
the junction of the left atrium and tube-like portion of the PV are 
considered necessary by most techniques. 
The different approaches proposed for catheter ablation include : 
a) Segmental/ostial PV isolation; b) Circumferential PV ablation; c) 
Circumferential/antral PV isolation; d) Electrogram-based ablation or 
complex fractionated atrial electrograms (CFAEs) ablation; e) Linear 
lesions; f) Autonomic ganglionated plexi ablation; g) ablation of AF Nest; 
h) Sequential ablation strategy.  
Segmental PV isolation requires ablation inside the vein or very close to 
the output into the atrium85,134. It is accepted that ablation in the PVs needs 
to be avoided thus an extensive atrial ablation, often circumferential is 
carried out with a trans-septal circular mapping catheter placed at the ostia 
of the four PVs134 which creates a series of segmental lesions until isolation 
of the vein can be demonstrated. Circumferential PV ablation has been 
widely employed135,136.Over time the lesion set has been modified with 
wider circumferential lesions (1-2 cm outside PV ostia) by adding posterior 
lines connecting PVs and the mitral isthmus line and, finally, by abolishing 
the evoked vagal reflexes, in order to prevent recurrences of atrial 
tachycardia137,138. 
Circumferential PV isolation can be monitored by various tools, according 
to operator preference. Selective pulmonary venography is widely 
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employed to define the relevant anatomy. Intracardiac Echocardiography 
(ICE), computerized mapping and navigation techniques (Carto, NaviX, 
etc) help to define anatomy and catheter guidance. Registration with other 
techniques such as Magnetic Resonance (MR) or Computed Tomography 
(CT) facilitates a more accurate anatomical definition. However the critical 
goal of all these techniques is to ensure that the lesion is made outside the 
PVs139. Some investigators have extended the PV isolation concept to 
include ablation of the PV antrum140 which, combined with spectral 
mapping, has been demonstrated to improve AF success in patients with 
long-lasting persistent AF141. CFAE ablation, instead of ablating sites in the 
pulmonary veins, targets sites in specific areas of the atria where the 
electrograms break up (become fractionated)142.These ablation sites are 
determined on an individual patient basis, offering a customized and often 
reduced area of treatment. Linear lesions are generally deployed at the LA 
roof and /or at the mitral isthmus143,144. Their goal is to create a 
bidirectional block and they have been demonstrated to be associated with 
conversion of AF, further demonstrating that such lesions may at least in 
some patients deeply modify the substrate of AF145,146. Based on previous 
experience by Pappone et al 138 four major left atrial ganglionated plexi 
have recently been identified in patients with AF. Plexi may be localized at 
the time of ablation using high-frequency stimulation delivered by a 
mapping catheter in the LA. For ablation, RF current (20-35W) can be 
applied at each site of positive vagal response to high-frequency 
stimulation. Pachon et al147 have developed a system for real-time spectral 
mapping that identifies sites in which the unfiltered, bipolar electrograms 
contain unusually high frequencies, namely fibrillar myocardium or the so-
called AF Nest. The investigators have successfully targeted biatrial AF 
Nests, without intentional PV isolation, as a novel approach for AF. The 
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adjunct of AF Nest ablation has shown a favourable impact on long-term 
outcome following a single antral PV isolation141.Finally, a stepwise 
approach has been recently developed in patients with long-lasting 
persistent AF with different sequences that target multiple atrial areas148. 
New ablation technologies are currently under intense investigation. 
Balloon-based ablation systems have been developed to create circular 
lesions around PVs at atrial level. Furthermore, new software algorithms 
have been developed to support the various methods of image integration 
(from MR or CT) and to further improve the image registration process. 
Finally, real-time catheter-based imaging systems for on-line 3-D cardiac 
chamber reconstruction based on ICE technology are under investigation. 
The absence of new anti-arrhythmics with an improved benefit/risk profile 
as well as the results of several recently published clinical trials 
demonstrating superior outcomes with catheter ablation for AF relative to 
anti-arrhythmic drug therapy149-151 suggest that AF ablation may warrant 
consideration as first-line therapy in selected patients152. 
Indeed some authors153 believe that first-line should at least be considered 
for those patients with symptomatic AF, mild to moderate structural heart 
disease, and paroxysmal or persistent AF. Ablation might particularly 
benefit younger patients with lone AF who are frequently symptomatic and 
for whom very-long-term anti-arrhythmic and anticoagulation poses higher 
risks and lifestyle costs. Asymptomatic or minimally symptomatic AF 
patients may also benefit from ablation and sinus rhythm in the long term, 
but until further clinical data are available, it is difficult to justify an 
invasive procedure to a patient who may not be aware that they have a 
problem. 
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Nonetheless there is no full consensus154,155 about AF ablation as first-line 
therapy. Areas of concern are the variable short-term efficacy of catheter 
ablation, its unknown long-term efficacy, significant procedure-related 
complications and the significant variance of success among laboratories 
using similar technique of ablation156. 
  
Surgical Treatment 
Indications For Surgery 
Based on the Heart Rhythm Society/ European Heart Rhythm Association/ 
European Cardiac Arrhythmia Society (HRS/EHRA/ECA) expert 
consensus statement on catheter and surgical ablation of AF156 “Stand-
alone” AF surgery should be considered for symptomatic AF patients  
who prefer a surgical approach have failed one or more attempts at catheter 
ablation are not candidates for catheter ablation. 
The term “lone AF ” is commonly employed in the surgical literature to 
refer to “stand-alone surgery” for AF, as compared with AF surgery 
performed in conjunction with another type of cardiac surgical procedure 
such as mitral valve replacement.  
This differs distinctly from the use of the term “lone AF” in the 
electrophysiological literature which includes AF developing in a subset of 
young patients (e.g. aged < 60 years), with no evidence of associated 
cardiopulmonary or other co-morbid disease (including hypertension) and 
which has a favorable prognosis . From this approach ‘lone’ AF is still a 
diagnosis of exclusion but it should be made only after careful assessment 
including detailed medical history, physical examination, laboratory testing 
with thyroid status, electrocardiogram, echocardiography and, possibly, 
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chest X-ray and exercise testing157 Surgery ought to be preferred also in the 
following cases156.  
Patients who have developed a contraindication to warfarin and who will 
benefit from the elimination of the left atrial appendage at surgery which 
reduces the incidence of postoperative stroke158. 
Patients with a left atrial thrombus which represents a contraindication to 
catheter-based ablation. 
Patients with a large left atria >5 cm (Relative indication). 
The referral of patients for surgery with symptomatic, medically refractory 
AF in lieu of catheter ablation remains controversial. There have been no 
head-to-head comparisons of the outcomes of catheter and surgical ablation 
of AF. The decision-making in these instances needs to be based on each 
institution’s experience with catheter ablation and surgical ablation of AF, 
the relative outcomes and risks of each in the individual patient, and patient 
preference156. 
However, the development of simpler, more effective and less invasive 
procedures will undoubtedly expand the indication for surgery, and as 
stated by Damiano and Bayley: “…it is misguided to view surgery as 
competitive with catheter-based procedures. Surgeons need to work 
together with electrophysiologists to define the indication for surgery, 
refine our procedures, improve intraoperative electrophysiological testing, 
and develop consensus for reporting our results. In the long run, the success 
of catheter ablation will likely increase surgical referrals. When 
electrophysiologists convince the medical community that catheter ablation 
is appropriate therapy for medically refractory atrial fibrillation, it will also 
provide justification for a surgical approach”. 
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Surgical Procedures 
The Cox-Maze III Technique 
In 1987, Dr. James Cox pioneered an open-heart surgical procedure to cure 
atrial fibrillation159-161.  He developed, in collaboration with cardiologist 
John Boineau and physiologist Richard Schuessler, the concept of using 
scar tissue to direct the electrical impulse from the sinus node to the AV 
node. To improve the results and simplify the operation, they modified the 
procedure twice, culminating in the Cox-Maze III technique162.  
In the Cox Maze III, sometimes referred to as the "Traditional Maze", the 
"cut and sew Maze", or simply the "Maze", right and left atrial incisions are 
made to interrupt the multiple, disorganized re-entrant circuits that 
characterize AF. In addition, these lesions direct the sinus impulse from the 
sinoatrial node to the atrio-ventricular node along a specified route. 
Multiple “blind alleys” off this main conduction pathway (the Maze 
analogy) allow coordinated electric activation of the atrial myocardium. 
Key components of the Maze procedure include isolation of the pulmonary 
veins and excision of the left atrial appendage. These features are 
maintained in most of the newer operations designed to ablate AF. 
Table 1 summarizes results of “cut and sew Maze” in published studies 
including variable percentages of patients with lone atrial fibrillation163-172. 
The Maze procedure requires cardiopulmonary bypass and cardiac arrest 
and, also in experienced hands, it requires 45 to 60 minutes of 
cardiopulmonary bypass and cardiac arrest163,173,174. Thus, even with these 
modifications, the Maze III remained complex and this may explain why 
many surgeons worldwide are reluctant to perform this procedure.  
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Surgical Ablation Techniques 
On the basis of advances in understanding of the pathophysiology of AF, a 
variety of new ablation tools have been developed to facilitate surgical 
ablation of AF. These probes and catheters rely on alternate energy sources 
to create long, continuous, linear lesions that block conduction. An optimal 
ablation device for AF surgery would (1) reliably create conduction block 
(i.e., transmural lesions) on the beating heart from either the endocardial or 
epicardial surface; (2) exhibit a precise dose-response curve; (3) create 
lesions rapidly and safely; (4) have adequate flexibility and 
maneuverability; and (5) be adaptable to a minimally invasive approach175.  
These new technologies have supported efforts to develop more limited 
lesion sets that can be performed less invasively, often through small 
incisions or ports. The ultimate goal has been to perform a curative lesion 
set epicardially on the beating heart, without the need for cardiopulmonary 
bypass especially in patients with LAF. 
Energy Sources 
The goal of any energy source is to create a scar by exposing tissue to 
extremes of temperature, inducing thermal injury, coagulation necrosis, and 
healing. To produce such an irreversible injury, the tissue must be heated to 
50°C or frozen to -60°C176. 
The various energy sources differ mainly in the method by which they 
transfer energy to the tissue and how deeply that energy is conducted into 
the tissue. Heat based energy sources include radiofrequency, laser, 
microwave, and high-intensity focused ultrasound. Cold-based sources 
include argon and nitrous oxide gases 177. Table 2 shows the energy sources 
available for the clinical use with their advantages and disadvantages. 
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The various technologies can be organized in two major Groups: those that 
use a unipolar energy source and those that use a bipolar clamp. The 
unipolar energy sources (cryosurgery, unipolar radiofrequency energy, 
microwave, laser, ultrasound) all share a common weakness. These energy 
sources radiate either heat or cold from a single source. With the exception 
of high-frequency ultrasound, the energy is unfocused. Furthermore none 
of the devices give the surgeon an indication of when the ablation results in 
a transmural lesion. Because most were released clinically without accurate 
dose–response curves, this led to occasional collateral cardiac and extra 
cardiac damage with these devices178-184. Moreover, unipolar energy 
sources have had difficulty creating transmural lesions when used from the 
epicardial surface on the beating heart185.  
This is due to the heat-sink effect of the circulating intracardiac blood. 
Melby and coworkers186 have shown that lesion depth on the beating heart 
is dependent on cardiac output, with reliable transmural lesions occurring 
only at very low cardiac outputs (<1 L/min). High Frequency Ultrasound 
(HIFU) is the one unipolar source that results in a focused delivery of 
energy. Thus, it potentially has the ability to create transmural lesions on 
the beating heart. Indeed, HIFU directly heats the tissue in the acoustic 
focal volume, making it much less susceptible to the heat-sink of 
circulating intracardiac blood. Although HIFU is effective, it has a fixed 
depth of penetration, which may be problematic because of the anatomical 
variability in atrial wall thickness. Also, a recent study has reported that 
gradual heating of surrounding tissue due to conductive heating can cause 
phrenic nerve injury when located within 4 to 7 mm of the focused 
ablation187. Bipolar radiofrequency ablation has been able to overcome 
some of these shortcomings188-190 because energy is delivered between two 
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closely positioned electrodes and is confined within the jaws of the clamp, 
eliminating the possibility of collateral cardiac or extra cardiac damage. By 
measuring the tissue conductance between the two electrodes, algorithms 
have been developed that have accurately predicted lesion transmurality. 
This allows these devices to adapt the energy delivery to the physiological 
characteristics of the tissue being ablated. Finally, bipolar ablation has the 
advantage of shorter ablation times when compared with unipolar devices. 
The weakness of these devices is that they can only ablate tissue that can be 
clamped within the jaws of the device. This has limited the potential lesion 
sets, particularly on the beating heart. These devices have also been 
incapable of fully ablating the right and left atrial isthmuses and have 
required adjunctive unipolar ablation to perform a complete Cox maze 
lesion set. 
The Cox Maze IV Technique 
In 2002, a new iteration of the Cox maze procedure was introduced, termed 
the Cox maze IV procedure, which replaced most of the incisions with 
linear lines of bipolar radiofrequency ablation191. Initially, the procedure 
had only a single inferior connecting ablation line between the pulmonary 
veins in an attempt to better preserve left atrial function. However, a 
second connecting superior lesion was added several years later to 
anatomically isolate the entire posterior left atrium (termed the box lesion 
set) in an attempt to improve early and late results. 
The Group of Dr Damiano192 has recently published updated results on 282 
patients undergoing Cox-Maze IV procedure, adopting a more rigorous 
follow-up of the patients, with all patients having either 
electrocardiographic or 24-h Holter monitoring at 3,6 and 12 months. 
Freedom from AF recurrence was 89 % at 12 months and 1-year freedom 
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from AF and anti-arrhythmic drugs was 67%. This Group had previously 
carried out a propensity analysis of matched patients undergoing the Cox- 
Maze III versus Cox-Maze-IV171 which showed that there was no 
significant difference between these two procedures in terms of the rates of 
freedom from AF at 3, 6, and 12 months with the advantage of shortening 
operative times while maintaining the efficacy of the traditional cut-and-
sew Cox-Maze III.  
Table 1 shows the published study employing the Cox-Maze IV procedure 
and including patients with LAF171, 191-199. 
Nonetheless, the growth of surgery for lone LAF has not paralleled that for 
AF associated with other types of heart disease. The traditional sternotomy 
approach has not achieved widespread application, despite its efficacy. 
Instead catheter-based procedures are used more often for LAF. In fact, in 
2007, only 700 procedures for LAF were reported for that year in the 
Society for Thoracic Surgeons database200.  
Indeed, sternotomy and cardiopulmonary bypass are invasive procedures 
with substantial associated morbidity which most patients are willing to 
avoid for treatment of AF.  
Minimally Invasive Surgery 
Recently, Cox201 defined the characteristics of the ideal technique required 
for the development and wide adoption of a surgical procedure for the 
treatment of AF. He reported that this procedure should be minimally 
invasive (preferably thoracoscopic), epicardial and without 
cardiopulmonary bypass. 
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Indeed, video-assisted beating heart surgery has the advantage of direct 
visualization and access to the epicardial surface of the heart through 
limited 1-cm skin incisions.  
Furthermore, it is performed on the beating heart thus avoiding 
extracorporeal circulation. In addition, this approach enables the surgeon to 
position the ablation device accurately around or on the structure he wishes 
to isolate in a very quick and precise way. Finally the large epicardial space 
makes the use of longer and bigger ablation catheters possible and, as a 
consequence, the lesions are easily made into lines thus reducing the risk of 
discontinuity compared to the point-like ablation achieved through an 
endocardial approach. 
Over the last decades a plethora of new ablation technologies and 
thoracoscopic and video-assisted thoracic surgical approaches have been 
introduced. 
The advent of reliable single lung ventilation under general anesthesia has 
afforded the surgeon easy access to either hemi-thorax for a variety of 
procedures. Furthermore, bilateral approaches during a single session are 
relatively easy to perform, enabling precise device placement, direct and 
immediate visual feedback for lesion creation, and straightforward 
management of the left atrial appendage. 
Nonetheless, thoracoscopic instruments are still somewhat primitive and 
generally may be characterized as having somewhat limited 
maneuverability. They also require specific skills and expertise. Finally, the 
vision provided on the operating room monitors is flat and two-
dimensional, lacking depth perception and visibility behind the heart, and 
in the transverse and oblique sinuses, is severely limited.  
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Recent developments in robotic technology have largely overcome these 
limitations. The robot allows the operator to see the field in three 
dimensions and the “wrist” of the operating instrument permits many more 
degrees of freedom. Unfortunately, there is considerable expense incurred 
with the use of the robot and considerable time spent in the setup of the 
operative field. Therefore almost all purely robotic procedures have been 
performed from the right side of the chest only, leaving considerable risk 
for incorrect positioning of ablative instruments and limiting the options for 
management of the left atrial appendage.  
Designed to overcome the limitations of the purely thoracoscopic and 
robotic approaches, video-assisted (“VATS”) methods have been gaining in 
popularity. VATS aims to reduce the size of the intercostal incision(s) yet 
maintain visibility through the use of a port-accessed camera. Although the 
visibility is excellent with this approach, it does require essentially “two 
operations” as each hemithorax is accessed separately.  
However, the choice between a thoracoscopic, VATS or a thoracotomic 
approach depends on the surgeon’s skills and preferences.  
The decision to opt for a single-side or a bilateral approach depends on the 
ablation device available. A single-sided approach is less traumatic but 
only monopolar devices will be used and, due to the properties of these 
devices on the beating heart, only a significant delay can be obtained and 
not a bi-directional conduction block. In contrast, bipolar radiofrequency 
clamps can guarantee transmural and continuous lesions but require a 
bilateral approach which makes the procedures more invasive and increases 
the possible complication rates (bleeding, phrenic nerve lesion, pulmonary 
complications). 
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The available incomplete literature makes it very difficult to decide 
whether one approach should be preferred considering the potential of a 
lower complication rate for the monolateral approach but probably a higher 
success rate in the long-term due to the completeness of the lines with a 
bilateral approach using bipolar clamps. 
Bilateral Thoracoscopic Approach  
The most widely employed minimally invasive approach to LAF has been 
the video-assisted bilateral mini-thoracotomy or thoracoscopic pulmonary 
vein island creation and left atrial appendage removal or exclusion, usually 
with ganglionic plexus evaluation and destruction. Most surgeons prefer 
this approach to avoid the difficult passage of the ablation device around 
the PVs (through the transverse and the oblique sinus) when performing a 
monolateral thoracoscopic approach.  
The percentage of success with this technique ranged from 42% to 91% in 
published papers (excluding case reports) at follow-up ranging from 6 and 
40 months (Table 3)202-220. 
Right-sided Thoracoscopic Approach 
A right sided port approach with two or three ports has been described by 
several authors221-226. Initially, microwave technology was employed 
followed by laser and unipolar suction-assisted radiofrequency. 
Unfortunately, significant published assessments are lacking and the only 
substantial reports available are for microwave technology.  
Recently Klinkenberg and coworkers226 published their experience with 15 
patients who underwent minimally invasive epicardial off pump 
monolateral right-sided video assisted thoracic surgery employing HIFU 
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energy. These authors reported very poor results with 27% of patients in 
sinus rhythm after 1.3 ± 0.6 years and 73% requiring a re-ablation.  
In contrast, in other reports221-225, the percentage of success ranged from 
60% to 100%. 
This approach is promising, although a limitation potentially includes the 
inability to remove the left atrial appendage. For this reason, Balkhy and 
coworkers223 combined the right thoracoscopic MW ablation with the 
incorporation of a new device for left atrial appendage exclusion (Surg-
ASSIST computer-mediated thoracoscopic stapling system [Power Medical 
Intervention, New Hope, PA, USA]).  
Right-sided Thoracotomic Approach 
A full maze lesion set using a right thoracotomy and a beating heart on 
cardiopulmonary bypass has been performed clinically with 
cryothermia227,228. More recently Lee and coworkers229 published their 
results in 22 consecutive LAF patients undergoing RF ablation through a 
right side thoracotomic approach. If these results are confirmed this 
approach has an important role to play in the treatment of LAF. 
Left-sided Thoracoscopic Approach 
Grandmougin and Tiffet230 presented a case of a 68-year old female with 
permanent LAF who, due to consequences resulting from chemotherapy 
and oral anticoagulation (anemia and hemithorax) and the poor health 
status of the patient underwent video-assisted thoracoscopic drainage 
associated with successful epicardial radiofrequency isolation of the 
pulmonary veins (stable SR at 3-month follow-up). On the basis of this 
experience, the authors raised the question of whether to perform ablation 
of both right and left PVs in the same operation rather than delaying an 
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additional ablation of the controlateral side according to rhythmologic 
results. 
Exclusion/Excision of the Left Atrial Appendage 
It is widely believed that formation and embolism of left atrial appendage 
thrombi are responsible for the increased risk of stroke in AF patients231.  
Excision or exclusion of the left atrial appendage is currently performed 
during surgical ablation of AF and is recommended in ACC/AHA 
Guidelines for patients undergoing mitral valve surgery1. 
Patients undergoing Cox-Maze procedure had an extraordinarily low 
incidence of late stroke. In a series of almost 200 consecutive patients with 
a mean follow-up of more than 5 years, there was only one incident of 
stroke during follow-up. Most patients were off all anticoagulation168 . This 
high success rate has been attributed to not only eliminating atrial 
fibrillation but also to the fact that the left atrial appendage is excised 
during this procedure. 
Recently, there has been great interest in development and assessment of 
endocardial and epicardial procedures for exclusion of the left atrial 
appendage232. Many of these approaches now use a stapler to exclude the 
appendage or, in some instances, endocardial suture exclusion. 
Nonetheless, Kanderian et al, demonstrated, at  transesophageal 
echocardiography (TEE) that only 55 of 137 (40%) of closures were 
successful and that LAA closure occurred more often with excision (73%) 
than suture exclusion (23%) and stapler exclusion (0%) (p > 0.001)233. 
In the available literature the ligation/exclusion of LAA was performed in 
618 (83.6%) patients undergoing minimally invasive surgical ablation for 
lone atrial fibrillation.. The occurrence of perioperative cerebrovascular 
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accident was low (0.32%)213,216 and comparable with the Cox Maze 
procedure (0.5%)168. Alike, the occurrence of cerebrovascular accident 
during the follow up was low (0.64%) and this figure compares favorably 
with occurrence rates reported after the Cox-Maze operation163,165168. 
However, notably, the percentage of patients with anticoagulant therapy 
was much lower in Cox Maze (16.3% ) compared to minimally invasive 
LAF patients (n=214, 31.4%). 
Excision of the left atrial appendage may be difficult during minimally 
invasive surgery and there has been growing concern regarding the safety 
of this maneuver. This has led to the development of new surgical tools 
making this potentially dangerous maneuver easier234-236. However, from 
our review the procedure resulted to be safe. Indeed, among LAF patients 
undergoing minimally invasive surgical ablation and LAA 
ligation/excision, we found only a case (0.16%) of serious complication 
related to tearing of the base of the LAA211. 
However, all these figures were not the result of  a meta-analysis of 
quantitative studies . Furthermore, the small number of patients undergoing 
minimally invasive surgery without a concomitant LAA procedure, do not 
allow us to draw any conclusion. Consequently, data must be evaluated in 
the light of these limitations and  further large prospective studies are 
necessary to determine whether patients who undergo LAA closure really 
demonstrate a reduction in thrombo-embolic events and whether 
anticoagulation in these patients has to be discontinued232. 
The Hybrid Approach 
The rationale of the Hybrid approach, which combines a mono or bilateral 
epicardial approach with a percutaneous endocardial ablation in a single-
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step procedure, is to limit the shortcomings of both techniques and, at the 
same time, to combine their advantages.  
A worldwide survey on the methods, efficacy and safety of catheter 
ablation in AF was published in 2005237 and updated in 2010238. It showed 
that the success rate without anti-arrhythmic drugs was 75% for 
paroxysmal AF, 65% for persistent and 63% for permanent AF. However, 
along with the disadvantage of a low success rate in patients with persistent 
and permanent AF, with this procedure there is the advantage of evaluating 
the end points of the ablation. It also allows surgeons to perform ablations 
in regions which can only be reached endocardially. On the other hand, the 
epicardial approach alone failed to guarantee satisfactory long-term results 
(Table 3). 
For this reason the hybrid approach has been introduced, with the surgeon 
performing a monolateral or bilateral thoracoscopy (depending on the 
ablation devices chosen and the lesion set he/she wants to create). 
Considering the different possible etiologies in paroxysmal, persistent and 
long-lasting persistent AF, the procedure can be tailored to the patient’s 
needs combining efficient epicardial lines with measured 
electrophysiological endpoints. The surgeon will for every patient at least 
isolate the pulmonary veins. If this is insufficient to treat the AF he/she has 
the possibility to make a roof line (connecting left and right superior 
pulmonary veins) and inferior line (connecting inferior left and right 
pulmonary veins). In addition he/she can create a left isthmus line which 
extends from left inferior pulmonary vein to the mitral annulus. On the 
right atrium he/she can isolate the superior vena cava and create a bicaval 
line. If necessary the risk for thrombo-embolic events can be reduced by 
excluding the left atrial appendage; this will also have an impact on the 
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substrate. After checking for possible incomplete transmurality of the 
epicardial lines endocardially, the electrophysiologist can complete any line 
by focused endocardial applications. Thus in case of an incomplete 
isolation of one of the pulmonary veins, or any other line, an endocardial 
ablation is added. Furthermore, lines that cannot be made epicardially are 
carried out endocardially such as right and left isthmus line.  
We previously published the experience of our Group (Department of 
Cardiac Surgery, Academic Hospital, Maastricht, The Netherlands and 
UCL Mont-Godinne, Belgium) with a hybrid procedure performing  a 
right-sided thoracoscopic box-lesion obtained with a monopolar 
radiofrequency catheter (Cobra Adhere XL, Estech, San Ramon, CA) and 
an associated endocardial radiofrequency239. We have recently reviewed 
data which were collected following Guidelines for reporting data and 
outcomes for the surgical treatment of atrial fibrillation240. 
Nineteen patients with paroxysmal (n=2), persistent (n= 7) or long-standing 
persistent (n=10) LAF underwent hybrid right-sided thoracoscopic 
procedure. Preoperative AF prevalence was 38.7% (paroxysmal 20%, 
persistent 34.7%, long standing persistent 63.6%). Postoperative 
electrocardiograms (ECG) were used to assess AF. Recommended ECG 
follow-up intervals were 1, 3, 6 months, 1 year and annually thereafter. We 
performed the analysis of the intermittent data available in terms of time-
related prevalence (burden) of AF, use of anti-arrhythmic drugs and use of 
Warfarin with ordinary or non-longitudinal (mixed) models that account for 
all repeated measurements. Fifty-six-week postoperative prevalence of AF 
was 13.3 % (68% Confidence Limits [CL] 11.0-17.4). It was 21.1% (17.6-
24.9) in long standing persistent (p<0.001 vs. preoperative value) and 0 % 
in persistent and paroxysmal (p<0.001).At 56 months prevalence of anti-
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arrhythmic drugs and Warfarin use were 26% ( CL 17.4-33.1) and 48% 
[68% CI 37.2-53.2%], respectively (Unpublished results).  
The comparison of these results with those of patients who had first 
epicardial procedure with a subsequent endocardial procedure241(using both 
microwave ablation [Flex 10, Boston Guidant, Santa Clara, CA] and 
radiofrequency ablation [Cobra Adhere XL, Estech, San Ramon, CA]) with 
results of the hybrid procedure employing the bipolar radiofrequency 
clamp242 (Atricure INC, West Chester, OH) in combination with a 
radiofrequency linear pen (Atricure INC) and the Coolrail system (Atricure 
INC) to create additional lesion lines, will be the subject of ongoing 
studies. 
In our policy, patients are referred for hybrid procedure in case of persistent 
or long-standing persistent AF with LA dilatation ( > 45mm) or after one or 
more failed catheter ablations. We don’t perform a MRI to make the 
decision. The indication is based on the history of AF and the LA size. A 
transthoracic echocardiography and a CT scan are carried out 
preoperatively (pulmonary vein anatomy, coronary artery) and potential 
candidates to a hybrid procedure undergo lung function test. The preferred 
approach is bilateral whereas the monolateral approach is chosen for 
patients with significant chronic obstructive pulmonary disease. 
To evaluate bidirectional block, we pace endocardially from both sides of 
the line and we assess the presence of double potentials on the line. We 
perform “endocardial touch” whenever linear lesions are not complete or 
when they cannot be completed from the epicardial side. We follow a 
stepwise approach (Figure 2) 243. 
If the patient had a previous catheter ablation we first do the surgical 
dissection thoracoscopically without ablating, in order to avoid surgical 
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trauma while the patient is heparinised. After the surgical dissection, the EP 
carries out a trans-septal puncture, the patient is heparinised, the isolation 
of the PVs is checked as well as any additional previous ablation line. The 
hybrid approach is then tailored to the EP findings. 
Figure 3 A-D depicts some endpoints reached at the end of the hybrid 
procedure. 
Previous cardiac surgery, in our opinion, is not an absolute contraindication 
for the hybrid procedure .The advantage of the hybrid approach is that a 
possible incomplete epicardial line in these patients because of difficult 
access due to adhesions can be mapped and completed endocardially. 
CFAEs mapping and ablation are greatly facilitated by endocardial 
mapping, nonetheless, until recently, the CFAEs had not been specifically 
targeted. Preliminary data of our ongoing study mapping the CFAEs before 
and after the epicardial ablation, show that only the CFAEs at the septum 
and at the base of the LAA remain and have to be ablated endocardially.  
In conclusion, combined epicardial surgical and percutaneous endocardial 
approaches aim to solve some of the problems related to each of the 
procedures independently. 
It presents some advantages: 1) There is no risk of tamponade during the 
trans-septal puncture since the pericardium is open. 2) The surgeon can 
protect the phrenic nerves and the esophagus and the effective surgical 
ablation reduces the fluoroscopy time. 3) Since the surgical ablation device 
is located on the antrum of the left atrium and left as a radiopaque marker, 
it is almost impossible to create stenosis of the pulmonary veins. 4) Most of 
the ablation lines are made epicardially, therefore the number of 
endocardial application ablation lines employed is small with consequent 
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reduction in the occurrence of embolic events which may complicate the 
endocardial ablation. 
Potential disadvantages are: 1) The procedure is time consuming and 
significantly longer than surgery-alone techniques: 2) The heparinization of 
the patient after the septal puncture might cause bleeding of surgically 
dissected areas. 
 
A Glance at the Future 
The treatment of LAF continues to progress and the future of surgery will 
focus on two areas: better understanding of the mechanism of LAF and 
developing techniques that are progressively less invasive. 
In understanding the mechanism of AF , more studies are now more 
focused on the autonomic ganglia which are located around the pulmonary 
veins , so they might be the true triggers and have a major role in the 
maintenance of AF244, and it is still disputed whether autonomic ganglia 
could reconnect or regrow245.However, the role of ganglia and their 
destruction during minimally invasive surgery remains an area of active 
research216,246-248. 
Ideally, the mechanism of AF should be defined before planning surgery 
but, unfortunately, the mapping systems available for non-invasive 
endocardial mapping have poor resolution and, although EPs have been 
able to map high-frequency activation in PVs as well as CFEAs, some 
patients require more sophisticated waveform. Epicardial activation 
sequence mapping has been the gold standard for this159 but, unfortunately 
it is invasive and time-consuming. For this reason some Groups have 
developed frequency mapping249,250 which identifies the fastest activating 
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regions during FA. It requires very little subjective analysis and can be 
done in real time. 
Furthermore, in, the area of noninvasive method to accurately diagnose AF 
patients electrocardiogram imaging (ECGI) is promising251-253. An inverse 
solution can be calculated by using anatomical information obtained by CT 
scan made at the time of the recording. Electrograms can be reconstructed 
on the atrial epicardial surface.  
The search for the ideal ablation technology able to create trans-mural 
linear lesions on the beating heart through a mini-invasive approach to 
minimize operative trauma is still ongoing. 
Although no publication has described them yet, other less invasive 
techniques are under evaluation, such as the subxiphoid approach. 
 
Conclusions 
Future success in the treatment of LAF will probably rely on a combination 
of available therapies (medical, catheter and surgical) because some of the 
maze lesions, e.g. the lesion of the mitral annulus, are very difficult to 
create on a closed beating heart. However, the ideal approach should be 
patient-tailored, employing a procedure which is adapted to the origin of 
the patient’s AF and takes into consideration triggers and substrate. This 
can only be achieved through a close collaboration between the surgeon 
and the electrophysiologist, knowing that the surgeon probably has the best 
tools to ablate, whereas the electrophysiologist has a better knowledge of 
this pathology and possesses the tools to measure the effectiveness of the 
performed ablation. 
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Aim and outline of this thesis 
 
In this thesis a new and innovative minimal invasive treatment of lone atrial 
fibrillation (LAF) has been studied. The desire to improve the outcome (increase 
of success rate and reduction of complication rate) of percutaneous endocardial 
ablation procedures and the necessity to minimize the invasiveness of existing 
surgical approaches has directed us towards the design of a single-step 
combined percutaneous endocardial procedure with a thoracoscopic epicardial 
procedure on the beating heart. A team of  electrophysiologists and 
cardiothoracic surgeons working simultaneously in a dedicated environment 
developed the so-called hybrid AF procedure. This dual endocardial / epicardial 
procedure was studied in different types of AF with a monolateral or bilateral 
thoracoscopic procedure. The results of this hybrid approach can guide us to 
determine if there is an add-on value of an epicardial access in the treatment of 
LAF and if so, which minimal invasive surgical technique is able to give us a 
three-dimensional knowledge and a three-dimensional treatment of AF. As a 
result we expect to obtain a higher single procedure long-term success rate with 
an acceptable low complication rate. 
 
In chapter one, a general introduction, we summarize the history of AF, the 
types and pathophysiology of AF, and past, current and possible future treatment 
options in patients with LAF. Building upon this knowledge, chapter two is an 
51
updated review of current state-of-the-art minimally invasive surgery for the 
treatment of LAF. 
In chapter 3 we present our results of a minimally invasive surgical treatment of 
lone atrial fibrillation employing a radiofrequency source through a bilateral 
thoracoscopy. This clinical experience was the basis of  our quest towards better 
understanding of the three-dimensional structure of AF and to try to improve the 
treatment modalities for LAF. 
In chapter 4 we describe a simplified hybrid technique to treat patients in lone 
atrial fibrillation with a combined percutaneous endocardial approach with a 
monolateral right thoracoscopic approach. An electrical isolation of the four 
pulmonary veins (box lesion) was aimed for with a monopolar radiofrequency 
catheter. This approach yielded unsatisfactory results after 1 year in patients 
with persistent and long-standing persistent AF, but with a high degree of safety. 
This experience prepared the field for a hybrid procedure using bipolar 
epicardial ablation devices with a bilateral thoracoscopy which is described in 
chapter 5. The results of this hybrid bilateral thoracoscopic approach are 
compared to the results of a hybrid right thoracoscopic approach in chapter 6. 
The hybrid bilateral approach using bipolar devices showed a good 1-year 
success rate independently of the AF type and seems to be the better choice for 
long-standing persistent and persistent LAF. 
52
 In an effort to further increase our understanding of the potential of the hybrid 
approach we compare the standard non-hybrid bilateral thoracoscopic approach 
with this new bilateral hybrid procedure in chapter 7. 
In chapter 8 we demonstrate the beneficial effect of minimally invasive 
radiofrequency surgical ablation on left atrial reverse remodeling and 
improvement of LA compliance and function employing two-dimensional 
speckle-tracking echocardiography 2D-STE. 
Finally, in chapter 9 the findings of this thesis are brought into perspective 
comparing the hybrid AF procedure to current general practice. The possible 
future implications are considered and discussed. 
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Figure  Legends 
 
 
 
Figure 1. Pathophysiology of Lone Atrial Fibrillation (see text).  Abbreviations: RAS: Renin-
angiotensin system; ANP: Atrial natriuretic peptide;LA: Left Atrial; BNP: Brain natriuretic 
peptide; ERP: Effective refractory period; PVS: Pulmonary Veins; SAS: Sleep Apnea 
Syndrome; PVS: Pulmonary Veins; CS: Coronary Sinus. 
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Figure 2 The steps of the hybrid approach.  Abbreviations: AF: Atrial Fibrillation; SR: 
Sinus Rhythm; PVI: Pulmonary Vein Isolation; CAFE: Complex Atrial Fractionated 
Electrograms; AT: Atrial tachycardia; Afl: Atrial Flutter; RA: Right Atrium; SVC: 
Superior Vena Cava. 
 
 
58
 
  
 
 
Figure 3. A. Conversion of atrial flutter to sinus rhythm: it is a typical counterclockwise 
flutter during hybrid AF ablation. During endocardial ablation of the posterior isthmus 
there is conversion to sinus rhythm. This was also the endpoint of the procedure. B. 
Closure of the box lesion: after the isolation of the PVs and making the roof and inferior 
line there was still a gap were the roofline meets the line around the left PVs. Indeed the 
clamp was too short to isolate the left PVs. The figure shows very late pulmonary vein 
potentials on Lasso 7-8 and 8-9 (410 milliseconds after pacing artifact in the coronary 
sinus). In the following beat those signals are disappeared due to complete isolation of 
the box and left pulmonary veins. C. Conversion of atrial tachycardia to sinus rhythm: 
59
 
  
during hybrid procedure, AF organized to atrial tachycardia. By endocardial ablation at 
the base of the right atrial appendage, we had conversion to sinus rhythm. This was the 
endpoint of the procedure. D. Endocardial exit block from the box: the figure shows 
pacing and local capture in the box (signals on Lasso 6-7 and 7-8, the Lasso catheter is 
within the box in this case!) and lack of conduction to the LA during sinus rhythm. 
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Abstract 
Background. Despite its proven efficacy, the Cox-Maze III procedure did not gain 
widespread acceptance for the treatment of stand-alone atrial fibrillation (SA-AF) 
because of its complexity and technical difficulty. Surgical ablation for SA-AF can 
now be successfully performed utilizing minimally invasive surgery (MIS). This 
article provides an overview of state-of-the-art minimally invasive surgery for the 
treatment of SA-AF. 
Methods. Papers selected for this review were identified on PUBMED and exclusion 
and inclusion criteria were applied to select the publication to be screened. Twenty 
eight studies were included; 27 (96.4%) were observational in nature whereas one
 
was prospective non-randomized. The total number of patients was 1,051 (range 14 
to 114). Mean age ranged from 45.3 to 67.1 years.  
Results. Suboptimal results were obtained when employing microwave and high 
focused ultrasound energies. In contrast, MIS ablation of SA-AF achieved 
satisfactory one-year results when the bipolar radiofrequency was employed as 
energy source, with anti-arrhythmic drugs (AAD)-free success rates comparable to 
percutaneous catheter ablation (PCA). The success rate in paroxysmal was even 
higher than in PCA. In contrast, ganglionated plexi (GP) ablation and LAA removal 
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seem not to influence the recurrence of AF and the occurrence of postoperative 
thrombo-embolic events.  
Conclusions.  MIS ablation of SA-AF achieved satisfactory one-year results when 
bipolar radiofrequency was employed. Nonetheless, the relatively high complication 
rate reported suggest that such techniques require further refinement .Finally, the 
preliminary results of the hybrid approach are promising but they need to be 
confirmed. 
 
Introduction 
Over the last 20 years, surgeons and electrophysiologists (EPs) have been making 
progress toward finding a cure for AF that offers patients an acceptable risk/benefit 
profile. 
The Cox maze III procedure has been shown to be an effective, but an invasive and 
complex procedure and, for this reason, it has not been widely accepted as a stand-
alone therapy
1,2
. 
Trans-venous pulmonary vein isolation (PVI) has become the cornerstone of catheter 
ablation for AF and is currently the therapy of first choice if patients warrant rhythm 
control and failed anti-arrhythmic drugs (AADs)
3,4 
. PVI is reported to be effective in 
60–85% of the patients, especially in patients with paroxysmal short lasting episodes 
of AF
3-5
. Nonetheless, in about one-third of patients, a second ablation procedure is 
necessary and complications may occur in up to 6% of patients
6,7
. 
The surgical treatment of atrial fibrillation has undergone dramatic changes over the 
last decade. New technologies have allowed the creation of transmural lesions on a 
beating heart through alternative, less-invasive incisions
8
. The introduction of these 
technologies has greatly simplified the performance of the Maze procedure and 
allowed for the development of minimally invasive surgery (MIS)
8
. Minimally 
invasive video-assisted techniques allow pulmonary vein island creation and left 
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atrial appendage removal or exclusion, usually with ganglionic plexi evaluation and 
destruction
9
. 
Nonetheless, it is still uncertain whether these procedures are effective in restoring 
permanent sinus rhythm
10
. We present a systematic literature overview of MIS for the 
treatment of stand- alone atrial fibrillation (SA-AF) and briefly discuss the hybrid 
approach which combines, in one-step, off pump epicardial ablation with endocardial 
mapping and touch-up ablation. 
 
Review criteria 
Papers selected for this review were identified on PUBMED (last search 30/09/2011) 
using the following search terms:  ‘stand alone atrial fibrillation’’, “Mini-Maze”, 
“video-assisted”, “epicardial ablation”, “endoscopic ablation”, “videothoracoscopy”, 
“minimally invasive”, “surgical ablation”, “bilateral thoracoscopic surgical ablation”, 
“right thoracoscopic surgical ablation”, “left atrial appendage exclusion”, and 
“ganglionic plexi ablation”. 
Exclusion criteria were: animal studies, reviews, case reports, concomitant surgery, 
not lone atrial fibrillation, not minimally-invasive surgery, not performed on the 
beating heart, not English, no full-text availability. These criteria were chosen to 
make a selection based on title and/or abstract. Inclusion criteria were: studies with > 
10 patients, follow-up of > 3 months, minimal invasive-beating heart surgery and 
surgery for lone atrial fibrillation.  
The search returned a total of 631 papers. A total of 40 articles were selected. Ten 
met inclusion criteria but were excluded because they had <10 patients
11-20
. Two were 
excluded because ablations were performed on a cardiopulmonary bypass
21,22
. The 
final selection included 28 studies
23-50
. 
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Definitions 
In recent years, it has been hypothesized that SA-AF and pathological AF are 
different disease processes with contrasting risk predictors
51
. The 2006 
ACC/AHA/ESC guidelines stated that there was no standard definition for lone AF
52
. 
The guidelines applied the term to “… individuals younger than 60 years without 
clinical or echocardiographic evidence of cardiopulmonary disease, including 
hypertension”
1, 21
. A recent international consensus on nomenclature and 
classification of AF mentions that only AF in the absence of heart disease is termed 
‘lone’ while in the absence of any disease it is termed “idiopathic”
53
. Indeed, lone AF 
does not necessarily mean “idiopathic”. By convention, the term “non-valvular AF” 
is restricted to cases in which the rhythm disturbance occurs in the absence of 
rheumatic mitral valve disease, a prosthetic heart valve, or mitral valve repair.
1
 
However, the reviewed publications were appraised employing a definition of AF as 
a stand-alone procedure for treating AF without concomitant surgery. 
 
Baseline Characteristics 
An overview of the selected studies is presented in Table 1. Studies were published 
between 2004 and 2011, and 27/28 (96.4%) were observational in nature whereas 
one
42
 was prospective non-randomized. Twenty-six studies (89.6%) were performed 
in a single center, one included 5 centers
36
, one 3 North American Institutions
35
 and 
one prospectively enrolled patients from two different centers
42
. Three studies of the 
groups of Edgerton et al
26, 31,,36
, Pruitt et al
25,29 
, Sirak et al
32,43
 and Cui
41,50
 et al. may 
report on overlapping patients, thus, when discussing results, we refer to their most 
recent publications. 
The total number of patients was 1,051 (range 14 to 114). Mean age ranged from 45.3 
to 67.1 years. Only two studies had a population with mean age <50 years
28, 39
. Two 
studies
45, 31
 did not report the population’s age. AF duration ranged from 0.6 to 12.1 
years. Three papers did not report AF duration
44,45,49
 and one paper
26
 classified 
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patients on the basis of AF duration: <6 m (n=3), 6-12 m (n=5), >12 m (n=73), and 
unknown (n=2). 
Only eight papers (34.8%) distinguished long-standing persistent (LSP) AF as 
requested by recent Guidelines
54
 and in two studies
43, 50
 100% of patients had LSP-
AF. A total of 443 patients (42.1%) with paroxysmal AF underwent minimally 
invasive surgery, 189 (18.0%) had persistent AF, 123 (11.8%) LSP and 95 (9.0 %) 
permanent, whereas 97 (9.2%) were not clearly defined and one paper reported 
paroxysmal and persistent AF together (n=104, 9.9%)
49
. 
Finally, 218 patients (20.7%) had one or more previous percutaneous catheter 
ablation (PCA). In one paper
40
 all patients had at least one PCA before surgery. 
 
Surgery 
Video-assisted thoracic surgery was employed in all studies (Table 2) . In their 2006 
paper Pruitt and coworkers
25
 performed a robotic-assisted pericardial ablation in 3/50 
(6%) of patients. Edgerton
26,31,36,37,42
 et al., McClelland and coworkers
27
, Beyer et
26
 al. 
and Stamou et al
43 
carried out a small thoracothomy (4-6cm) to introduce the 
endoscopic instruments into the thoracic cavity. 
Three studies
, 39,44,49
 employed a right monolateral approach where in the others a 
bilateral access was performed. These authors used monopolar radiofrequency
44, 49
 or 
high-intensity focused ultrasound (HIFU). Four studies
23, 25, 28, 29
 employed 
microwave (MW), whereas in the majority of them the energy source was bipolar 
radiofrequency. Excluding the three right thoracotomy accesses, patients in all studies 
but one
26
 underwent excision/ligation of the left atrial appendage (LAA). In 15 
studies LAA was stapled/legated in all patients. In four papers 
23, 25, 30, 36
 a variable 
percentage of patients (16%, 8%, 39% and 11%, respectively) did not have LAA 
stapler/ligation for unexplained reasons. Only a few groups clearly stated the 
indications for LAA removal:  La Meir
48 
performed LAA stapler/clip in patients with 
CHADS2 score≥1, in the presence of rapid firing coming from the LAA and when 
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the procedure was deemed safe (50%). Cui et al
41
 did not perform LAA excision in 
the first 10 patients (12.4%) because of the lack of the appropriate endoscopic 
equipment and Edgerton et al
42 
 did not remove LAA in 8 patients (15%) because the 
procedure was deemed hazardous.  
Seventeen groups (60.7%) carried out ganglionated plexi (GP) ablation. Additional 
left atrial lesions are reported in 10 papers. They consisted of a roof line connecting 
superior pulmonary veins
26, 31,37,47,48
, an inferior line connecting inferior pulmonary 
veins
47,48
, a connecting line between the superior line (or the box) and the left fibrous 
trigone
26,31,32, 37,43,,47
, a connecting line from the superior pulmonary vein and the 
LAA
23,25,26,,28, 29,31,32,37,43
 and a line from the right inferior pulmonary vein to the 
coronary sinus (CS)
32,43.
 
Additional right lesions are reported in four papers and indications were 
persistent/long-lasting persistent AF with LA volume >58 mL
48
, permanent/persistent 
AF
23
, continuous AF
25
 or it was not specified
29
. Lesion consisted of a superior vena 
cava (SVC) to inferior vena cava line
23, 25, 29, 48
, a line up to the tip of the right atrial 
appendage (RAA)
 23, 25, 29
, or a line toward the CS
23
. 
La Meir et al
48
 added an IVC circumferential isolation in 2 cases (to be sure that the 
SVC-IVC line would not stop at an area of conduction (in patients with a small 
portion of intrapericardial IVC). These authors also added a circumferential SVC 
isolation in case of a rapid firing coming from the SVC (n=10.7%). Klinkenberg et 
al.
39
 added a tricuspid-vena cava-isthmus line ablation in one patient during 
reoperation for bleeding. 
Electrophysiological testing of the lesions was carried out only by Krul and 
coworkers.
47
 In other groups entry and exit block was checked by baseline and post-
isolation sensing and pacing
26,31-38,40-42,45,46,48-50
. Speziale et al.
44
 measured the 
conductance across the lesion and a value <50% than predicted defined an adequate 
lesion. Finally, Mc Clelland et al
27
 performed ablations guided by epicardial 
mapping. 
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Follow-up, Rhythm Monitoring, Anticoagulation and Anti-arrhythmic 
therapy 
One-thousand-one-hundred-ninety-nine patients (87.4%) reached the maximum 
follow-up which was 100% complete in 13 papers (46.4%). In the others the follow-
up completeness ranged from 32% to 95% (Table 3). The longest follow-up was 36 
months
48
 and 9 studies reported a follow up <12 months which is the minimum 
recommended for evaluating procedural efficacy
4
. 
Excluding two which did not mention any continuous rhythm monitoring
23, 45
 and one 
which performed electrophysiological studies
25
, all the others papers employed at 
least one method of long-term monitoring (LTM). Fifteen studies (53.5%) utilized 
24-h Holter Monitoring (HM) at different intervals
28,33,35,40,41,44,46,47,49,50
, two 24-48 h 
monitoring
34,39
, one 7-day HM
48
 and one 30-day HM
27 
and in one it was not specified. 
In five (17.8%) HM was associated with another LTM: 14-21 day event recorder in 
Edgerton et al. 
26,31,36,42
 and Outpatient Telemetry (OT) in Sagbas et al
30
. Among 
papers which did not utilize HM, OT
24,43
, event monitoring
32,37
and trans-telephonic 
monitoring associated with event monitoring were the methods for rhythm 
assessment. 
Only a few papers clearly described the adopted protocol for anti-arrhythmic drugs 
(AAD) during the follow-up: AAD were withdrawn in patients in SR after 3 months 
in 7 papers
22,23,40, 41, 44 ,47 ,48
, at 6 months in two 
30 42 
and two more papers stated that 
AAD were stopped after demonstration of stable SR at 3 and 6 month visits 
44,49,50
. 
Sirak et al
32
 and Yilmaz at al 
46
 reported that AAD were withdrawn at the discretion 
of the referring cardiologist. 
Similarly, a standard protocol was not followed for oral anticoagulation (OA) 
therapy: it was discontinued at three months by Salanger et al
23
 and La Meir et al
48
 (if 
CHADS2 [cardiac failure, hypertension, age, diabetes, stroke (doubled)] score was 
<2), at 4 months by Cui et al
41
, at 6 months by Sagbas et al.
30
, Edgerton et al.
37
, Han 
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et al. (if CHADS2 score was <2)
38 
and Klinkenberg et al.
39
, at 6 months-1 year by 
Castella et al
40
 and at 1 year by McClelland et al
27
. Furthermore, in Wudel et al.
33
 and 
Yilmaz et al.
46
 anticoagulants were discontinued at the discretion of the referring 
cardiologist; Speziale et al.
44
 and Nasso et al.
49
 kept patients under OA until SR was 
maintained for 3 months, whereas Krul et al.
47
 discontinued OA when CHADS2 score 
was <1 without AF and AAD . Finally, Wang et al
50
 continued OA for at least 3 
months.  
Patients taking AAD at latest follow up was shown or could be calculated in 22/28 
(78.5%) studies. The range was from 2% to 53% (mean 26±15%). Patients still under 
OA therapy at follow up could be obtained from 15/28 (53.5%) studies. The range 
was from 0% to 63% (mean 39±19%). 
Quality of Life assessment was carried out employing the 36-item short form (SF-36) 
health survey questionnaire by Speziale et al.
44
 and Nasso et al.
49
, both showing an 
improvement in all indexes with the exception of vitality score. Pruitt et al
25,29
  
explored the perceived health status after surgery: 81.8% and 52.3% of patients were 
pleased with the outcome and 81.8% and 55.7% felt the operation had been 
beneficial, in the two publications, respectively. 
 
Results 
Only six papers
27,34,38,42,47,50 
, all utilizing RF, clearly defined the primary efficacy 
endpoint of surgery as suggested by current Guidelines (freedom from AF , off anti-
arrhythmic drugs at one  year [Table 4])
4
. The follow-up was 93.3% complete 
[251/269 pts.]) and the success rate ranged from 51% to 86%. One study reported a 2-
year success rate of 80%.  
With specific reference to the different type of AF, AAD-free success rate at 12 
months ranged from 65% to 92% in paroxysmal AF and from 67% to 80% in 
persistent AF. Only 3 studies
27,47,50
 reported  12-month AAD-free success rate in LSP 
(25% [4 pts. at follow up], 100% [1 pt. at follow up] and 80% [81pts. at follow up]).  
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Eight papers
26,30,31,32,33,35,36,37 
reported outcomes as freedom from AF and AAD at 6 
months (Table 5) . This rate ranged  from 57% to 91% in the whole population, from 
72% to 100% in paroxysmal and from 35%to 78% in persistent  AF. Two papers
36,37
 
showed this outcome 
in LS-P patients (32% [22 pts. at follow up] and 47% [15 pts. at follow up]) and one
30
 
report AAD free- in permanent  AF (72% [18pts. at follow up]).
 
Wolf et al
24
 Yilmaz et al
46
 and Nasso et al.
49 
reported freedom from AF-AAD at 
different intervals (Table 6) : 65% beyond  3 month-follow up, 65% at 12.6 month-
follow-up and 51% at 17.1-month follow-up, respectively.   
Three papers showed outcome as 12-month-freedom from AF (62% and 75%, 
respectively)
40,45 
or 3 month-freedom from AF (100 %)
43
. Furthermore, in  two 
publications
41,44
 80% (39/49) and 87% (40/46)
 
of patients are in sinus rhythm at 12 
and 6 months , respectively. 
La Meir et al 
48 
employed a method suggested by the Workforce on Evidence-Based 
Surgery of the Society of Thoracic Surgeons (STS), reporting time related prevalence 
of AF
55
.  
Four studies employing MW
23,25,28,29
 reported a freedom from AF success rate of 67% 
79.5%,86% and 42%, respectively. One group utilizing HIFU 
39 
reported a  6-month 
AF-AAD-free success rate of 33%. 
Krul al.
47 
carried out a roof and inferior line with 86% one-year freedom from AF-
AAD (22 pts.). It was 100% for Sirak et al
43
 (19 pts all LSP) and 58% for Edgerton et 
al
31
(24 pts)  at 6 months. In three studies utilizing MW
23, 25, 29
 an additional line 
toward LAA was performed. Unfortunately none of these papers reports AAD-free 
rate. 
Groups performing GP ablation reported a 6-month and 12 month AAD-free success 
rate ranging from 51% to 86% and 58% to 88%, respectively. Two studies employing 
bipolar RF
30,33
 without GP ablation reported an AAD-free success rate of 81% and 
91%, respectively. 
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Adverse Events 
Three early deaths have been reported (Table 5): one
26,31, 36 
occurred during the 
procedure as a consequence of tearing of LAA, one
41
 was due to cerebral infarction 
and for one death the cause was unknown 
36
. Overall, early complications occurred in 
125 patients and the complication rate ranged from 0 to 39%. Early complications 
were as follows: 12 conversions to sternotomy, 15 bleedings, 10 access-port 
complications, 11 cardiac complications, 8 cerebrovascular events and 28 pulmonary 
complications. Furthermore, 38 other complications occurred: 4 renal insufficiencies, 
16 diaphragmatic-phrenic nerve dysfunctions, one liver damage and 4 brachial 
plexopathies were observed. Finally, 10 patients required a pacemaker implantation 
and 2 underwent percutaneous catheter ablation (PCA) within 30 days. 
Three deaths occurred during the follow up and none was cardiac related: one 
unexplained death
25
 occurred in an obese patient who had severe pulmonary disease 
at the time of operation, one patient died from trauma and one from malignant 
neoplasm.
46
 Other complications included cerebrovascular accident (n=4), thrombo-
embolic event (n=1), anticoagulation-related complication (n=1)and post-
pericardiotomy syndrome (n=1). In addition, during the follow up, 27 patients 
underwent PCA, 13 surgical Cox-Maze, 5 had pacemaker implantations and one 
patient was re-hospitalized for congestive heart failure and atrial flutter. 
 
Discussion 
The key purpose of this review is to summarize and discuss published articles about 
MIS for the treatment of SA-AF. From this overview it is evident that results 
employing microwave (MW) energy are rather poor. Indeed Pruitt et al.
29 
in the most 
recent paper report a 42% rate with AAD at 12 months. MW is an unfocused heat 
energy which can create transmural endocardial lesion but it is not capable of creating 
epicardial lesion on the beating heart
56
, this may explain such unsatisfactory results. 
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In addition, results with High Frequency Ultrasound (HIFU) energy were also 
suboptimal: Klinkenberg et al
39
 reported a 6-month AAD-free success rate of 33%. 
Indeed, this energy source appears capable of creating endocardial lesions on the 
arrested heart but has not been able to create transmural lesion on the beating heart 
and this explains the poor outcome of this study. 
Bipolar radiofrequency is the most commonly adopted energy source for MIS as it 
has been demonstrated to produce permanent transmural linear lesions on the beating 
heart
56
. Two groups performed surgery through a monolateral right thoracotomy 
approach
44, 49
 with a success rate without AAD of 51% and with AAD of 87% and 
89%. The mono-lateral approach should significantly lower the possible complication 
rates (bleeding, pulmonary complications), should be less painful for patients and 
allow potentially faster recovery. Nonetheless, only monopolar devices were used 
because of the lack of maneuverability of bipolar clamps which can hamper the 
orientation of the probe and constrain the variety of achievable lesion sets when 
employed from the right side. There is concern about the ability of these devices to 
create transmural lesion with bidirectional conduction block on the beating heart
57
. 
Further studies are necessary to establish if this approach may represent a reliable 
alternative to bilateral bipolar surgical ablation.  
Among studies utilizing RF, freedom from AF-AAD at 12 months ranged from 51% 
to 86%; this figure was 65%-92% in paroxysmal and 67%-80% in persistent. Wang et 
al
50
reported 80% AF-AAD freedom with 81 patients reaching 1year-follow-up. These 
result are comparable to those following PCA
58
. Indeed, an updated worldwide 
survey
7
 reported a success rate free of AAD after PCA of 69.9%. It was 71.4% in 
paroxysmal, 59.4% in persistent and 59.7% in LSP. Similarly, minimally invasive 
surgery was more effective in paroxysmal and 4/7 studies
27,38,42,47
 showed an AAD-
free success rate higher than PCA. However, minimally invasive surgery also had 
better results in persistent in 3/3 studies reporting AAD-free success rates. In 
contrast, the success rate was lower in 2/3studies in LSP AF. 
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Furthermore, authors performing left additional lines had very high AAD-free 
success rates in persistent and LSP. This confirms that persistent and LSP AF cannot 
be successfully treated by PVI alone since the mechanisms for initiation and 
maintenance of AF lie in the changed left atrial substrate beyond the PVs. From a 
pathophysiological perspective, this is explained by structural and electrical 
remodeling of the atrial myocardium, which can then initiate and sustain AF 
independent of the PVs in patients with persistent/LSP AF. In these patients, the 
augmented number and location of drivers for fibrillation necessitates additional 
linear ablation strategies. 
Another interesting finding of this overview is that, from the analysis of the reported 
results, it seems that GP ablation is not an essential part of the minimally invasive 
surgery of SA-AF to prevent recurrence of AF. Indeed, groups performing GP 
ablation reported a 12 month AAD-free success rate lower than studies not 
performing GP ablation. The long-term efficacy of GP ablation has been questioned
59
 
and this was related to the possibility of autonomic ganglia to potentially reconnect or 
regrow
60
. Nonetheless, these data must be interpreted with caution because of the 
small number of studies with full results available and the short follow up, and the 
role of GPs and their destruction in AF must be further investigated.  
Mortality was low and comparable to PCA (0.4%)
54
. Postoperative complication rates 
are not negligible and higher than PCA
54
. Pulmonary problems, bleeding and 
diaphragm/phrenic nerve dysfunction were the most common complications. 
Nonetheless, the occurrence of TIA/stroke was very low and less than that reported in 
catheter based pulmonary vein isolation
54
. Interestingly, the incidence of 
cardiovascular accident was not different with or without LAA removal and, from 
these findings, it seems that this procedure is not a critical component of MIS. 
However, this finding must be interpreted with extreme caution due to the small 
number of publications and the lack of uniform anticoagulation policy. Certainly, it is 
necessary to clearly define the role of LAA removal in MIS ablation since the LAA 
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exclusion/closure is a potentially dangerous procedure and most of the reported 
bleedings were related to this maneuver. 
Unfortunately no randomized control trials have been published comparing MIS with 
PCA. At the moment there are two ongoing studies: the SCALAF success trial which 
compares the efficacy of circumferential pulmonary vein ostia ablation using surgical 
versus catheter techniques in the treatment of paroxysmal atrial fibrillation, and the 
FAST II trial that explores whether mini invasive thoracoscopic radiofrequency is 
more effective compared to a percutaneous catheter based technique in patients with 
symptomatic paroxysmal atrial fibrillation refractory to at least one anti-arrhythmic 
drug. The results of these studies will provide a great understanding of the role of 
both procedures in the treatment of SA-AF.  
In our recent paper
61
 we had given an overview of medical and surgical treatments of 
atrial fibrillation. The present study is mainly focused on providing a more detailed 
oversight of efficacy and complications of minimally invasive procedure. Krul et al
62
 
have recently published a review on the mini-Maze. They included only papers 
employing radiofrequency and performed an aggregate patient data (APD) meta-
analysis to compare published results. Our approach was different and we choose to 
give to the readership as much information as possible to allow them to make their 
own opinion about the effectiveness/safety of these procedures. Furthermore we 
believe that, although a well-designed meta-analysis can provide valuable 
information for researchers, there are too many critical caveats in performing and 
interpreting it which, therefore, can yield misleading information
63
 in particular when 
individual patient data (IPD) are not available
64
. Indeed, IPD meta-analysis offers 
advantages and, when feasible, should be considered the best opportunity for 
summarizing the results of multiple studies. However, the resources, time and 
cooperation required for such studies will continue to limit their use in many 
important areas of clinical medicine which can be meaningfully and cost-effectively 
approached only by APD-based meta-analyses. 
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Towards a multi-disciplinary approach: the Hybrid Procedure 
With the development of new tools and advanced techniques, the treatment of SA-AF 
moves towards a multidisciplinary approach involving cardiac surgeons and 
electrophysiologists
65
. 
The rationale of the so called “hybrid” approach is to combine, in one step, a 
minimally invasive epicardial technique with a percutaneous endocardial ablation in 
order to limit the shortcomings of both techniques and, at the same time, to combine 
their advantages. 
The potential for improved outcomes derives from combining levels of expertise. 
Surgeons are very good at making linear lesions and EPs at mapping for 
completeness. Lesions are more likely to be transmural when burning from the inside 
outwards and from the outside inwards simultaneously and the electrophysiologist 
can add an endocardial “touch-up” in the case of incomplete isolation of one of the 
pulmonary veins or if the connecting lesions are not transmural.  
Furthermore, as discussed above, a more extensive lesion set beyond PVI to include 
targets along the LA substrate is often necessary in persistent and LSP AF. 
Nonetheless, while the other lesions can be performed through the transverse sinus, 
the biggest challenge in the case of the full beating heart is making the connection to 
the mitral annulus, and this for different reasons: first, the visualization behind the 
LA of the full beating heart is very limited; second, there is the risk of collateral 
damage to the circumflex artery; third, the coronary sinus, which is used as the 
epicardial landmark for the mitral annulus, is unreliable and may leave a gap
66
.  
An attempt to address this problem was made by Edgerton et al.
37
 who developed the 
“Dallas lesion” in which a line was made connecting to the anterior annulus at the 
junction of the left and non-coronary cusps of the aortic root. Nonetheless, this line 
might not be transmural due to the inability of radiofrequency energy effectively to 
penetrate fatty tissue associated with the dome of the left atrium and the superior 
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vena cava. This is an indication for mapping conduction block which can be checked 
by using an hybrid approach.  
In contrast, mitral isthmus lesion can easily be carried out (or completed) 
endocardially by the EP. Another potential advantage of the hybrid technique is that, 
from the EP’s point of view, there is no longer a risk of phrenic nerve and esophageal 
injury because these structures can be protected by the surgeon if necessary, as well 
as no risk of tamponade since the pericardium is open. Furthermore, by reducing the 
total number of endocardial ablations the risk of emboli during these ablations should 
be potentially reduced
67
.  
A potential drawback of the single-step approach is the patient’s heparinisation after 
the trans-septal puncture which could increase the risk of epicardial bleeding and the 
risk of measuring a temporary block. 
The concept of “hybrid” procedure was first published by Pak and co-workers
68
who 
combined percutaneous epicardial catheter ablation (PECA) and endocardial ablation 
in difficult cases of AF. More recently, Krul et al.
47
 presented their experience with 
thoracoscopic PV isolation and ganglionated plexus (GP) ablation guided by peri-
procedural electrophysiological testing.  
Mahapatra et al.
69
 have recently published their initial experience with surgical 
epicardial catheter and endocardial ablation for persistent and long-standing 
persistent atrial fibrillation carried out in two sequential steps (during the same 
hospitalization). After a mean follow-up of 20.7±4.5 months 86.7 % patients 
(persistent and LSP) were free of any atrial arrhythmia and off anti-arrhythmic drugs, 
compared to 56.7 % of patients undergoing repeat catheter ablation. More recently, 
Pison and coworkers
70
, published results of a one-step hybrid thoracoscopic surgical 
and transvenous catheter ablation of atrial fibrillation in 26 patients. One-year off-
AAD success free of AF/AFL/AT was 93% for patients with paroxysmal AF and 
90% for patients with persistent AF.  
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Nonetheless, demonstration of the effectiveness and the safety of this approach 
awaits the completion of studies currently underway. Figure  1 shows the conversion 
of AF to sinus rhythm during the one-step hybrid procedure. 
 
Limitations 
This review has some important limitations which must be pointed out. First of all, a 
meta- analysis could not be carried out because of the heterogeneity of the papers and 
the lack of individual patient data. Second, the unavailability of data from prospective 
randomized studies on the minimally invasive surgical treatment of SA-AF vs. PCA 
was a drawback of this systemic review. Third, not all results are reported following 
HRS/EHRA/ECAS expert consensus which makes a comparison of the different 
studies difficult. 
 
Conclusions 
Minimally invasive surgical ablation of SA-AF achieved satisfactory one-year results 
when bipolar radiofrequency was employed as energy source, with AAD-free success 
rate comparable to PCA. The success rate in paroxysmal was even higher than in 
PCA. In persistent and long-standing persistent, results were improved by additional 
LA ablation lines. In contrast, GP ablation and LAA removal seem not to influence 
the recurrence of AF and the occurrence of postoperative thrombo-embolic events. 
Nonetheless, the relatively high complication-rate reported suggests that such 
techniques require further refinement. Finally, the preliminary results of the hybrid 
approach are promising but they need to be confirmed. 
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Studies were presented by year of publication and in alphabetical order . Abbreviations:  U/M: 
Unicentric/Multicentric study; Age expressed as mean ± SD or [range]; AF duration expressed y: years LA : 
Left atrial;  LA Diameter expressed a s as mean ± SD or median [ Interquartile range]; PCA: Percutaneous 
catheter Ablation ; PX: Paroxysmal atrial fibrillation; PR: Persistent atrial fibrillation; LSP: Long-standing 
Persistent atrial fibrillation; PM: Permanent atrial fibrillation; ns: not specified..  
Notes: *†< 60 mm (n=26) > 60mm(n=1); † * < 60 mm (n=26) > 60mm(n=1); †<46 mm (n=23), 46-59 
mm(n=24), ≥60 mm (n=3; ‡ AF classified as intermittent (n=33) and continuous (n=17); § <6 m (n=3), 6-12 m 
(n=5), >12 m (n=73), unknown (n=2).; ¶ Persistent and Long-standing persistent reported together). ** <46 mm 
(n=42), 46-59 mm(n=53), ≥60 mm (n=5) ; ††All patients had PCA by definition; ‡ ‡indexed by BSA;§§ 
Paroxysmal and persistent reported together; ¶ ¶ 41 patients treated with irbesartan.            
 
 
 
Table 1.  Minimally Invasive  surgery for Lone Atrial Fibrillation:  Baseline Characteristics. 
First Author Year U/M Pts. Age AF duration (y) LA diameter (mm) PCA PX PR LSP PM 
Salenger 23 2004 U 14 60±4 6.9 47.3±7.3 1 10 1 - 3 
Wolf24   2005 U 29 57.2±14.9 7.5   * 2 18 4 - 5 
Pruitt25  2006 U 50 59±10 6.1 † 11 ‡ ‡ ‡ ‡ 
Edgerton26 2007 U 83 60 § 52  21 72 ¶ 21 ¶ 21 - 
Mc Clelland27  2007 U 20 59±8 1.4 44±3 ns 11 5 4 - 
Koistinen28  2007 U 22 45.3±10.2 6.6 42.9±5.2 0 10 12 - - 
Pruitt29 2007 U 100 60±9 6.0 ** ns 64 11 - 25 
Sagbas30  2007 U 26 56±11 2.8 42.2±6.3 6 8 - - 18 
Edgerton31  2008 U 74 ns ns ns 20 46 14 14 - 
Sirak32  2008 U 32 61±10 7.7  48.2±8.2 ns 0 3 29 - 
Wudel33   2008 U 22 62±9 3.7  34.7 ± 11.5 7 14 8 - - 
Bagge34 2009 U 42 58 [36-71] 7  45 [26-62] 18 28 6 - 9 
Beyer35  2009 M (3) 100 65±11 4.9 43±6 ns 39 29 - 32 
Edgerton36  2009 M (5) 114 59.5±10.6 >1 (n=101) 47.2±8.3 24 60 32 22 - 
Edgerton37   2009 U 30 58±9 >1 52 ns - 10 20 - 
Han38  2009 U 45 64±8.7 6.2 43±6 12 33 12 - - 
Klinkemberg39  2009 U 15 47±10 5.0 38±5 ns 11 4 - - 
Castella40 2010 U 34 54±8.6  8.1 45.3 ±5.6 34†† 17 12 5 - 
Cui41  2010 U 81 58±10 5.9 49.7±11.4 4 49 17 - 15 
Edgerton42  2010 M (2) 52 60[42-79] >1 48 [3.7-6.0] 10 52 - - - 
Sirak43  2010 U 48 60±6 4.3  45 [34-63] 13 - - 48 - 
Speziale44 2010 U 46 54.9 ns 42±5 14 19 27 - - 
Stamou45 2010 U 20 ns ns ns ns ns ns ns ns 
Yilmaz46  2010 U 30 55.6±8.6 6.6 ns 18 19 8 - 3 
Krul47 2011 U 27 57±7 0.6 47±7  14 16 3 2 - 
La Meir48 2011 U 28 67.1±9.1 12.1 41.6±5.7 21 14 5 9 - 
Nasso49 2011 U 104 63.9±8 ns 21.3±5 ‡‡ 24 104§§ 104§§ - - 
Wang50 2011 U 83¶ ¶ 57±11  5.1 52.5±11.5 ns - - 83 - 
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Studies were presented by year of publication and in alphabetical order  
Abbreviations: GP: Ganglionated plexi (ablation); LAA: Left atrial appendage 
excision/closure; AL: Additional lines; Source: MW: Microwave; RF: 
Radiofrequency; Cryo: Cryotherapy; HIFU: High-Intensity Focused Ultrasound b: 
bipolar; u: unipolar;  I. Irrigated; NI: Not irrigated; VATS: video assisted 
thoracoscopic surgery; Rob: Robotic-assisted surgery; ns: not specified.                                                                                                                                                                                           
Notes: * during  reoperation for bleeding  a tricuspid-vena cava inferior isthmus  
ablation was performed in one pt. † Eight underwent additional mitral and tricuspid 
procedures ; ‡ Performed on Cardiopulmonary bypass; § LAA was excised if it was 
deemed to be significantly enlarged  or if the patient had suffered from a thrombo-
embolic event. 
 
 
Table 2. Minimally Invasive  surgery for Lone Atrial Fibrillation:  Surgery 
First Author Source Method Access GP LAA AL 
Salenger 23 MW VATS B N Y ( 9) Y 
Wolf24 RF(b)I VATS B N Y N 
Pruitt25 MW VATS (47) /Rob (3) B N Y(46) Y 
Edgerton26 RF(b)I Thoracotomy /VATS B Y Y Y 
Mc Clelland27 RF(b)I Thoracotomy /VATS B Y N N 
Koistinen28 MW VATS B N Y§ N 
Pruitt29 MW VATS B N Y Y 
Sagbas30 RF(b)I VATS B N Y (16) N 
Edgerton31 RF(b)I VATS B Y Y Y 
Sirak32 RF(b) NI VATS B Y Y Y 
Wudel33 RF(b)NI VATS B N Y N 
Bagge34 RF(b)I VATS B Y Y N 
Beyer35 RF(b) I NI Thoracotomy /VATS B Y Y N 
Edgerton36 RF(b)I Thoracotomy /VATS B Y Y(101) N 
Edgerton37 RF(b)I Thoracotomy /VATS B Y Y Y 
Han38 RF(b)I VATS B Y Y N 
Klinkemberg39 HIFU VATS R N N Y* 
Castella40 RF(b) NI VATS B Y Y N 
Cui41 RF(b) NI VATS B N Y  (71) N 
Edgerton42 RF(b)I Thoracotomy /VATS B Y Y(44) N 
Sirak43 RF(b)I VATS B Y Y Y 
Speziale44 RF(m) VATS R N N N 
Stamou45 RF(b) I NI Thoracotomy B Y Y N 
Yilmaz46 RF(b) NI VATS B Y Y N 
Krul47 RF(b) NI VATS B Y Y Y 
La Meir48 RF(b)I VATS B Y Y (14) Y 
Nasso49 RF(m) VATS R N N N 
Wang50 RF(b) NI VATS B Y Y N 
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Studies were presented by year of publication and in alphabetical order . Abbreviations:  F-Up: Follow-up; 
m=months; N (%): Number (percentage) of patients at follow-up; ADD: (%patients taking ) Antiarrhythmic 
Drugs; OA : (%patients taking ) Oral Anticoagulants. Endpoint: 1= freedom from AF,2=number of patients 
in sinus rhythm/with no AF; 3: No episodes of AF >15 sec at 6 months 4: Free of AAD (Class IC and III) and 
AF , no > 30 sec of AF ; 5: episodes of AF,  6: Absence of AF on all serial ECG, Holter Monitoring or 30-day 
event –free monitoring >6 months after procedure;  7:  No episode of AF o left Atrial Tachyarrhythmia (AT)  
after blanking period of 3 months;8:No AT, AF or Atrial Flutter (AFl)  >30 seconds during monitoring at 6 
months;  9: No AT, AF or Atrial Flutter (AFl) lasting >30 seconds off antiarrhythmic drugs, 10: Absence of 
AF AFl and AT on 96h HM or ECG >30 sec and no AF compliant; 11: No AF or Atrial Flutter (AFl)  >30 
seconds during ECG or Holter Monitoring:; 12:  Freedom from AT, AF or Afl off antiarrhythmic drugs after 
12 months;13: Time-related prevalence of AF ( defined as of AF o left Atrial Tachyarrhythmia after blanking 
period of 3 months. Follow-Up type: OC: Outpatient Clinic; MR: Medical Records; TI: Telephonic 
Interviews;; CV: Cardiologic Visits; M: Months; ns: not specified;  Rhythm Monitoring: ECG: 
Electrocardiograms HM: Holter Monitoring;, , OT : Outpatient (Cardiac ) Telemetry;  TTM : Trans 
Telephonic (event) Monitor Pm= Pace-maker; UCG: Ultrasonic Cardiographic evaluation,  EPS: 
Ectrophysiology studies ;  Notes: * 1 Patient underwent 15-day HM.    
 
Table 3. Minimally Invasive  surgery for Lone Atrial Fibrillation:  End-points and Rhythm Monitoring 
First Author F-Up (m) End-point N (%) F-Up type Rhythm Monitoring AAD   OA 
Salenger 23 12 1 14 (100) OC ns ns ns 
Wolf224 6 1 23(79) OC-MR-TI-CV (3-5-6 M) ECG (10) OT(13) 9  ns 
Pruitt25 7.6 2 44 (88) OC-TI  (ns) ECG  EPS  20 50 
Edgerton26 6 3 57 (69) OC(1-3-6 M) ECG, 14-21-day event recorder (24)24HM (24), Pm (9) 34 ns 
Mc Clelland27 17±3 4 20 (100) OC(1-2-3-6-W 3-6 M-every 6M) *30-day HM (12M) 25 ns 
Koistinen28 11.5±6 2- 5 22 (100) OC (1-3-6 M) 24HM (6M) 2  0 
Pruitt29 23.1 6 88 (88) OR-MR-EPS (ns)  ECG -HM (ns) 11 54 
Sagbas30 8±3 2 26 (100) OC (3-6 M) OT; 24HM (ns) 19 54 
Edgerton31 6 3 66 (89) 0C (1-3-6 M) ECG; 14-21-day event recorder (ns)24HM (ns) 47 ns 
Sirak32 6 1 19(40) OC 7-day event recorder (3-6-13-24M) ns ns 
Wudel33 18± 4 2 22 (100) OC (3-6-12 M) 24HM  (ns) 9 9 
Bagge34 12 1 41 (78) OC (3-6-12-M) 24-48HM (ns) 32 24 
Beyer35 13±8 7 100 (100) 0C (3M –every Year) 24HM (3M) 37 36 
Edgerton36 17±3.4 1 114(100) OC ( 1-3-6 M) 24 HM (26) 14- 21-day event recorder (68) Pm (15) 43 ns 
Edgerton37 6 8 30 (100) OC ( 1-3-6 M) ECG-Event Recorder  Pm 53 47 
Han38 12 9 43 (95) OC (6-12 M – Yearly) 30-day event recorder  (6m) TTM (12M) 35 33 
Klinkemberg39 1.3±0.6 y 10 15 (100) OC ( 2-6—12--24M) ECG 24HM (2m) 48 HM (6m)  40 ns 
Castella40 16±11 11 11 (32.3) OC ( 1-4-6-12 M) ECG 24HM (4-6M-1Y)  ns 63 
Cui41 12 11 49 (60) OC ( 1-3-6-12 M) ECG, 24-48 HM, Pm ,UCG ns ns 
Edgerton42 12 8 52 (100) OC ( 1-3-6-12 M) 24 HM 14-21-day event recorder Pm 11 19 
Sirak43 6 7 24 (75) OC (3-6-13 M) OT 12 ns 
Speziale44 9.3±3.2 3 46(100) OC ( 3-6 -12 M) ECG 24HM (6-12 M) ns ns 
Stamou45 12 ns 12 (60) ns ns   ns ns 
Yilmaz46 11±4 7 30 (100) OC(1-3-6-W 3-6-12M) ECG 24HM (3-6-12 M) 35 52 
Krul47 12 12  -9 22(71) OC ( 3-6-12-15-18-24 M) ECG 24HM (every 3 M) 14 48 
La Meir48 36 13 24(85.7) OC(2-W 1-6-12M-Yearly) ECG 7day-HM(2-W 1-6-12M-Yearly) 11.3 15.2 
Nasso49 17±6 1- 5 104(100) OC ( 3-6 –every 6 M) ECG, 24HM(3-6 M)   49 60 
Wang50 26 11 81 (97.5) OC ( 1-3-6-12 M-every 6 M) ECG  24-48 HM (3M)   21 ns 
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Studies were presented by year of publication and in alphabetical order . Abbreviations: N: 
Number of in-hospital complications; %:  Percentage of in-hospital complications; Bleed: 
Bleeding; Port (access port complications): Rev: Surgical Revision; Rib: Rib Fracture; Cardiac: 
VT: Ventricular tachycardia, Pe : Pericarditis/Pericardial effusion; Myocardial Infarction; 
Cerebral: CVA: Cerebro-vascular Vascular Accident; Dis: Disorientation/Confusion TIA: 
Transient Ischemic Attack; Pulmonary: PN: Pneumonia; PE: Pulmonary Embolism; PX: 
Pneumothorax; PLE: Pleural Effusion; H: Hemothorax; RD: Respiratory Distress; PAV: 
Prolonged assisted ventilation; Reint: Reintubation. Other: Phl: Phlebitis, D: Diafragmatic 
dysfunction, RI: Renal insufficiency; BP: brachial plexopathy; PM: Pacemaker implantation, 
Phre: Phrenic nerve injury, PCA: Percutaneous Catheter Ablation. Late: PM: Pacemaker 
implantation, RH: Re-hospitalization  C-MZ: Cox Maze procedure; CVA: Cerebrovascular 
Vascular Accident, PCA: Percutaneous Catheter Ablation,  ACC : Anticoagulation 
Complications, PP: Post-perdicardiotomy syndrome, INF: Infection; Esoph: Esophagitis He : 
Portal hernia, TEE: Thromboembolic event, ns: not specified (n of events [time]). 
* during  reoperation for bleeding a  tricuspid-vena cava inferior isthmus  ablation was 
performed in one of these pts.† referring to the some patients. 
 
Table 8. Minimally Invasive  surgery for Lone Atrial Fibrillation:  Adverse events. 
First Author N % Death Conversi
on 
Blee
d 
Port Cardia
c 
Cerebra
l 
Pulmona
ry 
Other Late 
Salenger 23 4 28.
5 
0 2 0 0 0 0 PN; PE 0 PCA(2[3-6-M]); 
PM([9M]) 
Wolf24 3 13.
0 
0 0 0 0 Pe 0 PX Phl RH 
Pruitt25 2 4 0 0 0 0 0 0 0 D (2) Death (1) C-MZ (5) 
Edgerton26 4 4.8 1† 0 0 0 0 0 H RI; BP 0 
Mc Clelland27 1 0.5 0 0 0 0 0 0 H 0 PCA (3[ns]) 
Koistinen28 5 2.2 0 0 2 0 0 0 0 Liv.Dam   D (2) PM ([ns]) 
Pruitt29 1
3 
13 0 0 2 0 0 CVA 0 D(7) PM (3) 4CVA, ACC  C-MZ (9) 
Sagbas30 2 7.6 0 0 0 0 0 0 PLE D 0 
Edgerton31 4 5.4 1† 0 0 0 0 0 H RI; BP 0 
Sirak32 1 3.1 0 1 0 0 0 0 0 0 PCA (5 [ within 3 M]) 
Wudel33 2 9 0 0 0 Rev 0 0 PE 0 PCA (1[7M]) 
Bagge34 1
7 
39 0 0 6 Rib  I (4) VT PP Dis  
Stroke 
H (2) 0 PP  INF  Esoph  He (ns) 
Beyer35 1
3 
13 0 0 0 0 0 TIA H (3) PE PM (5) Phre (3) ns 
Edgerton36 1
5 
13 2† 0 1 0 Pe VT 
(2) 
0 RD (5) RI (2) Phre BP ns 
Edgerton37 0 0 0 0 0 0 0 0 0 0 PM(2)  PCA (ns) 
Han38 0 0 0 0 0 0 0 0 0 0 PCA (8 [ 532±73 days]) 
PM 
Klinkemberg39 3 20 0 0 2* 0 Pe 0 0 0 PCA (6) 
Castella40 5 14.
7 
0 0 2 0 0 Stroke H PAV 0 ns 
Cui41 6 7.4 1 1 0 Rev (2) MI 0 Reint 0 ns 
Edgerton42 4 7.6 0 0 0 0 0 0 0 BP, PM PCA(2) 0 
Sirak43 2 4.2 0 1 0 0 0 0 0 PM PCA 
Speziale44 1 1.9 0 1 0 0 0 0 0 0 0 
Stamou45 3 15 0 0 0 0 Pe (3) 0 0 0 ns 
Yilmaz46 4 13.
3 
0 2 0 0 0 0 PX(2) 0 0 
Krul47 6 22.
2 
0 3 0 0 0 0 H PX PN 0 0 
La Meir48 0 0 0 0 0 0 0 0 0 0 0 
Nasso49 3 2.9 0 1 0 0 0 TIA 
Stroke 
0 0 Death (2) TEE 
Wang50 4 4.8 0 - - Rev (2) - Stroke Reint - - 
121
                                                                                                                      
  
Figure Legends 
 
 
 
 
 
 
Figure 1. Hybrid procedure: conversion to sinus rhythm during epicardial ablation of the right 
superior ganglionated plexi (GP). 
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Abstract 
Background and Aim of the Study. We present our results with minimally 
invasive surgical treatment of lone atrial fibrillation (LAF) employing a 
radiofrequency (RF) source through a bilateral thoracoscopy  
Methods. Between January 2007 and January 2011 twenty-eight consecutive 
patients (85.7% male, mean age 67.1±9.1 years) with LAF underwent video-
assisted bilateral radiofrequency (RF) ablation. Fourteen patients (50%), had 
paroxysmal, 5 (17.8%) persistent and 9 (32.2%) longstanding persistent LAF. 
All patients were followed-up according the Heart Rhythm Society/ European 
Heart Rhythm Association/ European Cardiac Arrhythmia Society 
(HRS/EHRA/ECA) and success/failure was reported as suggested by Society of 
Thoracic Surgeon (STS) guidelines. Mean follow-up was 27.8 ± 8.6 months.   
Results. Time-related prevalence of postoperative AF was 4.5 % at 36 months. 
Success was much more likely in subjects with paroxysmal (3-year prevalence, 
0%) or persistent (3-year prevalence, 0%) than long-standing persistent LAF 
(3-year prevalence, 8.3%). At 36 months the estimated prevalence of anti-
136
arrhythmic drugs was 11.3% (8.8-13.7). No major thrombo-embolic events 
were detected during the follow up period and 36-month prevalence of 
Warfarin use was 15 .2 % (11.5-18.1). Finally, no patient underwent electrical 
cardioversion. 
Conclusions. This approach yielded satisfactory results with a high degree of 
safety. Further larger studies are necessary to confirm our findings. 
 
Introduction 
The surgical treatment of lone atrial fibrillation (LAF) has entered a new era 
with the development of new tools and advanced endoscopic techniques
1
. 
Similarly, new energy sources have been adopted in an effort to reduce the 
invasiveness and technical concerns with the original Maze procedure
2,3
. As a 
result, a plethora of new surgical approaches have been introduced over the last 
decade
4
. Nonetheless, despite the high number of published cases, we remain 
far from a standardized surgical approach
5
. In addition, the wide variability in 
success rates obtained by different Groups
6-8 
has led to a great deal of confusion 
among both cardiologists and surgeons because of different AF cohorts, energy 
sources and lesion sets.  
Thus, the adoption of common criteria for reporting clinical results after 
procedures for AF has been encouraged by The Workforce on Evidence Based 
Surgery of the Society of Thoracic Surgeons (STS) to facilitate the comparison 
between experiences of various authors treating different cohorts of AF 
patients, at different times with different techniques
9
. 
Therefore, in the present study we report our results with minimally invasive 
surgical treatment of LAF employing a radiofrequency (RF) source through a 
bilateral thoracoscopy in terms of time related prevalence of postoperative AF.  
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We also analyzed prevalence of anti-arrhythmic medication use, prevalence of 
anticoagulant use and the cumulative incidence of postoperative cardioversion 
following the surgical procedure. 
 
Methods 
Patients 
The study followed the World Medical Association guidelines concerning 
ethical principles for medical research involving human subjects and was 
approved by the Institutional Ethics Board. All patients gave their informed 
consent. 
Between January 2007 and January 2011 twenty-eight consecutive patients 
with LAF underwent video-assisted bilateral radiofrequency (RF) ablation for 
LAF. 
Lone atrial fibrillation was defined following American College of 
Cardiology/American Heart Association/European Society of Cardiology 
(ACC/AHA/ESC) guidelines
10
 and updated ESC Guidelines were followed to 
distinguish type of AF and to score the AF-related symptoms (European Heart 
Rhythm Association [EHRA] score)
11
 . 
Exclusion criteria were a presence of atrial or left appendage thrombi at 
transesophageal echocardiography (TEE), ‘giant’ left atrium (diameter >65 
mm), coronary artery disease, and previous pulmonary or cardiac surgery. 
Patient characteristics are shown in Table 1. 
Assessment of AF 
Patients underwent in-hospital prolonged continuous telemetry monitoring 
(mean 187 ± 48 hours). In case of AF, any episode was recorded and computed 
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with the time of occurrence. In case of sinus rhythm (SR)  the absence of the 
event was recorded at the end of any 24-h time. After hospital discharge 
patients underwent 7-day Holter monitoring (HM). Seven-day HM was 
performed at 6 months, 1 year and yearly thereafter. Monitoring was performed 
with an external loop recorder (Del Mar Reynolds, Spacelabs Healthcare, 
Issaquah, WA, USA) and analyzed with Lifescreen Software (Del Mar 
Reynolds, Spacelabs Healthcare, Issaquah, WA, USA). For analysis, three 
rhythms were considered postoperative AF: AF, atrial flutter or atrial 
tachycardia lasting more than 30 sec after a 3-month blanking period. In 
addition, for the analysis of AF postoperative prevalence, all 
electrocardiograms (ECG) performed at the discretion of referring physicians 
during follow-up in the time comprised between Holter examinations were 
included when patients had at least two records available for analysis. Each 
telemetry record, ECG and Holter was treated as a discrete data 
(presence/absence of atrial fibrillation). A total of 392 postoperative Holter/ 
ECG data were retrieved. 
Thirteen patients (46.4%) reached 36-month follow up, 11 (39.3 %) reached 24-
month and 4 (14.3%) 12-month follow up. Thus, patients available at follow up 
at 12, 24 and 36 months were 28, 24 and 13, respectively. Mean Follow-up time 
was 27.8 ± 8.6 months. All patients were followed-up according the Heart 
Rhythm Society/ European Heart Rhythm Association/ European Cardiac 
Arrhythmia Society (HRS/EHRA/ECA) expert consensus statement on catheter 
and surgical ablation of AF
12
. Data and outcomes were reported following the 
Society of Thoracic Surgeon (STS) guidelines
9
. 
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Anticoagulation and Anti-arrhythmic Therapy 
Anti-arrhythmic drugs were given postoperatively to all patients but, although 
we recommend discontinuing anti-arrhythmic drugs 3 months after ablation if 
the patients appears to be AF free, continued use is at the discretion of the 
referring cardiologists. 
Electrical cardioversion was not attempted for patients who remained in AF 
after the surgical procedure and was reserved for patients who were still in AF 
after 3 and 6 months. 
Warfarin was administered on postoperative day I with INR target of 2.5.and 
stopped after 3 months if two following Holter recordings showed a SR or 
patients had a low thromboembolic risk and a CHADS2 [cardiac failure, 
hypertension, age, diabetes, stroke (doubled)] score <2 
12
. 
Echocardiography 
Patients underwent an echocardiography control at follow-up appointments. 
Measurements were carried out following accepted Guidelines
13
. Left 
ventricular volume and LV ejection fraction (LVEF) were assessed by the bi-
apical Simpson disk method
14
. Echocardiographic measurements were averaged 
over three cardiac cycles. 
Surgery 
Indication for surgery was based on the HRS/EHRA/ECA Guidelines
15
. The 
interventions were performed under general anesthesia with a double-lumen 
endotracheal tube for selective lung ventilation. All operations were performed 
by the same cardiac surgeon (M.L.M). 
The chest was entered in the second, fourth and sixth interspaces using 
respectively a 5-12-12mm port. Thoracoscopy of the right side was done first 
and was then followed by the left side. The pericardium was opened anterior to 
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the phrenic nerve on the right and posterior to the phrenic nerve on the left. The 
technique was as originally described by Yilmaz et al
16
.  
The rhythm was determined by placing a bipolar pen probe (Atricure Inc, 
Westchester, Ohio, USA) on the left atrium, and recordings were made with a 
physiological recorder
17
. 
Autonomic ganglia were identified by high-frequency stimulation to detect a 
vagal response at 20 predetermined epicardial sites around the pulmonary vein 
antra. Ganglionated plexi (GP) mapping was performed by placing the bipolar 
pen at each site and stimulating with an 18-mV, 1.5-ms pulse width impulse at 
1000 pulses per minute from a temporary external pacemaker. A positive 
response to GP stimulation was defined as prolongation of the RR interval by 
≥50%. 
Ablation of the right and left PVs was performed using a bipolar 
radiofrequency clamp (Atricure, Westchester, OH, USA). With the clamp 
placed on the antrum of the pulmonary veins, 3 to 6 ablations were performed 
(mean 3.8± 0.9). The end point for pulmonary vein ablation was entrance and 
exit block into and from the pulmonary veins. Entrance block was defined as 
failure to capture the pulmonary veins during pacing from the left atrium at 7.5 
V and 1.5-ms pulse width. Exit block was defined by failure to capture the left 
atrium when pacing from the pulmonary veins distal to the radiofrequency 
lesions at 7.5 V and 1.5-ms pulse width. A proprietary algorithm terminated 
radiofrequency energy (maximum, 28 W) after impedance changes indicated 
transmural injury. GPs were mapped before and after ablation of the pulmonary 
venous antrum. Bipolar radiofrequency energy at 15 W was delivered through 
the bipolar pen at sites demonstrating a vagal response. The end point for GP 
ablation was the elimination of a vagal response to stimulation. 
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Connecting lesions, the roof and inferior lines, were created using the Coolrail 
and/or the Max5 Pen (Coolrail, Atricure  Inc, Westchester, Ohio, USA).The 
lesions were tested after completion of both lines by pacing inside the isolated 
posterior left atrium and confirming exit block. 
The ligament of Marshall was ablated with radiofrequency energy or cauterized 
proximally and distally and then ablated with radiofrequency energy. LAA 
exclusion/ closure was performed under transesophageal echocardiographic 
(TEE) guidance in patients with CHADS2 score ≥1, and when it was deemed 
safe. Indeed, the left atrial appendage (LAA) was excised in 7 patients (25%) 
employing a stapler (Endo GIA, Covidien, Norwalk, CT) or, in 7 patients 
(25%) the base of the LAA  was closed employing a clip (Atricure, West 
Chester, OH). The absence of flow was confirmed by intraoperative 
transesophageal echocardiography. 
The lesion set is shown in Table 2.  
An inferior vena cava (IVC)-to-superior vena cava (SVC) lesion was added 
when patients had a right atrial volume higher than normal (58 ml) and were 
persistent or longstanding persistent. 
An IVC circumferential isolation was performed in two cases (7.1%) to be sure 
that the SVC - IVC line would stop at an area of no conduction – this for 
patients with a small portion of intra-pericardial IVC. A SVC circumferential 
isolation was carried out in three cases (10.7%). The isolation of the SVC and 
the IVC was confirmed by testing of the conduction block across the ablation 
line. The completeness of the SVC/IVC line could not be tested in the operating 
room because of the technical difficulty of proving this without using 
multipolar electrophysiology (EP) catheters and EP analyzing equipment. 
Mean operation time was 127 minutes ( range 102 to 174 minutes). 
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Data Analysis 
Parametric value was expressed as mean ± 1 standard deviation (SD), non 
parametric value as median and interquartile range (IQR) and categorical 
variables as percentages. Normally distributed variables were compared with 
paired-t test, non-parametric data were compared with Wilcoxon test while 
McNemar’s test was employed to compare paired categorical data. 
Because there is no practical method for continuous lifelong heart rhythm 
assessment, and self-reported AF underestimates its occurrence
18
, we report 
prevalence AF which was depicted versus time based on discrete Holter and 
ECG recordings as suggested by STS Guidelines
9 
.We analyzed all of the 
intermittent data available in terms of time-related prevalence of atrial 
fibrillation with a multiphase hazard decomposition method
19
. Non-time-related 
event data and time-related prevalences are presented as percentages with 
asymmetric 68% confidence limits (CLs), comparable to ±1 standard error. The 
CLs for AF prevalence were obtained with the bootstrap percentile method
20
.  
Analyses of prevalence of AF do not account for anti-arrhythmic medications. 
Prevalence of anti-arrhythmic medication use was estimated by mixed 
modelling based on medication use at each follow-up assessment
21
.With the 
same method we estimated the prevalence of Warfarin use at time of each 
follow-up. Finally, the use of electrical cardioversion was analyzed as repeated 
event and is presented as cumulative incidence (events per patient) 
21
.
 
Statistical analyses were performed using SPSS release 12.0 (SPSS, Chicago, 
IL, USA) and Curve Expert Professional release1.0.1 (D.G. Hyams, 
Chattanooga, TN, USA). 
P values less than 0.05 were considered significant. 
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Results 
There was no pulmonary vein injury, mortality, stroke or reoperation for 
bleeding All the procedures could be completed as  planned without any 
conversion to sternotomy, There were no requirement for blood transfusion. 
Median Intensive care unit (ICU) stay was 6.7 hours (IQR 4.3-13.9) and the 
median in-hospital length of stay was 8 days (IQR 6-9). 
Time-related prevalence of postoperative AF peaked at 33.0 % (30.7-36.9) at 
two weeks, it was 24.1% (21.7-28.3) at one month, fell to 6.2 % (11.6-18.1) at 
3 months, 6.0% (3.2-9.6) at 12 months, 5.0 (2.9-8.2) at 24 months and 4.5 % 
(2.2-7.6) at 36 months (Figure 1 A). 
Figure 1 B shows estimated prevalence of postoperative atrial fibrillation by AF 
type. In patients with long-standing persistent AF  it peaked at 47.8 % (44.7-
51.2) at two weeks, it was 42.2 % (39.7-45.4) at one month, 29.2 % (26.4-33.6) 
at 3 months, 14.9% (11.6-18.3) at 12 months, and it fell to 91.% (6.2-12.5) at 
24 months and  to 8.3 % (5.7-10.9) at 36 months (at any interval, p<0.001 vs. 
preoperative AF prevalence).In Persistent and paroxysmal LAF, postoperative 
AF time-related prevalence  peaked at 1 week at 11.3% (8.3-13.1) and 5.3 % ( 
2.8-6.1), respectively. In both groups it and it fell to 0% thereafter (p<0.001 vs. 
preoperative prevalence). 
At 36 months the estimated prevalence of anti-arrhythmic drugs was 11.3% 
(8.8-13.7). No major thromboembolic events were detected during the follow 
up period and 36-month prevalence of Warfarin use was 15 .2 % (11.5-18.1). 
Finally, no patient underwent electrical cardioversion (cumulative incidence, 
0/patient). 
The echocardiographic control showed a significant reduction in left atrial (LA) 
size (41.6 ±5.7 mm vs. 37.7 ± 7.1 mm, p=0.04), LA volume (68.28 ±20.5 ml vs. 
144
46.06 ±14.6 ml, p=0.007), right atrial (RA) size (60.2  ± 18.7 mm vs. 45.3 
±18.9 mm, p<0.001) and an increment in left ventricular ejection fraction (52.5 
±5.1% vs. 63.2 ±43, p=0.009). 
 
Comments 
In the last few years the number of patients with lone AF considered as 
candidates for a stand-alone surgical procedure has been increasing. Minimally 
invasive  video-assisted thoracoscopic surgical techniques, which enables 
surgical treatment of AF through an epicardial approach on a beating heart, 
have been recently introduced. 
The MAZE procedure yielded excellent results
22,23
, but the acceptance of this 
technique for patients with LAF has not been universal because of its invasive 
nature. Furthermore, percutaneous ablation techniques, which have become the 
second line strategy for patients with lone AF, have certain disadvantages. 
Major complications such as pulmonary vein stenosis, thromboembolism, and 
atrio-esophageal fistula have been reported in more than 6% of cases, and the  
need for a second or third procedure is not uncommon
24,25
. Moreover, a 
worldwide survey on the methods, efficacy and safety of catheter ablation in 
AF ,published in 2005
26
 and updated in 2010
27
,  showed that the success rate 
without anti-arrhythmic drugs was 75% for paroxysmal AF, 65% for persistent 
and 63% for permanent AF.  
The minimally invasive approach can be a monolateral
6-8
or bilateral
28,29
 
depending on the surgeons’ preference as well as the ablation devices chosen. 
A single-sided approach is less traumatic but only monopolar devices will be 
used and, due to the properties of these devices on the beating heart, only a 
significant delay can be obtained and not a bi-directional conduction block. In 
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contrast, bipolar radiofrequency clamps guarantee transmural and continuous 
lesions, and the bipolar approach allows the surgeon to exclude/close the left 
atrial appendage. On the other hand, the procedure is more invasive and it 
increases the possibility of  complications (bleeding, phrenic nerve lesion, 
pulmonary complications).  
The current literature is extremely difficult to interpret. This confusion is 
compounded by a lack of consensus on methods and timing of follow-up 
evaluation as well as the absence of strict definitions of success. 
The Workforce on Evidence-Based Surgery of the Society of Thoracic 
Surgeons
9
 proposed an approach to report success/failure. They suggested 
analyzing all the intermittent data available in terms of time-related prevalence 
(burden) of atrial fibrillation.  
In the present study we report our results with minimally invasive surgical 
treatment of LAF employing a radiofrequency (RF) source through a bilateral 
thoracoscopy in terms of time related prevalence of postoperative AF. Adopting 
this method, time-related prevalence of postoperative AF after bilateral 
minimally invasive RF ablation was, in our experience, 4.5 % at 36 months. 
Success was much more likely in subjects with paroxysmal (3-year prevalence, 
0%) or persistent (3-year prevalence, 0%) than long-standing persistent LAF 
(3-year prevalence, 8.3%). 
These results compare favorably with data reported in the literature, although 
these were obtained with different methods. Indeed, excluding case reports, 
success expressed as number/percentage of patients in sinus rhythm after video-
assisted radiofrequency bilateral pulmonary vein isolation ranged from 72 % to 
90% with a maximum follow up of 18.1±4.1 months
30-35
. In two recently 
published papers, Yilmaz and coworkers
36
 (30 pts.) and Sirak et al
8
 (48 pats.) 
reported 12-month freedom from AF of 77% and 94%, respectively. 
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MacClelland and coworkers
31
 reported, at a mean follow-up of 20.6±4 months, 
a success rate of 91%, 80% and 25% , in subjects with  paroxysmal , persistent 
and long-persistent AF, respectively.  
Analysis of prevalence of AF did not account for anti-arrhythmic medications 
used. Prevalence of anti-arrhythmics was reported separately. This figure was, 
in our experience, 11.3% at 36 months. The comparison with published data is 
problematic. Our figures are in keeping with those published in the literature in 
which the number of patients taking anti-arrhythmic drugs after bilateral 
thoracoscopic radiofrequency AF ablation ranges from 7.4 % to  40 %
30-39
.  
This procedure demonstrated, in our experience, a high degree of safety with no 
major complications and no major thrombo-embolic events detected during the 
follow up period. 
Furthermore, the 36-month estimated prevalence of Warfarin use was very low 
(15%)  in comparison with published data
24,30,31,33
. In addition, no patient 
underwent electrical cardioversion and, at latest follow up, the left atrial 
volume was reduced by 32.5% , the left atrial size by 9.3% and the right atrial 
size by 24.5%. Finally, patients showed an increment in LVEF by 16.9% from 
the baseline value. 
 
Limitations of the Study 
This study has several limitations which have to be pointed out. First of all, the 
patient population is small and the follow up interval is short. Larger series, 
with long-term follow up and comparing different energy sources, are needed to 
identify the ideal approach  for minimally invasive LAF surgical ablation. 
Furthermore, 50% of patients in our cohort had paroxysmal AF and this might 
have influenced our favorable results.  
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To overcome this limitation, we analyzed  AF prevalences in paroxysmal, 
persistent   and  long-persistent  patients and compared pre-procedural and post-
procedural AF prevalence by AF type. 
Larger studies will help to establish whether the bilateral approach and the 
advantage of removing the LA appendage outweighs the clear advantages of a 
less traumatic monolateral approach which may be combined with the 
endocardial ablation in the so called hybrid procedures. The comparison of 
these results with those of patients using a monopolar radiofrequency clamp 
and those undergoing hybrid approach will be the subject of ongoing studies.  
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Figure 1.A.Time-related prevalence of Atrial Fibrillation. B. Time-related 
prevalence of Atrial Fibrillation by AF type  .Observations available at each 
interval (1year, n=172; 2 years: n=274; 3 years: n=392) 
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Figure 2. A. Time-related prevalence of class I/III anti-arrhythmic use. B. 
Time-related prevalence of Warfarin use. 
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Data are presented as mean ± 1standard deviation or median [Interquartile ranges]. Discrete data are expressed 
as numbers (percentages). Abbreviations: M/F: Male/Female; BMI: Body Mass Index; AF: Atrial fibrillation; 
EHRA: European Heart Rhythm Association; LVEF: Left Ventricular Ejection Fraction.*Reported with 68% 
CI. 
Table 1. Preoperative Data (n=28) 
 
Age 67.1 ± 9.1 
M/F 24/11(85.7/14.3) 
BMI 28.6±3.6 
Diabetes 0(0) 
Hypertension 14(50.0) 
Preoperative catheter ablation 
AF 
Flutter 
 
13(46.4) 
8 (28.5) 
Type of preoperative AF 
Paroxysmal 
Persistent 
Long-standing persistent 
 
14 (50.0) 
    5 (17.8) 
    9 (32.2) 
Prevalence of AF
* 
Paroxysmal 
Persistent 
Long-standing persistent 
 
21.9 {17.8-24.0} 
32.7 {28.9-36.2} 
68.4 {63.6-72.2} 
EHRA Score 3 [3-4] 
Duration of preoperative AF (yrs.) 12.1±3.7 
Antiarrhythmic Drugs 
Amiodaron 
Dysopiramide 
Flecainide 
Propaphenon 
Sotalol 
 
7(25.0) 
2(7.1) 
16 (57.1) 
1 (3.5) 
11(39.2) 
Electrical cardioversion 14 (50.0) 
Medical conversion 9 (32.1) 
Previous Catheter Ablation 
For AF 
For Atrial Flutter 
 
13 (46.4) 
8 (28.5) 
Previous Cardiac Surgery 0(0) 
Previous PTCA 0(0) 
Preoperative Pace Maker 2 (7.1) 
Anticoagulant status 
Sodium Warfarin 
Aspirin 
 
25 (89.2) 
6 (21.4) 
LA diameter 42.2±5.2 
LA Volume 80.9±25.7 
LVEF 
 
60.1±7.1 
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Table 2. LAF Surgery: Lesion Set 
 
Left atrium  
Right PV Isolation 28 (100) 
Left PV Isolation 28 (100) 
Connection inferior PVs 28 (100) 
Connection superior PVs 28 (100) 
Excision of LAA 7 (25) 
Closure of LAA with a clip 7 (25) 
Right atrium  
SVC to IVC lesion 8 (28.5) 
SVC circumferential isolation 3 (10.7) 
IVC circumferential isolation 2 (7.1) 
Autonomic ganglia  
Mapping of autonomic ganglia 28(100) 
Ablation of autonomic Ganglia 28(100) 
Data are presented as number (percentage). Abbreviations: PV: Pulmonary vein; LAA: Left atrial appendage; SVC: 
Superior Vena Cava; SVC: Superior Vena Cava. 
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Chapter 4 
 
The Hybrid Approach for The Surgical Treatment of Lone Atrial Fibrillation: 
One-year Results  Employing a Monopolar Radiofrequency Source. 
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Parise, Francis Wellens, Gian Franco Gensini and Jos Maessen. 
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Abstract 
Background. The hybrid technique combines a mono or bilateral epicardial 
approach with a percutaneous endocardial ablation in a single-step procedure. 
We present our early results with this technique employing a monopolar 
radiofrequency source through a right thoracoscopy in patients with lone atrial 
fibrillation (LAF). 
Methods. Between June 2009 and  December 2010 nineteen consecutive 
patients (mean 60.8 ± 8.6 years, 84.2% male) underwent right unilateral  
minimally invasive hybrid procedure for LAF at our Institution. Ten patients 
(52.6.6%) had long-standing persistent AF while four (21.1%) had persistent 
and five (26.3%) paroxysmal AF. All patients were followed-up according the 
Heart Rhythm Society/ European Heart Rhythm Association/ European Cardiac 
Arrhythmia Society (HRS/EHRA/ECA) and Society of Thoracic Surgeon (STS) 
guidelines . 
Results. There were neither early nor late deaths. It was possible to complete all 
the procedures as planned without any conversion to cardiopulmonary bypass. 
No patient died during the follow up. 
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At one year, 7/19 (36.8 %) patients were in sinus rhythm with no episode of AF 
and off anti-arrhythmic drugs (AAD). Time-related prevalence of postoperative 
AF peaked at 44.4 % (41.3-47.4) at two weeks, was 30.4 % (27.3-34.9) at three 
months, fell to 14.2 % (11.6-18.1) by 6 months and was 13.3 % (11.0-17.4) at 12 
months  Among patients with long-standing persistent (LSP) AF, 20% (2/10) 
were in Sinus rythm and off AAD . One-year success rates were 50 % (2/4) in 
persistent and  60% (3/5) in paroxysmal AF. At 12 months estimated prevalence 
of anti-arrhythmic drugs and Warfarin use were 26% (22.4-33.1) and 48% (37.2-
53.2), respectively.  
Conclusions. One year results combining the percutaneous endocardial with the 
right thoracoscopic epicardial technique were, in our experience, not 
satisfactory, particularly in patients with LSP and persistent AF. Our findings 
need to be confirmed by larger studies. 
 
Background 
Despite being more effective than percutaneous catheter ablation (PCA)
1-3
, the 
MAZE operation failed to achieve widespread application as a stand-alone 
procedure because of  its complexity and invasiveness. Indeed, the Society for 
Thoracic Surgeons (STS) database
4
 reported, in 2007, only 700 MAZE 
operations performed in patients with lone atrial fibrillation (LAF). In addition, 
along with its suboptimal success rates, PCA showed a non-negligible incidence 
of major complications
3
.  
New technologies have allowed the creation of transmural lesions on a beating 
heart through alternative, less invasive incisions
5
. Nonetheless, results reported 
in the literature with these approaches are highly variable
6-8
.  
More recently, a sequential one-step surgical / catheter-based approach has been 
introduced showing satisfactory results in patients with persistent LAF
9
. This so-
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called hybrid procedure combines the advantages of PCA and video-assisted 
thoracoscopic epicardial procedures and it is expected to overcome the 
shortcomings of these techniques
10
.  
As originally described, the hybrid technique employs a bilateral thoracoscopic 
epicardial approach. We have recently introduced a less-invasive hybrid single-
sided approach through a right thoracoscopy and, as far as we know, there are no 
reports in the literature about the effectiveness of this procedure. 
Therefore, we present one-year results with minimally invasive hybrid-right 
thoracoscopic approach employing a monopolar radiofrequency (RF) source for 
the treatment of LAF. 
 
Methods 
Patients 
Ethical Committee approval was waived according to the National law 
regulating observational retrospective studies (Dutch WMO law). However, all 
patients gave their informed consent to access their data for scientific purposes. 
Between January 2008 and June 2010 nineteen consecutive patients underwent 
minimally invasive right-thoracoscopic hybrid ablation of  LAF employing a 
monopolar RF source. LAF was defined as suggested by American College of 
Cardiology/American Heart Association/European Society of Cardiology 
(ACC/AHA/ESC) Guidelines
11
 and updated ESC Guidelines were followed to 
distinguish the type of AF and to score the AF-related symptoms (European 
Heart Rhythm Association [EHRA] score)
12
. Indication for minimally invasive 
surgery was based on the Heart Rhythm Society/ European Heart Rhythm 
Association/European Cardiac Arrhythmia Society ( HRS/EHRA/ECA) 
Guidelines
13
. A trans-thoracic echocardiography (TTE) and a computed 
tomography (CT) scan were carried out preoperatively (pulmonary vein 
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anatomy, coronary arteries) and potential candidates for the hybrid procedure 
underwent a lung function test (spirometry). Exclusion criteria were: 1) Presence 
of left atrial or left appendage thrombus at transesophageal echocardiography 
(TEE); 2) ″Giant″ left atrium (diameter >6.5 cm); 3) Associated coronary artery 
disease; 4) Previous pulmonary or cardiac surgery.  
Patient characteristics are shown in Table 1. 
Follow-up and Assessment of AF 
All patients were followed-up according to Heart Rhythm Society/ European 
Heart Rhythm Association/European Cardiac Arrhythmia Society 
(HRS/EHRA/ECA)
13
. Main outcomes were also reported following the Society 
of Thoracic Surgeon (STS) guidelines
14
. After hospital discharge patients 
underwent 7-day Holter Monitoring (HM) which was repeated at 3 months, 6 
months and 1 year. All patients reached 1-year follow up. Monitoring was 
carried out with an external loop recorder (Del Mar Reynolds, Spacelabs 
Healthcare, Issaquah, WA,USA) and analyzed with Lifescreen Software (Del 
Mar Reynolds, Spacelabs Healthcare, Issaquah, WA, USA). For analysis, three 
rhythms were considered postoperative AF: AF, atrial flutter or atrial 
tachycardia lasting more than 30 sec. In addition, all electrocardiograms (ECG) 
performed at the discretion of referring physicians/cardiologists during the first 
three months after surgery and between Holter examinations were included 
when patients had at least two records available for analysis. Each ECG and 
Holter was treated as discrete data (presence/absence of atrial fibrillation) to 
calculate AF estimated prevalence
14
. A total of 222 postoperative Holter/ ECG 
data were retrieved. 
Echocardiography 
Echocardiography was performed preoperatively and at 3 month- and 12 month- 
follow-up appointments using a commercially available echocardiographic 
system (Philips iE33; Philips Medical Systems, Eindhoven, The Netherlands). 
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All the parameters were analyzed “off-line” by an experienced 
echocardiographer (F.L.) using the Xcelera software (Philips Medical Systems 
Eindhoven, The Netherlands). In the parasternal long-axis views LA maximum 
antero-posterior (A-P) diameter was measured. LA superior-inferior (S-I) 
diameter was measured from the mitral annular plane to the posterior wall 
of the LA in the apical 4-chamber view. In the apical 4-chamber view, LA 
maximum volume (LA max), at the end of LV systole, just before the opening of 
the mitral valve and LA minimum volume (LA min) at the end of LV diastole, 
just after the closure of the mitral valve, were measured
15
. LA emptying fraction 
(LAEF) was calculated as follows: (LA max-LA min /LA max) x 100.  
LA maximum volume was also measured by biplane area-length method
16
 and 
indexed to body surface area (LAVI). LARR was defined as a reduction in 
LAVI ≥15% at late follow up17.  
Anticoagulation and Anti-arrhythmic Therapy 
Anti-arrhythmic drugs (AAD) were given postoperatively to all patients but, 
although we recommend discontinuing anti-arrhythmics 3 months after ablation 
if the patients appears to be AF free, continued use is at the discretion of 
referring cardiologists. Electrical cardioversion was not attempted for patients 
who remained in AF after the surgical procedure and was reserved for patients 
who were still in AF after 6 months. Warfarin was administered on 
postoperative day II with INR target of 2.5 and stopped after 3 months if the 
Holter recording showed a sinus rhythm (SR) or patient had a low thrombo-
embolic risk  and a CHADS2 [cardiac failure, hypertension, age, diabetes, stroke 
(doubled)] score <2. 
Surgical Technique 
The interventions were performed under general anesthesia with a double-lumen 
endotracheal tube for selective lung ventilation. The chest was entered in the 
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second, fourth and sixth interspaces using respectively a 5-12-12mm port. The 
technique was as previously reported
18
. 
High frequency stimulation (HFS) of the right vagal nerve at the level of the 
mediastinum and at the four major ganglionated plexi (GPS, [right superior GP, 
right inferior GP, left superior GP and left inferior GP)] was carried out and the 
vagal response on the atrio-ventricular node was recorded (10V, 1.5-ms pulse 
width impulse at 1000 pulses per minute from a temporary external pacemaker 
[Oscor, Oscor INC., Palm Harbor, FL]). The isolation of pulmonary veins was 
performed with a Cobra® Adhere XL (Estech, Danville, Ca) temperature-
controlled, monopolar radiofrequency system. The temperature was set at 60°C, 
the timing at 120 seconds. The number of ablations performed ranged from 2 to 
4 (mean 2.8± 0.4). The ablation catheter was pushed under the superior caval 
vein (SCV) into the transverse sinus and placed behind the left atrial appendage 
(LAA) encircling the four PVs to create the box-lesion. Before starting the 
ablation, the fat pad in the atrial groove was bluntly dissected to provide a better 
placement of the probe and enhance a higher penetration energy to destroy the 
GPs located inside this fat pad. After creation of the box lesion the vagal 
response at level of GPS was tested again. The endpoint for 
ganglionated plexi (GP) ablation was the elimination of a vagal response to 
stimulation. In all patients this vagal response could no longer be induced with 
HFS, except for the right inferior GP which, being located outside the box lesion 
was not ablated in any patient. 
A left femoral vein puncture was made and a HIS bundle catheter (St Jude 
Medical, Inc, Minnetonka, MN, USA) and a coronary sinus (CS) catheter 
(Medtronic, Inc, Minneapolis, MN, USA) were placed under fluoroscopic 
guidance. Through the right femoral vein, a single trans-septal puncture was 
made using TEE and fluoroscopy and a long sheath 8F (SL0, St. Jude Medical 
Daig Division, Inc., Minnetonka, MN, USA) was advanced into the LA. The 
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patient was heparinzed to keep the activated clotting time >300 seconds. During 
rapid ventricular pacing from the HIS catheter, contrast was injected through the 
long sheath in order to visualize PVs and the LA. PVs were mapped with a 
suitably sized circular mapping catheter (Lasso, Biosense Webster, Inc, 
Diamond. Bar, CA, USA) placed at the ostium of the PVs. 
In all patients epicardial pacing and endocardial recordings were utilized to 
demonstrate entrance and exit block; entrance block was defined as failure to 
capture the PVs during pacing from the left atrium at 18 V and 1.5-ms pulse 
width and the absence of pulmonary vein potentials (PVPs) seen on the Lasso 
catheter. Exit block was defined by failure to capture the left atrium during the 
pacing from the PVs and by failure to capture when pacing from each dipole of 
the Lasso catheter with an output of 10 mA and 2.0 ms pulse width. 
We identified the conduction gaps from the endocardium which were closed 
endocardially with a 3.5 mm tip catheter (ThermoCool, Biosense Webster, Inc., 
Diamond. Bar, CA, USA) through the sheath in the LA. The precise location of 
the linear lesions was visualized with the Cobra® Adhere XL (Estech,Danville, 
Ca) in situ and using fluoroscopy. Gaps in linear lesions were defined as low 
amplitude and fragmented or narrowly split double atrial potentials. 
In case of AF persistence, a left isthmus line was made endocardially from the 
mitral annulus towards the CS employing the ThermoCool catheter 
(ThermoCool, Biosense Webster, Inc., Diamond. Bar, CA, USA) The endpoint 
of ablation of the mitral isthmus was the bidirectional block which was achieved 
when the following criteria were met: 1) proximal-to-distal activation sequence 
along the CS catheter after pacing lateral to the line in the LA appendage; 2) 
Late activation on the opposite side after pacing on the septal side of the line 
through the CS; 3) widely separated local double potentials along the whole 
length of the ablation line. 
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Finally, if the patient had a history of typical right atrial flutter or this 
arrhythmia became apparent during the procedure, we performed a cavo-
tricuspid isthmus line (CTI) endocardially. The endpoint was bidirectional block 
and the presence of widely separated double potentials along the whole 
length of the ablation line. 
Statistical Analysis 
Normal values were expressed as mean ± one standard deviation (SD), non-
normal values as median and interquartile range (IQR) and categorical variables 
as percentages. Student t, Wilcoxon and McNemar’s tests were employed where 
appropriate. We analyzed all the intermittent data available in terms of time-
related prevalence of AF
14
 with a multiphase hazard decomposition method
19
. 
Prevalence of AF was presented as percentage with asymmetric 68% confidence 
obtained with the bootstrap percentile method
20
. 
Analyses of prevalence of AF do not account for anti-arrhythmic medications. 
Prevalence of anti-arrhythmic medication use was estimated by mixed modeling 
based on medication use at each follow-up assessment. With the same method 
we estimated the prevalence of Warfarin use at the time of each follow-up. 
Finally, the use of electrical cardioversion was analyzed as a repeated event and 
is presented as cumulative incidence
21
. 
Statistical analysis was performed using SPSS release 12.0 (SPSS, Chicago, IL, 
USA) and Curve Expert Professional release1.0.1 (D.G. Hyams, Chattanooga, 
TN, USA). P values less than 0.05 were considered significant. 
 
Results 
None of the patients showed entrance and/or exit block after the epicardial 
ablation. Seventeen patients had at least one PV not isolated, which needed an 
endocardial touch-up (Table 2). After completing endocardial PV isolation the 
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entire population had a conduction delay > 200 ms. in the posterior LA but no 
patient had complete block. Three patients (15.7%) underwent mitral isthmus 
line and in all cases a complete block was achieved. A cavo-tricuspid isthmus 
(CTI) line was carried out in two patients (10.5 %) with successful bidirectional 
block. All surgical procedures were completed as planned without any 
conversion to cardiopulmonary bypass. Median operative time was 216 minutes 
(IQR 132-391). There were neither early deaths nor complications during the 
postoperative course. Median Intensive care unit (ICU) stay was 6.9 hours [IQR 
4.0-14.0] and median in-hospital length of stay was 3.6 days [2.7-4.3]. 
No patient died during the follow up. There was a significant improvement in 
median EHRA (European Hear Rhythm Association) score at follow up ( 1[IQR 
1-2], p<0.001 vs. baseline). 
At one year, 7/19 (36.8 %) patients were in sinus rhythm and off -AAD. 
Furthermore, 63.1% (12/19),  patients were free from AF, AFL or AT >30 s but 
still under anti-arrhythmic therapy (p=0.1). 
Time-related prevalence of postoperative AF was 44.4 %(41.3-47.4) at two 
weeks, 30.4 % (27.3-34.9) at three months,14.2 % (11.6-18.1) at 6 months and 
13.3 % (11.0-17.4) at 12 months (Figure 1 A). 
Among patients with long-standing persistent AF, 20% (2/10) were in SR and 
off AAD . One-year success rates were 50 % (2/4) in persistent and  60% (3/5) 
in paroxysmal AF. 
At 12 months the estimated prevalence of anti-arrhythmic drugs (Figure 2 A) 
was 26% (22.4-33.1). AAD-prevalences by AF type were 38.1 % (34.3-43.4) for 
long-standing persistent, 26.3 % (22.2-30.7) for  persistent and 14.9% (9.9-17.8) 
for paroxysmal AF. 
Finally, time-related prevalence of Warfarin (Figure 2 B) at 1 year was 48.2% 
(44.2-52.2). This figure was 52.5% (48.8-55.2) in long-standing persistent, 
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35.3% (32.5-39.2) in persistent and 19.4% (16.3-23.3) in paroxysmal AF. The 
cumulative incidence of electrical cardioversion was 0.05/patient.  
LA Function and Remodeling 
Table 3 shows postoperative echocardiographic data. At 3 month- follow-up 
biplane LAVI was reduced by 16% (p=0.05). It further decreased but not 
significantly at 1 year (p=0.09). Based on the cut-off value (≥15% reduction in 
LAVI) LARR occurred in 47.3 % (n=9) of patients. LAEF increased not 
significantly at 3 month- (p=0.6) and at 12-month- (p=0.56) controls. Finally, 
LA diameters decreased significantly at 3 months (LA A-P, p=0.02; LA S-I 
p=0.03) whereas at one year there was a further reduction which did not reach 
statistical significance (LA A-P, p=0.73; LA S-I p=0.81). 
 
Discussion 
Minimally invasive surgical epicardial thoracoscopic approaches have gained a 
growing popularity but data regarding their efficacy are controversial
6-9, 22-25
. 
The hybrid approach combines, in one step, a thoracoscopic epicardial ablation 
with a PCA procedure
9,26
.The surgeon, through a thoracoscopy, can isolate the 
pulmonary veins and the posterior wall of the LA whereas the endocardial 
“step” offers the possibility of evaluating the endpoints of the ablation and it 
gives the opportunity to add an endocardial “touch-up” in case of incomplete 
epicardial PVs isolation. In addition, the electrophysiologist (EP) can make 
lesions in regions which cannot be reached epicardially. Moreover, this 
technique may potentially decrease the complication rate of both surgical and 
catheter ablation procedures. Indeed, from the point of view of the surgeon, the 
risk of post-operative arrhythmias is reduced since ablation lines and lesion set 
can be controlled endocardially and the risk of injury is lower, since the EP can 
make lesions in areas which cannot be easily reached by the surgeon. 
171
 
 
  
On the other hand, from the EP point of view, there is no risk of phrenic nerve 
and esophageal injury because these structures can be protected by the surgeon 
and the possibility of tamponade is low since the pericardium is open. 
Furthermore, by reducing the total number of endocardial ablations the risk of 
embolism is potentially reduced
27
. 
We present our one-year results with minimally invasive hybrid-right 
thoracoscopic approach employing a monopolar radiofrequency (RF) source for 
the treatment of LAF. Little information exists in the literature about the hybrid 
technique
10, 29
 and, to the best of our knowledge, no data exist on the right 
monolateral monopolar hybrid approach. 
The monolateral right-thoracoscopic approach could theoretically reduce the 
rates of complications (bleeding, pulmonary complications) and significantly 
shorten patients' recovery time. Nonetheless, only monopolar devices can be 
used through the right-thoracoscopy because of the lack of maneuverability of 
bipolar clamps (which can hamper the orientation of the probe and constrain the 
variety of achievable lesion sets when employed from the right side), but many 
concerns have been raised regarding the ability of monopolar devices to create 
transmural lesion with bidirectional conduction block on the beating heart
28
.  
This technique demonstrated, in our experience, a high degree of safety with no 
major complications and no major thrombo-embolic events detected during the 
follow up period. 
Nonetheless, at one year only 36.8 %(7/19) patients were in SR and off AAD. 
Among patients with long-standing persistent AF, 20% (2/10) were in SR and 
off AAD .One-year success rates were 50 % (2/4) in persistent and  60% (3/5) in 
paroxysmal AF. Furthermore, at 12 months, the estimated prevalence of anti-
arrhythmic drugs  was 26% (38.1 % in LSP, 26.3 %in persistent and 14.9% in 
paroxysmal AF). The incidence of patients without recurrent AF but with AAD 
was not significantly lower compared with patients off-AAD (p=0.1)  although 
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this data must be interpreted taking into account the small number of patients in 
the study. Therefore, this limitation does not allow us to draw any conclusion 
about the role of AAD in the development of AF recurrence following 
minimally invasive surgery. 
However, the success rate, in this series, was lower than published papers 
employing monopolar devices
30
  and it might be explained by the high number 
of  patients with long-standing persistent (LSP) and persistent  AF which 
represent 73.6% of our cohort. Indeed, LSP and persistent AF may be 
considered to be advanced stages of the arrhythmia characterized by significant 
changes in the atrial tissue and muscle (substrate modification) that leads to 
chaotic electrical activity. Thus, these patients might need more areas in the 
heart ablated than in the monolateral approach and they might benefit much 
more from procedures which increase the likelihood that ablation lines are 
transmural although this aspect may be addressed by the EP who can complete 
any line by focused endocardial applications. Indeed, in our experience, the 
incidence of incomplete, non trans-mural gap lesions was high, none of the 
patients showed entrance and/or exit block after the epicardial ablation and ,after 
completing PV isolation endocardially, all patients had a conduction delay > 200 
ms. in the posterior LA but no patient had complete block. 
With this current knowledge we have stopped using monopolar devices for the 
surgical treatment of AF, even for patients where a monolateral approach may 
have a potential advantage i.e. in case of reduced pulmonary function. In these 
patients we now perform a monolateral approach from the right or left side, 
depending on the wish to close the LAA, using bipolar devices
10
 and isolating 
the opposed PVs endocardially with RF energy.  
Finally, at latest follow up only 47.3% of patients experienced LARR and there 
was no significant improvement in LAVI and LAEF. Due to the small number 
of patients, we could not compare echocardiographic data by AF type. However, 
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again, the high percentage of subjects with LSP or persistent AF reflects a 
greater extent of substrate modifications and atrial structural remodeling and this 
could explain the lack of LARR. Indeed, all five patients with paroxysmal AF 
showed a ≥15% decrease in LAVI. 
 
Limitations of the Study 
This study has some limitations which have to be pointed out. The small patient 
population and the short follow-up do not allow us to draw definite conclusions . 
Larger series with long-term follow up are needed. 
Second, only a small number of patients in this series underwent right-sided and 
isthmus lesions and this might have influenced the results.  
Third, our study did not compare the hybrid right thoracoscopic approach with 
the hybrid  bilateral thoracoscopic approach to evaluate the real impact of these 
different techniques on outcome of LAF patients and to evaluate whether the 
excision of the LAA, besides the management for prevention of thrombo-
embolic events, might have a contribute to different rhythm outcome. 
Furthermore we did not compare PCA with surgical thoracoscopic approaches. 
However, all these aspects will be the subjects of ongoing studies. 
Fourth, while data regarding postoperative AF prevalence were obtained from a 
large number of observations and this allowed us to compare prevalence by AF 
type, we could not evaluate LAVI, LAEF and LA diameters in any subgroup of 
patients. 
Finally, atrial function was studied employing only the emptying fraction and 
neither pulsed-wave Doppler nor Tissue Doppler Imaging (TDI) nor LA strain 
were employed, which would have given more detailed information about LA 
function after AF surgical ablation. All these aspects deserve further 
investigations. 
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Conclusions 
One year results combining the percutaneous endocardial with the right 
thoracoscopic epicardial technique were, in our experience, not satisfactory , 
particularly in patients with LSP and persistent AF. This approach might still be 
considered a possible alternative to PCA  in selected patients with  paroxysmal 
lone atrial fibrillation and impaired pulmonary function referred to surgery when 
the LAA excision/ligation is not deemed necessary. Our findings need to be 
confirmed by larger studies. 
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List of Abbreviations 
LAF: Lone Atria Fibrillation 
PCA: Percutaneous Catheter Ablation 
RF: Radiofrequency 
LSP: Long-standing persistent 
EHRA score: European Heart Rhythm Society score 
SCV: Superior caval vein 
ICV: Inferior Caval Vein 
LAA: Left Atrial Appendage 
GP: Ganglionated plexi 
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PVs: Pulmonary Veins 
CTI: Cavo-tricusoid isthmus (lesions) 
CS: Coronary sinus 
SR: Sinus Rhythm 
EP: Electrophysuologist 
LARR: Left Atrial Reverse Remodeling 
LAVI: (Biplane) Left atrial volume index 
 LAMax: Maximum left atrial volume 
LAMin: minimum left atrial volume 
 LAEF : Left atrial emptying fraction 
 LA A-P: Left atrial antero-posterior diameter 
LA S-I: Left atrial antero-posterior diameter. 
IQR: Interquartile Range 
TEE: Transesophageal Echocardiography 
TTE: Transthoracic echocardiography 
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Figure Legends 
 
 
 
Figure 1A.Time-related prevalence of Atrial Fibrillation after hybrid procedure. B. 
Time-related prevalence of Atrial Fibrillation by AF type. 
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Figure 2A. Prevalence of class I/III anti-arrhythmic use after hybrid procedure. B. 
Prevalence of Warfarin use hybrid procedure. 
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Normal data were presented as mean ±1 Standard deviation (SD), non parametric data as 
Median and [Interquartile Range]and discrete data as percentage (%).  
Abbreviations: M/F: Male/Female; BMI: Body mass index; AF: Atrial fibrillation; CI: 
Confidence Interval; EHRA: European Hear Rhythm Association; LAVI: (Biplane) Left 
Atrial Volume Index; LAMAX: Maximum Left Atrial Volume; LAMIN: Minimum Left Atrial 
Volume; LAEF: Left Atrial emptying Fraction; LA A-P: Left Atrial Antero-Posterior 
Diameter; LA S-I : Left Atrial Superior-Inferior diameter. 
Table 1. Baseline Patient Characteristics (n=19). 
 
Age 61.2 ± 8.6 
M/F 16/3 (84.2/15.8) 
BMI 27.6 ± 4.6 
Hypertension 7(36.8) 
TIA/CVA 1(5.2) 
Preoperative catheter ablation 
AF 
Flutter 
 
4(21.1) 
5(26.3) 
Type of preoperative AF 
Paroxysmal 
Persistent 
Long-standing persistent 
 
5 (26.3) 
4 (21.1) 
10(52.6) 
Prevalence of AF (68% CI) 
Paroxysmal 
Persistent 
Long-standing persistent 
 
20.0 (16.8-23.3) 
34.7 (31.2-38.9) 
63.6 (59.9-67.1) 
 
EHRA Score 4 [3-4] 
Duration of preoperative AF (yrs.) 5 [3-8.5] 
Antyarrhythmic Drugs 
Amiodaron 
Dysopiramide 
Flecainide 
Propaphenon 
Sotalol 
 
2 (10.5) 
1(5.3) 
6 (31.5) 
1(5.3) 
5 (26.3) 
Electrical cardioversion 15 (78.9) 
Previous Catheter Ablation 
For AF 
For Atrial Flutter 
 
6 (31.5) 
5 (26.3) 
Preoperative Pacemaker 2(10.5) 
Anticoagulant status 
Sodium Warfarin 
Aspirin 
 
16 (84.2) 
5 (26.3) 
LAVI (mL/m
2
) 47±11 
LAMAX (mL/m
2
) 49±20 
LAMIN (mL/m
2
) 30±15 
LAEF (%) 38±12 
LA A-P (cm) 5.0±0.5 
LA S-I (cm) 6.4±0.5 
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       Abbreviations. PVs: Pulmonary Veins; 
 
 
 
Table 2. Lesions Set  
Left atrium  
Right PVs Isolation 19 (100) 
Left PVs Isolation 19 (100) 
Inferior line 19 (100) 
Roof line 19 (100) 
Isthmus lesion 3 (15.7) 
Endocardial gaps closure 17 (88.4) 
Right atrium  
Cavo-tricuspid isthmus line 2 (10.5) 
Ablation of autonomic Ganglia 19 (100) 
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Normal data were presented as mean ±1 Standard deviation (SD).*Significance vs. Baseline. 
Abbreviations: LAVI: (Biplane) Left atrial volume index; LAMax: Maximum left atrial volume; 
LAMin: minimum left atrial volume; LAEF : Left atrial emptying fraction; LA A-P: Left atrial 
antero-posterior diameter; LA S-I: Left atrial antero-posterior diameter. 
 
Table 3. LA remodeling 
 
LAVI (mL/m
2
)  
3 months 45 ±10 
12 months 40 ±11 
                                                      p 0.09 
LAMax(mL/m
2
)  
3 months 46 ±15 
12 months 45 ±13 
                                                      p 0.7 
LAMin(mL/m
2
)  
3 months 27 ±10 
12 months 25 ±8 
                                                      p 0.86 
LAEF (%)  
3 months 41 ±14 
12 months 43 ±14 
                                                      p 0.56 
LA A-P (cm)  
3 months 3.9 ± 0.4 
12 months 3.7 ±0.4  
                                                      p 0.73 
LA S-I (cm)  
3 months 5.9 ± 0.6 
12 months 5.8 ± 0.6 
                                                      p 
 
0.81 
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Chapter 5 
 
Hybrid Thoracoscopic Surgical and Transvenous Catheter Ablation of Atrial 
Fibrillation. 
 
Laurent Pison, Mark La Meir, Jurren van Opstal, Yuri Blaauw, Jos Maessen and Harry J. 
Crijns. 
J Am Coll Cardiol. 2012 Jul 3;60(1):54-61. 
Abstract 
Objectives. The purpose of this study was to evaluate the feasibility, safety, and 
clinical outcome up to 1 year for patients undergoing a combined simultaneous 
thoracoscopic surgical and transvenous catheter atrial fibrillation (AF) ablation . 
Background. The combination of the transvenous endocardial approach with 
the thoracoscopic epicardial approach in a single AF ablation procedure, 
overcomes the limitations of both techniques and should result in better 
outcomes. 
Methods. We followed a cohort of 26 consecutive patients with AF who 
underwent a hybrid thoracoscopic surgical and transvenous catheter ablation 
(CA) with a follow-up of up to 1 year. 
Results. Twenty-six patients (42% persistent AF) underwent a successful hybrid 
procedure. There were no complications. Mean follow-up was 470±154 days. In 
23% of the patients, the epicardial lesions were not transmural and endocardial 
touch-up was necessary. One-year success defined according to the Heart 
Rhythm Society/European Heart Rhythm Association/European Cardiac 
Arrhythmia Society consensus statement for the catheter and surgical ablation of 
AF, was 93% for patients with paroxysmal AF and 90% for patients with 
persistent AF. Two patients underwent CA for recurrent AF or left atrial flutter 
after the hybrid procedure.  
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Conclusions. A combined transvenous endocardial and thoracoscopic epicardial 
ablation procedure for AF, is a feasible and safe procedure with a single-
procedure success rate of 83% at 1 year. 
 
Introduction 
In paroxysmal atrial fibrillation (AF), success rates of catheter ablation (CA) 
exceed 80% and recurrence is mostly associated with pulmonary vein (PV) 
reconnection (1,2). By combining PV isolation, complex and fractionated atrial 
electrogram ablation, and linear lesions in persistent AF patients, success rates 
without anti-arrhythmic drug (AAD) surpass 70% (3,4). However, multiple 
procedures are often necessary and creating linear lesions is sometimes 
challenging.  
Surgical AF ablation has evolved from the original Cox-maze procedure towards 
a minimally invasive video-assisted procedure with new ablation tools to isolate 
the PVs and create linear lesions without opening the heart (5).
 
Nevertheless, 
even bipolar radiofrequency (RF) energy cannot guarantee transmural lesions 
(6).
 
Linear lesions like the mitral isthmus, cannot be created solely from the 
epicardium, and proving bidirectional block epicardially, can be challenging (7).  
Combining a transvenous endocardial and thoracoscopic epicardial approach in 
a single procedure, overcomes these shortcomings. 
We report our initial experience with long term follow-up of minimally invasive 
epicardial bilateral PV isolation and linear lesions in combination with 
endocardial proof of conduction block and endocardial touch-up if indicated. 
 
Methods 
Patient Selection 
Twenty-six consecutive patients with symptomatic AF underwent a hybrid 
thoracoscopic surgical and transvenous CA with a follow-up of 1 year. 
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Definitions of paroxysmal/persistent/longstanding persistent AF, success and 
failure of ablation, and follow-up monitoring were based on the Heart Rhythm 
Society/European Heart Rhythm Association/European Cardiac Arrhythmia 
Society consensus statement (3).
 
Patients had failed at least 1 AAD. Other 
selection criteria were previously failed CA, left atrium (LA) volume ≥ 29ml/m2, 
persistent or longstanding persistent AF, or patient preference for a hybrid 
procedure instead of a percutaneous approach. Eleven patients (44%) had a prior 
CA for AF or atrial flutter (AFL). All patients underwent transthoracic 
echocardiography, cardiac computed tomography, and pulmonary function test  
preoperatively.  
Hybrid procedure 
The procedure was performed under general anesthesia with double-lumen 
endotracheal tube placement for selective lung ventilation. Transoesophageal 
echocardiography was used to exclude a thrombus in the LA. On the right side, a 
12 mm  cameraport was placed in the 5th intercostal space mid axillary line and 
in the 6th or 7th intercostal space anterior axillary line. A 5 mm workingport 
was placed in the 3rd intercostal space anterior axillary line. The pericardium 
was opened anterior to the phrenic nerve. Blunt dissection was used to open the 
transverse and oblique sinuses.   
Via femoral venous approach, a His bundle (St. Jude Medical, St. Paul, MN, 
USA) and coronary sinus catheter (Medtronic, Minneapolis, MN, USA) were 
placed under fluoroscopy and transseptal puncture was performed with a long 
sheath 8F (SL0, St. Jude Medical, St. Paul, MN, USA) into the LA. We then 
heparinised the patient (1000 units of heparin per 10 kilograms bodyweight and 
a heparin infusion) with activated clotting time above 300 seconds. During rapid 
ventricular pacing, we injected contrast through the long sheath to visualize LA 
anatomy. The PVs were mapped with a circular mapping catheter (Lasso, 
Biosense Webster, Diamond Bar, USA). Antral isolation of the right PVs as 
pair, was performed with 4 to 6 applications using a bipolar RF clamp (Atricure, 
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West Chester, OH, USA) (Figure 1). Each application had a duration of about 15 
seconds with a median output of 10 to 15 Watt. The same port incisions were 
made on the left side but placed more posteriorly (Figure 2). The pericardium 
was divided posterior to the phrenic nerve.  Left PV isolation was conducted as 
described above. We did not attempt ablation of the ganglionated plexi. 
In patients with severe chronic obstructive pulmonary disease , we performed a 
thoracoscopic epicardial isolation of the PVs only on the right and the left PVs 
were isolated using a cryothermal energy balloon catheter (Arctic Front, 
Cryocath, Montreal, Quebec, Canada) endocardially to avoid bilateral sequential 
lung deflation. 
The endpoint for PV ablation, was entrance and exit block. We defined exit 
block as local capture in the PV during pacing from the Lasso catheter (output 
10mA, pulse width 2 ms) without conduction to the LA. In the case of sinus 
rhythm after PV isolation, reinduction of AF was attempted 5 times by pacing in 
the coronary sinus for 10 seconds at the shortest cycle length resulting in 1:1 
atrial capture. AF was considered inducible if it lasted more than 1 minute. If AF 
became noninducible, isoproterenol was infused at rates of 10 to 30 µg/min. If 
AF had not terminated or still was inducible, linear lesions were deployed. 
A roof line (connecting both superior PVs) and inferior line (connecting both 
inferior PVs) were made epicardially using a bipolar RF pen or linear pen device 
(Isolater Pen and Coolrail, Atricure, West Chester, OH, USA). If the right 
atrium was dilated, two additional ablation lines were placed: one encircling the 
superior caval vein using the clamp, the other connecting both caval veins using 
the pen.  
By making a roof and inferior line, we isolated the posterior LA (box lesion). If 
entrance and exit block were not reached, we identified the conduction gaps 
endocardially and ablated those with a 3.5-mm-tip catheter (ThermoCool, 
Biosense Webster, Diamond Bar, USA). The location of the linear lesions was 
visualised with the linear pen device in situ and using fluoroscopy.  
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A left isthmus line was made in 3 patients using the bipolar RF pen device. The 
line was started from the ablation line on the antrum of the left inferior PV 
towards and crossing the coronary sinus. All patients needed an endocardial 
touch-up ablation to reach bidirectional block, starting from the mitral annulus 
towards or inside the coronary sinus. If the patient was known with typical AFL 
or if this arrhythmia occured during the procedure, the cavotricuspid isthmus 
(CTI) was ablated endocardially. The endpoint was bidirectional block. In 7 
patients the LA appendage was removed using a stapling device. 
The pericardium was approximated with a stitch, and a chest tube was placed in 
both pleural cavities. There was no drain left in the pericardial space.  
Low molecular weight heparins were started six hours after the procedure and 
on the second postoperative day, acenocoumarol was reinitiated. 
Patients restarted as soon as possible their pre-operative AAD regimen. 
Acenocoumarol and AADs were discontinued after the 6-month monitor 
confirmed the absence of atrial arrhythmia.  
Long-Term Follow-Up 
Any symptomatic patient not in sinus rhythm was cardioverted before the 3-
month follow-up visit. One patient had a pacemaker, which was used for 
monitoring. The remaining patients underwent 7-days continuous Holter 
monitoring at 3, 6, 9, and 12 months. If 7-days Holter was not available, the 
patients underwent at least 24 hours Holter monitoring. According to current 
guidelines, success was defined as no episode of AF, AFL, or any atrial 
tachycardia (AT) lasting more than 30 seconds off AAD after the three months 
blanking period. 
Statistics 
Data were retrospectively entered into a database. Statistical analysis was 
performed using SPSS 16.0. Continuous variables are summarized with means 
and standard deviations. Outcome is displayed with a Kaplan Meier plot and 
compared with a log-rank test. Any episode of AF, AFL, or AT lasting more 
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than 30 seconds detected after the 3-month postprocedural period by ECG, 
pacemaker interrogation, or 7-days/48 hours/24 hours continuous Holter monitor 
performed at 6, 9, and 12 months, was considered as a failure.  
 
Results 
Perioperative Results 
Twenty-six patients underwent a hybrid procedure between May 29, 2008, to 
February 25, 2010. Patient baseline characteristics are shown in Table 1. Ten 
patients had persistent AF and 1 longstanding persistent AF. Eleven patients had 
1 or 2 (patient 25) previous CAs. None of the PVs were isolated in those patients 
and there were no epicardial scars indicative of transmural lesions. Mean follow-
up was 470±154 days (221 to 858 days). Mean length of hospital stay was 7±2 
days (5 to 13 days) and mean ICU stay for postprocedural recovery was 1,0±0,2 
days (1 to 2 days). The median length of the hybrid procedure (from initial skin 
incision to skin closure) was 280±84 minutes (195 to 505 minutes). 
Eleven patients were in AF at the start of the procedure. In all patients we 
achieved bidirectional block of all the PVs (Figure 3). In 2 patients we did not 
perform any other lesion, because AF was not inducible. In 1 patient with 
inducible AF after PV isolation, we performed an additional roof line only. In 1 
patient with inducible right AFL after PV isolation, we performed an additional 
CTI line only. Thereafter, no arrhythmia could be induced. In 22 patients we 
created a box lesion epicardially. In 17 patients (77%) we were able to 
demonstrate endocardial entrance and exit block in the box during sinus rhythm. 
After endocardial touch-up in 5 patients (23%), we completed the box lesion. In 
3 patients there was a gap at the junction of the right superior PV with the roof 
of the LA. One patient had a gap in the lateral portion of the roof line and 1 
patient in the middle of the inferiorline. Because of ongoing AF or organisation 
into a mitral isthmus dependent AFL, we performed in 3 patients a mitral 
isthmus line epicardially. In all cases, it had to be completed from the 
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endocardium or coronary sinus with a mean of 1.6±0.5 applications of RF 
energy, resulting in bidirectional block (Figure 4). In 2 patients, a CTI ablation 
was performed. One patient needed electrical cardioversion at the end of the 
procedure due to ongoing AF. All the other patients were in sinus rhythm. 
Twenty-four (92%) patients were discharged on their pre-operative AAD 
regimen (amiodarone, 6/24; 25%). All patients were discharged on 
acenocoumarol.  
Follow-Up 
Twenty-four (92%) patients reached 1 year follow-up and 96% underwent 7-
days Holter monitoring 1 year after the procedure. The remaining 2 (8%) 
patients, reached 6 months follow-up and there was 100% compliance with 7-
days Holter monitoring (Table 2).  
At one year, 22 of 24 (92%) patients were in sinus rhythm with no episode of 
AF, AFL or AT lasting longer than 30 seconds on office follow-up, Holter 
monitoring or pacemaker interrogation (Figure 5). None of those patients was on 
AAD and 5 (21%) patients were on acenocoumarol. One-year success defined 
according to the Heart Rhythm Society/European Heart Rhythm 
Association/European Cardiac Arrhythmia Society consensus statement 
(freedom of AF/AFL/AT off AAD), was 93% for patients with paroxysmal AF 
and 90% for patients with persistent AF. Two (9%) of those 22 patients 
underwent CA for recurrent AF or left AFL after the hybrid procedure (Table 3). 
There was no statistically significant difference in patients with or without 
previous CA, regarding the presence of sinus rhythm after one year without 
AAD (p = 1.0).  
This means a single-procedure success rate (sinus rhythm without AAD and/or 
redo procedure) of 79% at 1 year for paroxysmal AF (11 out of 14 patients) and 
90% for persistent AF (9 out of 10 patients) and an overall single-procedure 
success rate of 83% at 1 year.  
At six months, 2 of 2 (100%) patients were in sinus rhythm with no episode of 
AF, AFL or AT lasting longer than 30 seconds. One of those patients was taking 
flecainide and they both were on acenocoumarol. None of those patients had an 
additional CA procedure. 
The management of patients with recurrent supraventricular tachycardia (SVT) 
after the three months blanking period, is summarized in Table 3. Four (15%) of 
26 patients had SVT recurrence, with a mean of 99±94 (range, 29 to 239) SVT-
free days after the blanking period. Two of these 4 patients underwent an 
electrophysiologic study and CA. One patient was found to have AF due to a 
gap at the junction of the right superior PV with the roof of the LA. The other 
patient had a left AFL. These 2 patients have been followed for at least five 
months and have not experienced any SVT anymore off AAD. The remaining 2 
patients with SVT recurrence, are treated with AAD for paroxysmal AF.  
Complications 
No deaths or conversion to cardiopulmonary bypass were encountered. No 
patient demonstrated paralysis of the phrenic nerve. One patient had a pleural 
effusion drained 3 weeks after surgery. One patient stayed hospitalized for 13 
days due to difficult to control chestpain at the insertion sites of the 
workingports without signs of infection.  
 
Discussion 
Main findings 
This report describes for the first time the combined simultaneous thoracoscopic 
surgical and transvenous CA of paroxysmal and persistent AF. These two 
complementary techniques performed in combination, bear the potential of 
treating AF with one single ablation procedure.  According to accepted 
definitions, our overall one-year freedom of arrhythmia without AADs was 92%
  
with only 2 patients needing a second CA procedure (3). Of note, almost half 
persistent and over a third of patients had one or more previous CA. The 
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robustness of the hybrid approach lies in its complimentary nature as 
represented by the fact that in almost a quarter of patients CA was needed to 
finish incomplete epicardial surgical lesions by endocardial touch-up, and 
additional lesions like the mitral isthmus line can be performed rather fast. 
Hybrid procedure versus percutaneous catheter ablation techniques 
Jaïs et al found that if AF was inducible after PV isolation in patients with 
paroxysmal AF, the addition of linear lesions, with the endpoint of 
noninducibility, resulted in 91% of patients free from arrhythmia without AAD 
during a follow-up of 18±4 months (8). To reach that number, however, 31% of 
patients needed a second procedure. Using the same endpoint, our success 
percentage off AAD was comparable but only 9% of patients needed a second 
procedure.  
The single-procedure, drug-free success rate of the stepwise ablation approach 
for persistent AF as described by Haïssaguerre et al, was 62% at 11± 6 months 
(9). Allowing for repeat procedures and the use of AAD, the one year success 
rate increased to 95%. In our series we followed a comparable ablation strategy 
and the single-procedure, drug-free success rate at one year was 83%. Allowing 
for redo-procedures, this number increased to 92%. 
The hybrid approach appears to result in better endpoints regarding 
rhythmcontrol, both for paroxysmal and persistent AF, using the same endpoints 
and ablation strategy as described in other trials.  
Approximately 80% of patients have at least partial recovery of PV conduction 
at 4 months after PV isolation with unipolar RF (10).
 
Bipolar RF energy, as used 
in our series,  overcomes the heat-sink by clamping the tissue and excluding the 
effect of  the circulating blood on ablation which seems to result in more 
persistent lesions (11).
 
But even for such devices, epicardial fat can prevent 
transmurality. In our series, the box lesion was incomplete after epicardial 
ablation alone in 23% of the patients, i.e. endocardial touch-up with unipolar RF 
energy was necessary to achieve bidirectional block. The possibility to perform 
such an endocardial touch-up, is one of the major advantages of this procedure. 
Hybrid procedure versus surgical ablation techniques 
By  replacing the incisions of the traditional Cox-maze III procedure with less 
invasive linear lesions of ablation using bipolar RF, Damiano et al introduced 
the Cox-maze IV procedure (12).
 
This approach still requires cardiopulmonary 
bypass and at least one small right thoracotomy. The freedom of AF recurrence 
was 91% at 12 months and 67% of patients off AAD. These figures are 
comparable with our results although in the case of the hybrid procedure, no 
cardiopulmonary bypass is needed nor a thoracotomy. None of the existing 
surgical ablation technologies (even bipolar RF) can guarantee complete 
transmurality. We solved this issue by applying RF endocardially in the case of 
incomplete lesions. Another shortcoming of the surgical approach is the inability 
to precisely locate AF triggers and to map ATs or reentry arrhythmias known to 
occur during AF ablation (13).
 
In the setting of a hybrid procedure however, it is 
possible to perform extensive mapping in order to tailor the lesion set. Finally, 
during an epicardial surgical AF ablation on the beating heart, it is technically 
not possible to create a linear lesion across the CTI. In our series, this was safely 
performed endocardially in 3 patients.  
Hybrid procedure versus surgical ablation with epicardial mapping 
In 2009, Lockwood et al described techniques for assessing conduction block 
across surgical lesions based on epicardial mapping (7).
 
Using combinations of a 
focal and bipolar RF device as in our series, they achieved complete block 
across linear lesions by the first set of RF applications in only 21%. Several 
factors like epicardial fat and local myocardial thickness, limit the depth of 
penetration of RF and thus the creation of transmural lesions (14).
 
After 
localisation of the gaps, epicardial ablation was repeated until complete 
bidirectional block across all the linear lesions. 
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In our series, pacing manoeuvers and  mapping techniques  were performed 
from the endocardial side. In 23% of our patients we were not able to create a 
complete box lesion, even after repeating epicardial ablation. To create 
completely transmural lesions, we applied unipolar RF endocardially at the 
remaining gaps. 
Krul et al described a series of 31 AF patients, treated with thoracoscopic PV 
isolation and ganglionated plexi ablation (15).
 
In patients with nonparoxysmal 
AF, LA ablation lines were created and conduction block verified epicardially 
with custom made catheters. After 1 year, they reported comparable results to 
our series (86% of patients had no recurrence of SVT off AAD). Although the 
autonomic nervous system seems to play an important role in AF, there is up to 
now too little evidence to advocate a systematic ganglionated plexi ablation 
strategy (16,17).
 
In animal models, return of ganglionated plexi activity was 
observed 4 weeks after selective ablation and little is known about the 
electrophysiological impact reinnervation will have on the long term outcome 
(18).
 
An important conceptual difference between studies is that Krul et al. could 
only perform epicardial lesions without the possibility of add on endocardial 
lesions including endocardial touch-ups to improve transmurality, as well as 
performing CTI and left sided isthmus ablation. In addition, they could only 
check completeness of ablation lesions from the epicardium which may be 
insufficient to show complete electrical block.  
 
Limitations 
The low number of patients in this single-center retrospective study prevents 
definitive conclusions, also in view of the limited power of the log rank test we 
used to compare groups. However, future larger studies may corroborate our 
results. 
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Although patients with previous CA had at most a PV isolation procedure and 
none of the PVs appeared to be isolated in any of these patients, it cannot be 
excluded that previous CA favourably influenced the results. 
The single procedure success rate was similar – rather than lower - in patients 
with persistent compared to those with paroxysmal AF. Although this may be 
due to low sample size, it may also be considered an expression of the 
robustness of the hybrid procedure. 
In the current series, the overall clinical success may have not recognized some 
episodes of asymptomatic arrhythmia by the relatively short periods of 
ambulatory monitoring performed.  
The safety of this procedure may be a concern because of the extent of ablation 
and the full heparinisation during the procedure. 
The longer-term impact of this ablation strategy on the atrial systolic function 
remains unknown.  
An ablation strategy based on non-inducibility, could lead to overtreatment of 
some patients. As demonstrated by Jaïs et al, despite being still inducible after 
PV isolation and deployment of linear lesions, some patients remained 
arrhythmia free without AAD (8). 
 
Conclusions 
A combined transvenous endocardial and thoracoscopic epicardial ablation 
procedure for paroxysmal and recent persistent AF resistant to AAD, has a 
single-procedure success rate of 83% at one year. Recurrent arrhythmias can be 
handled with AAD or CA. 
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Abbrevations 
AAD = anti-arrhythmic drug 
AF = atrial fibrillation 
AFL = atrial flutter 
AT = atrial tachycardia 
CA = catheter ablation 
CTI = cavotricuspid isthmus 
LA = left atrium 
PV = pulmonary vein 
RF = radiofrequency 
SVT = supraventricular tachycardia  
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Figure 1. Right Pulmonary Vein Isolation 
A large antral lesion (arrow) is created using a bipolar radiofrequency clamp and resulting in 
complete isolation of the right pulmonary veins (PV). The antrum of the right PVs is clearly 
visible (∗). RL = right lung. 
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Figure 2. Placement of Ports on Left Side of the Patient 
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Figure 3. Flow Diagram of the Stepwise Lesion Sets  
See text for details. AF = atrial fibrillation, CTI = cavotricuspid isthmus, LA = left atrium, 
NSR = normal sinus rhythm, PVI = pulmonary vein isolation, RA = right atrium. 
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Figure 4. Linear Lesion at the Mitral Isthmus  
Two instruments placed epicardially, visualise the location of this linear lesion (∗ = left 
inferior pulmonary vein, ▲ = coronary sinus). Bidirectional block across the mitral isthmus 
was determined using the following criteria: 1) widely separated double potentials along the 
whole linear lesion (↔), 2) pacing lateral to the line results in a proximal-to-distal activation 
sequence in the coronary sinus, 3) pacing immediately septal from this linear lesion with the 
coronary sinus catheter (■), results in late activation (170 to 190 ms) on the ablation catheter 
(†) at the lateral side of this line, 4) the conduction time from the septal side of the linear 
lesion to the lateral side gets shorter as the septal pacing site is moved further from the line. ‡ 
= His catheter,  =  transesophageal echocardiography probe. 
 
 
206
 
 
 
 
Figure 5. Outcome of Hybrid Ablation Procedure 
Kaplan-Meier curve showing the outcomes of hybrid ablation procedure. At 1 year follow-up, 
hybrid ablation resulted in an overall single-procedure success rate of 83% (79% for 
paroxysmal atrial fibrillation (AF) and 90% for persistent AF). An event was considered a 
patient who, at any time, had recurrent supraventricular tachycardia. 
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Table 1. Baseline Characteristics  
Baseline characteristics of all included patients with lesion set and follow-up results. No 
patient had previous cardiothoracic surgery or a cerebrovascular accident. Atrial fibrillation 
duration prior to intervention, is expressed in months. 
BMI = body mass index, CA = catheter ablation, CAD = coronary artery disease, COPD = 
chronic obstructive pulmonary disease, EF = ejection fraction, F = female, M = male, NSR = 
normal sinus rhythm, Parox = paroxysmal, Pers = persistent, PVI = pulmonary vein isolation. 
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Table 2. Monitoring 
Anti-arrhythmic drug (AAD) use, type and result of monitoring in all included patients. The 
duration of AAD intake after the hybrid procedure (AAD stop) is given for each patient. 
Patient 6, 12, 15, and 17 had arrhythmia recurrence.  
NA = not available, NSR = normal sinus rhythm, Parox = paroxysmal, Pers = persistent, PM 
= pacemaker, 24 h/48 h/7 d = 24 hours/48 hours/7 days continuous Holter monitoring. 
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Table 3. Supraventricular Tachycardia Recurrences after Hybrid Procedure and Management 
PAF = paroxysmal atrial fibrillation. 
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Chapter 6 
 
Minimally Invasive Hybrid Treatment of Lone Atrial Fibrillation: Early 
Results of Monolateral Versus Bilateral Thoracoscopic Approach Employing 
Radiofrequency Sources. 
 
Mark La Meir, Sandro Gelsomino, Fabiana Lucà, Roberto Lorusso, Gian Franco Gensini,, 
Laurent Pison, Francis Wellens and Jos Maessen.  
J. Interact Cardiovasc Thorac Surg. 2012 Apr;14(4):445-50. 
 
 
Abstract 
Objectives. We compare results of hybrid monolateral versus hybrid bilateral 
thoracoscopic approach employing radiofrequency (RF) sources for the 
surgical treatment of lone atrial fibrillation (LAF).  
Methods. Between January 2008 and June 2010 fifty-four consecutive 
patients with LAF underwent hybrid minimally invasive surgical 
ablation.Nineteen patients (35.1%) underwent monolateral monopolar RF 
ablation whereas 35 (64.9%) had a bilateral thoracoscopic approach 
employing a bipolar RF clamp.Seven-day Holter Monitoring (HM) was 
performed at, 3, 6 months and 1 year. 
Results. One-year time-related prevalence of postoperative AF in patients 
undergoing monolateral thoracoscopic approach or bilateral thoracoscopic 
ablation were 13.3 % (11.0-17.4) and 5.2 % (4.2-6.7), respectively (p<0.001). 
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It was 21.1% (17.6-24.9) and 8.2% (5.1-11.6) in long standing persistent 
(p<0.001), 13.2 % (10.6-17.8) and 3.8 % (1.4-6.9) in persistent (p<0.001) and 
5.6 % (2.8-8.3) and 3.2(1.0-6.5) in paroxysmal AF (p=0.64) in monolateral 
and bilateral group, respectively.At 12 months estimated prevalence of 
antiarrhythmic drugs were 26% (22.4-30.1) and 18.0% (15.5-21.7, p=0.04) 
whereas prevalence of Warfarin use were 48.2% (44.2-52.2) and 29.0% 
(26.2-33.1, p<0.001) in monolateral and bilateral group, respectively.LA 
reverse remodeling occurred in 47.3% (n=9) of monopolar patients (n=9) and 
in 77.1% (n=27) of bipolar patients (p=0.03). 
Conclusions. Hybrid bilateral approach with a bipolar device for the 
treatment of LAF  showed a good one-year success rate independently of the 
AF type and a seems to be the better choice for LAF fibrillation more than 
paroxysmal. In contrast, the hybrid monolateral approach when combined 
with an endocardial touch-up may represent a reliable alternative in selected 
paroxysmal LAF patients. 
 
Introduction 
With the development of new tools and advanced endoscopic techniques the 
surgical treatment of lone atrial fibrillation (LAF ) moves towards 
increasingly less invasive techniques
1
 . Because these minimally invasive 
approaches are performed on the beating heart they have the potential to 
promote a multidisciplinary approach involving cardiac surgeons and 
electrophysiologists (EPs)
2
. A so called hybrid procedure has been recently 
introduced to overcome the shortcomings of percutaneous catheter ablation 
and video-assisted thoracoscopic epicardial procedure and, together, to 
combine their advantages
3
. The hybrid technique originally described 
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combines a bilateral thoracoscopic epicardial approach followed by a 
percutaneous trans-septal procedure
3,4
. In order to reduce the invasiveness of 
the procedure, we have recently introduced, in selected patients, a hybrid 
single-sided approach employing a monopolar radiofrequency source through 
a right thoracoscopy.  
Nonetheless, no information exist whether, in hybrid procedures, theoretical 
advantages of a right thoracoscopic approach outweigh the clear advantages 
of employing bipolar radiofrequency clamps (transmural and continuous 
lesions, ligation/excision of the LAA) in bilateral thoracoscopic approach. 
Therefore, we present our short-term experience with the hybrid procedure in 
LAF and compare results of hybrid monolateral versus a hybrid bilateral 
thoracoscopic surgical ablation employing radiofrequency (RF) sources in 
terms of early and late complications, prevalence of postoperative atrial 
fibrillation, antiarrhythmic medications and anticoagulant use. Furthermore, 
we explore whether any difference exists between the two approaches in 
terms of left atrial (LA) function and LA reverse remodeling (LARR). 
 
Methods 
Patients 
The study followed the World Medical Association guidelines concerning 
ethical principles for medical research involving human subjects and was 
approved by Institutional Ethics Board. All patients gave their informed 
consent. 
Between January 2008 and June 2010 fifty-four consecutive patients with 
LAF underwent a single step hybrid minimally invasive surgical treatment of 
LAF combined with a percutaneous endocardial step employing a 
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radiofrequency (RF) source. Nineteen patients (35.1%) underwent 
monolateral right-side thoracoscopic ablation whereas 35 (64.9%) had a 
bilateral thoracoscopic procedure. All operations were performed by the same 
cardiac surgeon (M.L.M).  
Lone atrial fibrillation was defined following American College of 
Cardiology/American Heart Association/European Society of Cardiology 
(ACC/AHA/ESC) guidelines
5
and updated ESC Guidelines were followed to 
distinguish type of AF and to score the AF-related symptoms (European 
Heart Rhythm Association [EHRA] score)
6
 . 
Indication for minimally invasive surgery was based on the HRS/EHRA/ECA 
Guidelines
7
. Patients were referred for hybrid procedure in case of 
paroxysmal, persistent or long-standing persistent AF with left atrial (LA) 
dilatation (> 4.5cm), after one or more failed catheter ablations, or on 
patient's preference. The indication was based on the history of AF and LA 
size. A transthoracic echocardiography and a computed tomography (CT) 
scan were carried out preoperatively (pulmonary vein anatomy, coronary 
arteries) and potential candidates for a hybrid procedure underwent lung 
function test (Spirometry).The right  thoracoscopic approach was preferred 
for patients with ≥moderate chronic obstructive pulmonary disease (COPD) 
following European Respiratory Society (ERS) diagnostic criteria
8 
Exclusion criteria were a presence of atrial or left appendage thrombi at 
transesophageal echocardiography (TEE), ‘giant’ left atrium (diameter >6.5 
cm), coronary artery disease, and previous pulmonary or cardiac surgery.  
Patient characteristics are shown in Table 1.No significant difference was 
detected between groups. 
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Follow-up and Assessment of AF 
All patients were followed-up according the Heart Rhythm Society/ European 
Heart Rhythm Association/ European Cardiac Arrhythmia Society 
(HRS/EHRA/ECA) expert consensus statement on catheter and surgical 
ablation of AF
6
. Data and outcomes were reported following the Society of 
Thoracic Surgeon (STS) guidelines
9
.
 
Seven-day Holter Monitoring (HM) was performed  at 3, 6 months and 1 
year. All patients reached 1-year follow up. Monitoring was carried out with 
an external loop recorder (Del Mar Reynolds, Spacelabs Healthcare, 
Issaquah, WA, USA) and analyzed with Lifescreen Software (Del Mar 
Reynolds, Spacelabs Healthcare, Issaquah, WA, USA). For analysis, three 
rhythms were considered postoperative AF: AF, atrial flutter or atrial 
tachycardia lasting more than 30 sec. In addition, all electrocardiograms 
(ECG) performed at the discretion of referring physicians/cardiologists 
during the first three months after surgery and in the time comprised between 
Holter examinations were included when patients had at least two records 
available for analysis. Each ECG and Holter was treated as a discrete data 
(presence/absence of atrial fibrillation) to calculate estimated prevalence
9
. A 
total of 628  postoperative Holter/ ECG data were retrieved (bilateral 
thoracoscopy, n=408; right thoracoscopy, n=222).  
Anticoagulation and Anti-arrhythmic Therapy 
Anti-arrhythmic drugs (AAD) were given postoperatively to all patients but, 
although we recommend discontinuing AAD three months after ablation if 
the patients appear to be AF free, their continued use was at the discretion of 
referring cardiologists. 
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Electrical cardioversion was not attempted for patients who remained in AF 
after the surgical procedure and was reserved for patients who were still in 
AF after 3 months and 6 months. 
Warfarin was administered on postoperative day 2 with INR target of 2.5 and 
stopped after 3 months if the Holter recording showed a sinus rhythm (SR) or 
patients had a low thromboembolic risk (CHADS2 score<2). 
Echocardiography 
Echocardiography was performed preoperatively and at 3 month- and 12 
month- follow-up appointments using a commercially available 
echocardiographic system (Philips iE33; Philips Medical Systems, 
Eindhoven, The Netherlands). All the parameters were analyzed “off-line” by 
an experienced echocardiographer (F.L.) using the Xcelera software (Philips 
Medical Systems Eindhoven, The Netherlands). 
In the parasternal long-axis views LA maximum antero-posterior (A-P) 
diameter was measured. 
LA superior-inferior (S-I) diameter was measured from the mitral annular 
plane to the posterior wall of the LA in the apical 4-chamber view. In the 
apical 4-chamber view, LA maximum volume (LA max), at the end of LV 
systole, just before the opening of the mitral valve and LA minimum volume 
(LA min) at the end of LV diastole, just after the closure of the mitral valve, 
were measured
10
. LA emptying fraction (LA EF) was calculated as ([La max-
LA min]/La max) x 100. LA maximum volume was also measured by biplane 
area-length method
11
and indexed to body surface area (LAVI). LARR was 
defined as a reduction in LAVI ≥15% at late follow up12. 
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Surgery 
The interventions were performed under general anesthesia with a double-
lumen endotracheal tube for selective lung ventilation. The chest was entered 
in the second, fourth and sixth interspaces using respectively a 5-12-12mm 
port. Thoracoscopy of the right side was done first and, in case of bilateral 
approach, it was followed by the left side. The technique for the monolateral 
approach was as previously reported
13
. The bilateral procedures were carried 
out as originally described by Yilmaz et. al
14
.  
In all patients (monolateral and bilateral) high frequency stimulation (HFS) 
of the right vagal nerve at the level of the mediastinum and at the four major 
ganglionated plexi (GPS,[right superior GP, right inferior GP, left superior 
GP and left inferior GP)] was carried out and the vagal respone on the atrio-
ventricular node was recorded (10V , 1.5-ms pulse width impulse at 1000 
pulses per minute from a temporary external pacemaker [Oscor, Oscor INC., 
Palm Harbor, FL]) 
In patients undergoing a monolateral approach, the isolation of pulmonary 
veins was performed with a Cobra® Adhere XL (Estech, Danville, Ca) 
temperature-controlled, monopolar radiofrequency system. The temperature 
was set at 60°C, the timing at 120 seconds. The number of ablations 
performed ranged from 2 to 4 (mean 2.8± 0.4).The ablation catheter was 
pushed under the superior caval vein (SCV) into the transverse sinus and 
placed behind the left atrial appendage (LAA) encircling the four PVs to 
create the box-lesion. Before starting, the ablation the fat pad in the atrial 
groove was bluntly dissected to provide a better placement of the ablation 
probe and enhance higher penetration energy to destroy the GPs located 
inside this fat pad. 
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sheath 8F (SL0, St. Jude Medical Daig Division, Inc., Minnetonka, MN, 
USA) was advanced into the LA. The patient was heparinised to keep the 
activated clotting time >300 seconds. During rapid ventricular pacing from 
the His catheter, contrast was injected through the long sheath in order to 
visualize PVs and the LA. PVs were mapped with suitably sized circular 
mapping catheter (Lasso, Biosense Webster, Inc, Diamond. Bar, CA, USA) 
placed at the ostium of the PVs. 
In all patients, epicardial pacing and endocardial recordings were utilized to 
demonstrate entrance and exit block; entrance block was defined as failure to 
capture the PVs during pacing from the left atrium at 18 V and 1.5-ms pulse 
width and the absence of pulmonary veins potentials (PVPs) seen on the 
Lasso catheter. Exit block was defined by failure to capture the left atrium 
during the pacing from the PVs. by failure to capture when pacing from each 
dipole of the Lasso catheter with an output of 10 mA and 2.0 ms pulse width.  
In case of sinus rhythm after PV ablation, induction of AF was attempted 5 
times by pacing in the coronary sinus for 10 second at the shortest cycle 
length resulting in 1:1 atrial capture. AF was considered inducible if it lasted 
more than 1 minute. If AF was not inducible isoproterenol was infused at 
rates of 10-20 µg/min. If AF was still inducible (or was not terminated) linear 
lesions were carried out.  
We identified the conduction gaps from the endocardium and ablated those 
with a 3.5 mm tip-catheter (ThermoCool, Biosense Webster, Inc., Diamond. 
Bar, CA, USA) trough the sheath in the LA. The precise location of the linear 
lesions was visualized with the Cobra® Adhere XL (Estech, Danville, Ca) 
and with the Coolrail probe (Atricure Inc, Westchester, Ohio, USA) in situ 
and using fluoroscopy. Gaps in linear lesions were defined as low amplitude 
and fragmented or narrowly split double atrial potentials.  
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In case of persistence of AF, a left isthmus line was made starting from the 
ablation line on the antrum of the left inferior PV and crossing the CS, using 
the the Max 3 pen. (Atricure Inc, Westchester, Ohio, USA) on the epicardial 
side. This line was completed by the EP endocardially from the mitral 
annulus towards the CS with the ThermoCool  catether (ThermoCool, 
Biosense Webster, Inc., Diamond. Bar, CA, USA) 
The endpoint of ablation of the mitral isthmus was the bidirectional block 
which was achieved when the following criteria were met:  1) proximal-to-
distal activation sequence along the CS catheter after pacing lateral to the line 
in the LA appendage; 2) Late activation on the opposite side after pacing on 
the septal side of the line through the CS; 3) widely separated local double 
potentials along the whole length of the ablation line. 
In the bilateral group, an inferior vena cava (IVC)-to-SVC and SVC 
circumferential lesions were added when patients with persistent and long-
standing persistent AF had a right atrial volume ≥58 ml. IVC circumferential 
isolation was performed in patients with a small portion of intrapericardial 
IVC to be sure that the SVC-IVC line would stop at an area of no conduction. 
The isolation of the SVC and the IVC was confirmed by testing of 
conduction block across the ablation lines. 
In both groups, if the patient had a history of typical right atrial flutter or this 
arrhythmia became apparent during the procedure, we performed a cavo-
tricuspid isthmus line (CTI) endocardially. The endpoint was bidirectional 
block and the presence of widely separated double potentials along the whole 
length of the ablation line. 
In the bilateral group, in patients with CHADS2 score ≥1, or in presence of a 
rapid firing coming from the LAA, and when the procedure was deemed safe, 
LAA exclusion/ closure was performed under transesophageal 
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echocardiographic (TEE) guidance employing a stapler (Endo GIA, 
Covidien, Norwalk, CT) or a clip (Atricure, West Chester, OH). The absence 
of flow was confirmed by intraoperative transesophageal echocardiography. 
The lesion set in the two Groups is shown in Table 2. 
Statistical Analysis 
Normal values were expressed as mean ± one standard deviation (SD), non-
normal values as median and interquartile range (IQR) and categorical 
variables as percentages. T test, Wilcoxon and McNemar’s tests were 
employed where appropriate. 
We analyzed all of the intermittent data available in terms of time-related 
prevalence of atrial fibrillation with a multiphase hazard decomposition 
method
15
.Non-time-related event data and time-related prevalences are 
presented as percentages with asymmetric 68% confidence limits (CLs), 
comparable to ± one standard error. The CLs for AF prevalence were 
obtained with the bootstrap percentile method
16
.  
Analyses of prevalence of AF do not account for antiarrhythmic medications. 
Prevalence of antiarrhythmic medication use was estimated by mixed 
modeling based on medication use at each follow-up assessment. With the 
same method we estimated the prevalence of Warfarin use at time of each 
follow-up. Finally, the use of electrical cardioversion was analyzed as 
repeated event and is presented as cumulative incidence (events per patient)
 9
 
and the Gray's test
17
was employed to compare two different cumulative 
incidence curves.  
Statistical analyses were performed using SPSS release 12.0 (SPSS, Chicago, 
IL, USA) and Curve Expert Professional release1.0.1 (D.G. Hyams, 
Chattanooga, TN, USA).P values less than 0.05 were considered significant. 
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Results 
Early Results 
In the monolateral group none of the patients showed entrance and/or exit 
block after the epicardial ablation. Seventeen patients had at least one PV not 
isolated, which needed an endocardial touch-up. After completing PV 
isolation endocardially all these patients had a conduction delay superior to 
200 msec. at the level of the posterior wall of the LA but none had block.  
In the bilateral group, two patients with paroxysmal AF had no extra lesions 
besides PVs antral ablation because AF was no longer inducible. In three 
patients with inducible AF after PVs ablation, we performed an additional 
roof line and no more arrhythmias were seen. A roof and an inferior line were 
carried out in the other 30 patients of the bilateral group. During endocardial 
mapping 30 patients (86%) showed entrance and exit block whereas in 3 
patients (8.5%) there was a clear gap at the junction of the right superior PV 
with the roof of the left atrium, one patient (2.8%) showed a gap in the lateral 
portion of the roof line and one patient (2.8%) had a gap in the middle of the 
inferior line. These gaps were closed endocardially. 
Three patients (15.7%) in the monolateral and 7 (20.0 %) in the bilateral 
Group had a mitral isthmus line and in all case a complete block was 
achieved. In the bilateral group 10 patients (28.5%) 
had an IVC-to-SVC lesion, 8 (22.8% a circumferential SVC lesion and 3 
(8.5%) a IVC circumferential isolation.  
A cavo-tricuspid isthmus (CTI) line was carried out in two (10.5 %) and 3 
patients (8.5%), of the monolateral and bilateral group, respectively, with 
successful bidirectional block. 
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All the procedures could be completed as planned without any conversion to 
cardiopulmonary bypass. Median operative time was 216 minutes (IQR 132-
391) in the monolateral and 268 minutes (IQR 186-477) in the bilateral 
procedure (p<0.001). There were neither early deaths nor complications 
during the postoperative course. Median Intensive care unit (ICU) and 
median in-hospital length of stay were comparable in the two groups (6.9 
hours [IQR 4.0-14.0] vs. 6.2 hours [5.5-13.4], p=0.61; 3.6 days [2.7-4.3] vs. 
3.4 days [2.6-4.1], p=0.8).   
No patient died during the follow up. There was a significant improvement in 
median EHRA (European Hear Rhythm Association) score in both groups 
(both, 1[IQR 1-2], p<0.001 vs. baseline). Finally, no thromboembolic event 
occurred during the follow-up. 
AF Recurrence  
Time-related prevalence of postoperative AF (Figure 1 A-B) in  patients 
undergoing  monolateral thoracoscopic approach or bilateral thoracoscopic 
ablation were 44.4 % (41.3-47.4) and 35.5 % (33.2-38.2) at two weeks 
(p=0.06), 30.4 % (27.3-34.9) and 27.4 % (24.5-31.4) at three months 
(p=0.08), 14.2 % (11.6-18.1) and 6.6 % (5.8-8.3) at 6 months (p=0.001),13.3 
% (11.0-17.4) and 5.2 % (4.2-6.7) at 12 months (p<0.001), respectively.  
Figure 1 C-D shows estimated prevalence of postoperative atrial fibrillation 
by AF type. At 1 year it was 21.1% (17.6-24.9) and 8.2% (5.1-11.6) in long 
standing persistent (p<0.001), 13.2 % (10.6-17.8) and 3.8 % (1.4-6.9) in 
persistent (p<0.001) and 5.6 % (2.8-8.3) and 3.2 (1.0-6.5) in paroxysmal AF 
(p=0.64) in monolateral and bilateral group, respectively 
At 12 months estimated prevalence of AAD were 26% (22.4-30.1) and 18.0% 
(15.5-21.7, p=0.04)  
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When comparing prevalence of AAD by AF type, it was significantly lower 
in the bilateral group in patients in long-standing persistent AF (26.2 % 
[17.6-30.4] vs.38.1 % [34.3-43.4], p<0.001) and in persistent (16.0 % [13.4-
20.6] vs. 26.3 % [22.2-30.7], p<0.001) where it was comparable in 
paroxysmal AF (12.2 % [9.7-15.4] vs.14.9 % [9.9-17.8], p=0.7). 
One-year prevalence of Warfarin use were 48.2% (44.2-52.2) in the 
monolateral and 29.0% (26.2-33.1, p<0.001) in the bilateral group, 
respectively (Figure 2 A-D).  
This difference was still observed in long standing-persistent (52.5% [48.8-
55.2] vs.35.5 % [29.7-38.2] vs., p<0.001) and persistent (35.3% [32.5-39.2] 
vs.22.7 % [16.1-24.8], p<0.001) whereas in paroxysmal AF data were 
comparable (19.4% [16.3-23.3] vs.17.3 % [15.4-21.2], p=0.6) 
Finally, the cumulative incidence of electrical cardioversion was 0.05/patient 
in monolateral Group and 0.04/patient in bilateral group (p=0.841). 
In the bilateral group, four patients (2 long-standing persistent, 1 persistent 
and 1 paroxysmal) had a supraventricular tachycardia (SVT) occurring more 
than three months after the hybrid procedure. Two patients underwent an 
electrophysiological study and catheter ablation. One patient was found to 
have AF due to a remaining gap at the junction of the right superior PV with 
the roof of the LA. The other patient had a left atrial flutter. These 2 patients 
have been followed for at least five months and have not experienced any 
SVT anymore off AAD. The other two patients with SVT were medically 
treated. 
In the monolateral group 5 patients with long-standing persistent LAF had 
SVT recurrence occurring more than three months after the hybrid procedure. 
One patient underwent electrophysiological study which showed incomplete 
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isolation of the 4 PVs and a gap in the ablation line infero-posterior at the 
right side. This patient had a catheter ablation whereas the other patients were 
treated by rate control. 
Echocardiographic results 
Table 3 shows echocardiographic data. At 3 month- follow-up biplane LAVI 
was significantly reduced only in patients undergoing bipolar hybrid 
procedure (p=0.05 and p=0.03 in monopolar and bipolar, respectively). It 
further decreased in both groups without reaching statistical significance but 
it was lower in the bilateral group. Based on the cut-off value (≥15% decrease 
in LAVI) LARR occurred in 47.3 % (n=9) of patients in the monolateral 
group and in 85.7 % (n=30) of patients in the bilateral group (p<0.001).  
LAEF raised only in patients undergoing bipolar hybrid procedure (p=0.6 and 
p=0.02 in monopolar and bipolar, respectively). It further increased not 
significantly in both groups at 12-month- control. Nonetheless, LAEF was 
significantly higher in the bilateral group at each control. 
Both LA diameters decreased significantly at 3 months (LA A-P, p=0.02; LA 
S-I p=0.03) and one year (LA A-P, p=0.04; LA S-I p=0.008) in patients 
undergoing bipolar hybrid procedure. In patients who underwent monopolar 
hybrid ablation LA diameters decreased significantly at 3 months (LA A-P, 
p=0.02; LA S-I p=0.03) whereas at one year there were a further no-
statistically-significant reduction (LA A-P, p=0.73; LA S-I p=0.81). 
Comment 
Percutaneous ablation techniques have become the second line strategy to 
cure patients with lone AF. Nonetheless, a worldwide survey on the methods, 
efficacy and safety of catheter ablation in AF showed that the success rate 
without AAD was suboptimal and major complications were not infrequent
18
. 
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In the last few years the number of patients with lone AF considered as 
candidates for a stand-alone surgical procedure have been increasing 
although a standard surgical method for the treatment for LAF has not been 
established yet
1
. Minimally invasive, off-pump, video-assisted thoracoscopic 
surgical techniques enabling surgical treatment of AF through an epicardial 
approach on a beating heart are being employed worldwide but success rates 
reported in literature are highly variable
19,20
. 
Thus, we introduced a dual endocardial and epicardial single-step approach to 
reduce the complication rate and improve the results
3. 
The surgeon who has 
epicardial access on the beating heart through a thoracoscopy, isolates the 
pulmonary veins, makes a roof line (connecting left and right superior 
pulmonary veins) and inferior line (connecting inferior left and right 
pulmonary veins).In addition he/she has the possibility of making a left 
isthmus line from left inferior pulmonary vein to the coronary sinus (which 
can to be completed endocardially towards the mitral annulus) and to isolate 
the SVC. The endocardial “step” gives the possibility of evaluating the end 
points of the ablation as well as the opportunity to add an endocardial “touch-
up” in case of incomplete isolation of one of the pulmonary veins or if the 
connecting lesions are not transmural. Furthermore the EP can make lesions 
in regions which cannot be reached epicardially.  
In addition, this procedure should potentially reduce the complication rate of 
standard surgical and catheter ablation procedures. Indeed, from point of 
view of the surgeon, the risk of post-operative arrhythmias is reduced since 
the lines and lesion set are controlled endocardially and also the risk of injury 
is lower, since the surgeon is no longer forced to perform ablations in areas 
which are difficult to reach, which can be ablated by the EP. 
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On the other hand, from the EP point of view, there is no more risk for 
tamponade since the pericardium is open and the phrenic nerve and the 
esophagus can be protected by the surgeon if necessary. Furthermore, by 
reducing the total number of endocardial ablations the risk of emboli during 
these ablations should be potentially reduced 
21
.  
A potential drawback of the single-step approach is heparinization after the 
transseptal puncture which could increase the risk of epicardial bleeding and 
the risk of measuring a temporary block. 
In this study we presented our short-term experience with the hybrid 
procedure in LAF and compare results of hybrid monolateral and hybrid 
bilateral thoracoscopic approach employing radiofrequency (RF) sources.  
To the best of our knowledge no data exist in the literature on the right 
thoracoscopic single-step hybrid procedure. The single-sided right 
thoracoscopic approach was preferred in patients with ≥moderate COPD in 
order to reduce the invasiveness of the procedure and the pulmonary 
complication rate. A device specifically designed for a monolateral right 
thoracoscopic off-pump procedure was used (Cobra® Adhere XL) which has 
been proven to provide safe and effective cardiac ablation
22
. This device 
enables focused energy delivery through suction technology which allows 
constant contact throughout the procedure between probe and tissue. In 
addition, the precise energy delivery also prevents collateral tissue damage. 
This device was chosen because of the lack of maneuverability of bipolar 
clamps which can hamper the orientation of the probe and constrain the 
variety of achievable lesion sets when employed from the right side. In the 
absence of significant pulmonary disease a bilateral thoracoscopic approach 
was chosen following the technique originally described by Yilmaz et. al
14
. 
The current literature is extremely difficult to interpret. This confusion is 
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compounded by a lack of consensus on methods and timing of follow-up 
evaluation as well as the absence of strict definitions of success. The 
workforce on evidence-based surgery of the Society of Thoracic Surgeons 
9
 
proposed an approach to report success/failure. They suggested analyzing all 
the intermittent data available in terms of time-related prevalence (burden) of 
atrial fibrillation
9 
In the present study we report our results as time-related 
prevalence of postoperative AF, ADD use and Warfarin use. 
Time-related prevalence of AF at one year was significantly lower in the 
bilateral group (p<0.001) in long-standing persistent and persistent AF. 
Accordingly, these patients showed a lower 12-month- prevalence of AAD 
and Warfarin use (all, p<0.001) in long-standing persistent and persistent AF 
whereas in paroxysmal AF there was no statistically significant difference. 
Longer duration of AF is known to cause progressive remodeling and 
increased LA volume and long-standing persistent and persistent AF may be 
considered to be advanced stages of the arrhythmia characterized by 
significant changes in the atrial tissue and muscle (substrate modification) 
that leads to chaotic electrical activity. Thus, these patients might need more 
areas in the heart ablated than what is done in the monolateral approach and 
they might benefit much more from the bilateral/bipolar procedure which 
increases the likelihood that ablation lines are transmural. Indeed it has been 
demonstrate that monopolar sources are unable to create transmural lesions 
when used from the epicardial surface on the beating heart
23
especially when 
the wall thickness is greater than 4 mm
24
. Nonetheless, Wong and co-
workers
25
 describe a combined technique where irrigated unipolar RF is 
sequentially applied endocardially and then epicardially  along the same 
linear line of block gaining  satisfactory results in terms of conduction block.  
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In any case, these shortcomings should be addressed by EP who can check 
for possible incomplete transmurality of the epicardial lines endocardially 
and can complete any line by focused endocardial applications. In our 
experience with the hybrid monolateral approach with a monopolar device all 
the PVs where isolated after the endocardial touch-up, but all patients had 
only conduction delay and no block from the box lesion. So the transient 
success could be related to the recovery of conduction from the roof and 
inferior line.  
However, in both groups, the prevalence of Warfarin use was not low and 
this may be related to the fact that 63.1% (n=12) of patients in the monopolar 
group and 51.4% (n=18) had a preoperative CHADS2 score >2. However, 
However, although we recommend stopping Warfarin after 3 months if the 
patient has a CHADS2 score<2 and she/he is in SR at the Holter recording, 
this is often at the discretion of referring cardiologists.  
In addition, only patients undergoing bilateral approach showed a significant 
improvement in LA function as well as a significant reduction in LA 
dimensions and LAVI and, based on the cut-off value (≥15% decrease in 
LAVI) LARR occurred in 47.3 % of patients in the monolateral group and in 
85.7 % of patients in the bilateral group (p<0.001). Due the small number of 
patients in the monolateral group we could not compare LAEF, LA diameters 
and LA volumes by AF type. However, a high percentage of patients (73.7 
%) in this group had a long-standing persistent or persistent AF with and 
higher extent of substrate modifications and atrial structural remodeling and 
this could explain the lack of LARR in this group. Indeed, all the five patients 
with paroxysmal AF in the monopolar group showed a ≥15% decrease in 
LAVI. 
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Finally, no difference was detected in early and late clinical outcomes, EHRA 
score and freedom from thrombo-embolism. The latter finding suggest that , 
in our experience , the excision /closure of LA appendage did not have any 
repercussion on the incidence of postoperative embolic events even though 
the small number of patient and the limited follow-up time of our study 
suggests extreme caution in interpreting these data. 
 
Limitations of the Study 
This study has some limitations which have to be pointed out. The small 
patient population does not allow to draw any conclusion about effectiveness 
of this technique. Furthermore, the follow-up was limited. Larger series with 
long-term follow up are needed to confirm the effectiveness of the hybrid 
approach and to establish whether the right-sided thoracoscopic hybrid 
procedure may represent a suitable less-invasive choice for all LAF patients 
referred to surgery.  
Furthermore, while data regarding postoperative AF prevalence were 
obtained from a high number of observations and this allowed us to compare 
prevalence by AF type, we could not compare echocardiographic parameters 
in subgroup of patients. 
Moreover, our study did not compare results of the hybrid approach to 
catheter ablation. However, this will be the subject of ongoing studies.  
Finally, atrial function was studied employing only the emptying fraction and 
neither pulsed-wave Doppler nor Tissue Doppler Imaging (TDI) and LA 
strain were employed which would have given more detailed information 
about LA function after AF surgical ablation. All these aspects deserve 
further investigations 
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Conclusions 
Even with the above mentioned limitations, we can conclude that the hybrid 
bilateral approach with a bipolar device for the treatment of LAF  showed a 
good one-year success rate independently of the AF type and a seems to be 
the better choice for LAF fibrillation referred to surgery. In contrast, the 
hybrid monolateral approach was ineffective in long-standing persistent and 
persistent LAF. Nonetheless, it had comparable one-year results in 
paroxysmal AF thus, when combined with an endocardial touch-up, it may 
represent a suitable less-invasive alternative in these patients. Our findings 
need to be confirmed by further larger studies. 
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Normal data were presented as mean ±1 Standard deviation (SD), non parametric data as Median and [Interquartile 
Range]and discrete data as percentage (%).Abbreviations: M/F: Male/Female; BMI: Body mass index; AF: Atrial 
fibrillation; CI: Confidence Interval; EHRA: European Hear Rhythm Association; LAVI: (Biplane) Left atrial 
volume index; LAMax: Maximum left atrial volume; LAMin: minimum left atrial volume; LAEF : Left atrial emptying 
fraction; LA A-P: Left atrial antero-posterior diameter; LA S-I: Left atrial antero-posterior diameter. 
 
 
 
 
 
 
 
Table 1. Hybrid Procedures: Preoperative Data (n=54) 
 
 Right 
Thoracoscopy 
(n=19) 
Bilateral 
Thoracoscopy 
(n=35) 
p 
Age 61.2 ± 8.6 57.1 ±9. 5 0.073 
M/F 16/3 (84.2/15.8) 24/11 (68.5/31.4) 0.23 
BMI 27.6 ± 4.6 26.8±3.6 0.84 
Diabetes 0(0) 1(2.8) 0.71 
Hypertension 7  (36.8) 15(42.8) 0.55 
TIA/CVA 1(5.2) 0(0) 0.28 
Type of preoperative AF 
Paroxysmal 
Persistent 
Long-standing persistent 
 
5 (26.3) 
4 (21.1) 
10(52.6) 
 
16 (45.7) 
8 (22.8) 
11(31.5) 
 
 
0.054 
Prevalence of AF (68% CI) 
Paroxysmal 
Persistent 
Long-standing persistent 
 
20.0 [16.8-23.3] 
34.7 [31.2-38.9] 
63.6 [59.9-67.1] 
 
22.3 [19.2-257] 
32.6 [29.1-36.9] 
61.3 [57.4-65.0] 
 
 
0.74 
EHRA Score 4 [3-4] 4 [3-4] >0.9 
Duration of preoperative AF (yrs.) 5 [3-8.5] 5 [4.2-9.0] 0.66 
Antyarrhythmic Drugs 
Amiodaron 
Dysopiramide 
Flecainide 
Propaphenon 
Sotalol 
 
2 (10.5) 
1(5.3) 
6 (31.5) 
1(5.3) 
5 (26.3) 
 
7 (20.0) 
2 (5.7) 
15 (42.8) 
2 (5.7) 
11 (31.4) 
 
 
 
0.08 
Electrical cardioversion 15 (78.9) 17 (48.5) 0.06 
Previous Catheter Ablation 
For AF 
For Atrial Flutter 
 
6 (31.5) 
5 (26.3) 
 
12(34.3) 
9 (25.7) 
 
0.65 
 
Preoperative Pace Maker 2 (10.5) 2 (7.1) 0.88 
Anticoagulant status 
Sodium Warfarin 
Aspirin 
 
16 (84.2) 
5 (26.3) 
 
30 (85.7) 
10 (28.5) 
 
0.76 
LAVI (mL/m
2
) 47±11 50±12 0.08 
LAMax(mL/m
2
) 49±20 52±25 0.63 
LAMin(mL/m
2
) 30±15 32±18 0.90 
LAEF (%) 38±12 38±11 0.90 
LA A-P (cm) 5.0±0.5 5.2±0.5 0.77 
LA S-I (cm) 6.4±0.5 6.3±0.7 0.60 
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Discrete data were presented as number (percentage). Abbreviations. PVs: Pulmonary Veins; LA: Left 
atrium  
 
 
 
 
 
 
 
Table 2.  Hybrid Procedures: Lesion set (n=54) 
 
 Right  
Thoracoscopy 
(n=19) 
Bilateral 
Thoracoscopy 
(n=35) 
Left atrium   
Right PVs Isolation 19 (100) 35 (100) 
Left PVs Isolation 19 (100) 35 (100) 
Inferior line 19 (100) 31 (88.5) 
Roof line 19 (100) 32 (91.4) 
Isthmus lesion 3 (15.7) 7 (20.0) 
Endocardial gaps closure 17 (88.4) 5 (14.2) 
Excision of LA appendage - 8 (22.8) 
Closure of LA Appendage with a clip - 7 (20.0) 
Right atrium   
Superior vena cava to inferior vena cava lesion - 10 (28.5) 
Superior vena cava circumferential isolation - 8  (22.8) 
Inferior vena cava circumferential isolation - 3 (8.5) 
Cavo-tricuspid isthmus line 2 (10.5) 3 (8.5) 
Ablation of autonomic Ganglia 19 (100) 35 (100) 
239
 
Figure Legends 
 
 
 
 
 
 
 
Figure 1.A Time-related prevalence of atrial fibrillation (solid line) and 68% confidence limits 
(broken lines) after hybrid monolateral approach with a monopolar device. B Time-related 
prevalence of atrial fibrillation (solid line) and 68% confidence limits (broken lines) after 
hybrid bilateral approach with bipolar device. C Time-related prevalence of atrial fibrillation by 
AF type after hybrid monolateral approach with a monopolar device. D Time-related 
prevalence of atrial fibrillation by AF type after hybrid bilateral approach with a bipolar device. 
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Figure 2. A. Time-related prevalence of class I/III anti-arrhythmic use a after hybrid 
monolateral approach with a monopolar device.. B. Time-related prevalence of class I/III anti-
arrhythmic use after hybrid bilateral approach with bipolar device. C Time-related prevalence 
of Warfarin use after after hybrid monolateral approach with a monopolar device. D Time-
related prevalence of Warfarin use after hybrid bilateral approach with bipolar device. 
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Abstract 
Background. We compared short-term results of hybrid versus standard 
surgical bilateral thoracoscopic approach employing radiofrequency (RF) 
sources in the surgical treatment of lone atrial fibrillation (LAF) 
Methods and Results.  Between January 2008 and July 2010 sixty-three 
consecutive patients with LAF underwent minimally invasive surgery. 
Thirty-five (55.5%) had hybrid approach whereas 28 (45.5%) underwent 
bilateral thoracoscopic standard procedure (no-hybrid group). All 
patients underwent continuous 7-day Holter Monitoring (HM) at 3, 6 
months and 1 year. Time-related prevalence of postoperative AF at 12 
months in hybrid and no-hybrid procedure were 5.2 % (68% CI 4.2-6.7), 
and 6.0 % (3.2-9.6) , respectively (p=0.56),.The hybrid group yielded 
better results in long standing persistent AF (8.2% [5.1-11.6] and 14.9% 
[11.6-18.3].One-year estimated prevalence of anti-arrhythmic drugs 
(AAD) were 18.0% (15.5-21.7) and 16.7% ([13.9-21.5] p=0.65) in 
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hybrid and no hybrid group, respectively.When comparing prevalence of 
AAD by AF type, it was significantly lower in hybrid patients in long-
standing persistent AF (26.2 % [17.6-30.4] vs. 38.7% [32.9-42.7], 
p<0.001). One-year prevalence of Warfarin use was significantly higher 
in hybrid (29.0% [26.2-33.1] and 13.4% [9.9-16.3] with no difference by 
AF type. LA reverse remodeling occurred in 81.7% (n=30) of hybrid 
patients and 67.8% (n=19) of no-hybrid patients at latest control 
(p=0.02). Left atrial emptying fraction increased in both groups 
(50±14%, p<0.001 and 52±12%, p=0.004 in hybrid and no-hybrid, 
respectively) without differences between groups (p=0.6). 
Conclusions. The hybrid procedure yielded excellent results in long-
standing persistent AF. Our findings need to confirmed by further larger 
studies.  
 
Introduction 
The introduction of different energy sources
1
 and the development of 
minimally invasive procedures as an alternative to the original "cut-and-
sew" technique
2,3
  allowed a new dawn in the surgical treatment of atrial 
fibrillation. Meanwhile, electrophysiologists (EPs) developed more 
complex ablation systems that allowed the creation of linear lesions, 
similar to the surgical ones, while mapping the atria with three-
dimensional (3D) navigation systems
4
. Nevertheless, the reported success 
rate is suboptimal in both fields
5, 6
 and the most beneficial ablation 
methodology for patients with lone atrial fibrillation (LAF) still remains 
a matter of debate. 
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In the attempt to improve results obtained by standard procedures, the so 
called "hybrid approach" has recently been introduced, which combines a 
thoracoscopic epicardial ablation with a percutaneous trans-septal 
procedure.  Nonetheless, no information exists whether this technique 
has clear advantages over standard thoracoscopic video-assisted surgery. 
The aim of this study was, therefore, to compare short-term results of 
hybrid versus standard surgical bilateral thoracoscopic approach 
employing radiofrequency (RF) sources  in terms of early and late 
complications, prevalence of postoperative atrial fibrillation, prevalence 
of antiarrhythmic medications and anticoagulant use, left atrial (LA) 
remodeling and LA function. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Methods 
Patients 
The study followed the World Medical Association guidelines 
concerning ethical principles for medical research involving human 
subjects and was approved by Institutional Ethics Board. All patients 
gave their informed consent. 
Between January 2008 and July 2010 sixty-three consecutive patients 
with LAF underwent minimally invasive surgical treatment of LAF 
employing a radiofrequency (RF) source.  
Thirty-five (55.5%) had a hybrid approach whereas 28 (45.5%) 
underwent bilateral thoracoscopic standard procedure (no-hybrid group). 
Lone atrial fibrillation was defined following American College of 
Cardiology/American Heart Association/European Society of Cardiology 
(ACC/AHA/ESC) guidelines
7
. 
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Indication for minimally invasive surgery was based on the 
HRS/EHRA/ECA Guidelines
8
. Patients were referred for hybrid 
procedure in case of paroxysmal, persistent or long-standing persistent 
AF with LA dilatation (> 4.5cm), after one or more failed catheter 
ablations, or on patient's preference. The indication was based on the 
history of AF and LA size. A transthoracic echocardiography and a 
computed tomography (CT) scan were carried out preoperatively 
(pulmonary vein anatomy, coronary arteries) and potential candidates to 
a hybrid procedure underwent lung function test (Spirometry). Exclusion 
criteria were a presence of atrial or left appendage thrombi, ‘giant’ left 
atrium (diameter >6.5 cm), coronary artery disease, and previous 
pulmonary or cardiac surgery. Table 1 shows patients baseline 
characteristics. Patients in the hybrid group had larger LA volumes and 
dimensions and a significantly higher CHADS2 [cardiac failure, 
hypertension, age, diabetes, stroke (doubled)] score. The other variables 
were comparable between groups. 
Follow-up and Assessment of AF 
All patients were followed-up according the Heart Rhythm Society/ 
European Heart Rhythm Association/ European Cardiac Arrhythmia 
Society (HRS/EHRA/ECA) expert consensus statement on catheter and 
surgical ablation of AF
9
. Data and outcomes were reported following the 
Society of Thoracic Surgeon (STS) guidelines
10
. 
Seven-day Holter Monitoring (HM) was performed at 3, 6 months and 1 
year. All patients reached 1-year follow up. Monitoring was carried out 
with an external loop recorder (Del Mar Reynolds, Spacelabs Healthcare, 
Issaquah, WA, USA) and analyzed with Lifescreen Software (Del Mar 
Reynolds, Spacelabs Healthcare, Issaquah, WA, USA). For analysis, 
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three rhythms were considered postoperative AF: AF, atrial flutter or 
atrial tachycardia lasting more than 30 sec. In addition, all 
electrocardiograms (ECG) performed at the discretion of referring 
physicians/cardiologists during the first three months after surgery and in 
the time comprised between Holter examinations were included when 
patients had at least two records available for analysis. Each ECG and 
Holter was treated as a discrete data (presence/absence of atrial 
fibrillation) to calculate the estimated prevalence of AF
10
. A total of 785 
postoperative Holter/ ECG data were retrieved (no-hybrid procedure, 
n=377 hybrid procedure, n=408). 
Anticoagulation and Anti-arrhythmic Therapy 
Anti-arrhythmic drugs (AAD) were given postoperatively to all patients 
but, although we recommend discontinuing AAD three months after 
ablation if the patient appears to be AF free, their continued use was at 
the discretion of referring cardiologists. 
Electrical cardioversion was not attempted for patients who remained in 
AF after the surgical procedure and was reserved for patients who were 
still in AF after 3 months and 6 months. 
Warfarin was administered on postoperative day 2 with INR target of 2.5 
and stopped after 3 months if the Holter recording showed a sinus rhythm 
(SR) or patients had a low thromboembolic risk (CHADS2  score<2). 
Echocardiography 
Echocardiography was carried out preoperatively and at 3 month- and 12 
month- follow-up appointments using a commercially available 
echocardiographic system (Philips iE33; Philips Medical Systems, 
Eindhoven, The Netherlands). All the parameters were analyzed “off-
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line” by an experienced echocardiographer (F.L.) using the Xcelera 
software (Philips Medical Systems Eindhoven, The Netherlands).Left 
atrial A-P diameter was measured in parasternal long-axis view  In the 
apical 4-chamber view, LA maximum volume (LA max), at the end of 
LV systole, just before the opening of the mitral valve and LA minimum 
volume (LA min) at the end of LV diastole, just after the closure of the 
mitral valve, were measured
 
and LA emptying fraction    (LA EF) was 
calculated as ([La max-LA min]/La max) x 100. LA maximum volume 
was also measured by biplane area-length method
12
and indexed to body 
surface area (LAVI). Left atrial reverse remodeling (LARR) was defined 
as a reduction in LAVI ≥15% at late follow up13. 
Surgery 
All operations were performed by the same cardiac surgeon (M.L.M)   
All hybrid procedures were carried out at the hybrid operative room of 
the Department of Cardiology, Maastricht University Medical Center, 
Maastricht, The Nederlands involving the same electrophisiologist (L.P.) 
The interventions were performed under general anesthesia with a 
double-lumen endotracheal tube for selective lung ventilation. The chest 
was entered in the second, fourth and sixth interspaces using respectively 
a 5-12-12mm port. Thoracoscopy of the right side was done first 
followed by the left side. The technique was as originally described by 
Yilmaz et al
14
. 
High frequency stimulation (HFS) of the right vagal nerve at the level of 
the mediastinum and at the four major ganglionated  plexi (GPS,[right 
superior GP, right inferior GP, left superior GP and left inferior GP)] was 
carried out  and the vagal respone on the atrio-ventricular node was 
recorded (10V , 1.5-ms pulse width impulse at 1000 pulses per minute 
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from a temporary external pacemaker [Oscor, Oscor INC., Palm Harbor, 
FL]). The isolation of pulmonary veins was performed with the Atricure 
bipolar radiofrequency clamp (Atricure Inc, Westchester, Ohio, USA). 
With the clamp placed on the antrum of the pulmonary veins (first from 
the right side and then from the left side) a mean of 3.0±0.4 and 3.8±0.9 
ablations were performed in hybrid and no-hybrid group, respectively 
(p=0.44). A roof and inferior line were created using the Coolrail linear 
pen (Atricure Inc, Westchester, Ohio, USA) or the Max 3 unidirectional 
bipolar pen. (Atricure Inc, Westchester, Ohio, USA) connecting PVs 
from the right side, trough the transverse and oblique sinuses, with the 
PVs from the left side. The endpoint was entrance and exit block for the 
created “box”. Entrance block was defined as the absence of atrial 
potentials inside the area of the lesions. Exit block was defined as failure 
to capture the remaining LA when pacing from the posterior LA with 
proven local capture with an output of 18V and 1.5 ms pulse width.   
After creation of the box lesion (PVs isolation-roof-inferior line) the 
vagal response at level of GPS was tested again. The end point for 
ganglionated plexi (GP) ablation was the elimination of a vagal response 
to stimulation. In all patients this vagal response could no longer be 
induced with HFS, except for the right inferior GP which, being located 
outside the box lesion resulted not to be ablated in any patient. Thus the 
inferior GP was ablated with the Max 3 pen. (Atricure Inc, Westchester, 
Ohio, USA).  
In the hybrid Group a left femoral vein puncture was made and a His 
bundle catheter (St Jude Medical, Inc, Minnetonka, MN, USA) and a 
coronary sinus (CS) catheter  (Medtronic, Inc, Minneapolis, MN, USA) 
were placed under fluoroscopic guidance. Through the right femoral 
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vein, a single trans-septal puncture was made using TEE and fluoroscopy 
and a long sheath 8F (SL0, St. Jude Medical Daig Division, Inc., 
Minnetonka, MN, USA) was advanced into the LA. The patient was 
heparinised to keep the activated clotting time >300 seconds.  
During rapid ventricular pacing from the His catheter, contrast was 
injected through the long sheath in order to visualize PVs and the LA. 
PVs were mapped with suitably sized circular mapping catheter (Lasso, 
Biosense Webster, Inc, Diamond. Bar, CA, USA) placed at the ostium of 
the PVs. 
In all patients epicardial pacing was utilized to demonstrate entrance and 
exit block; entrance block was defined as failure to capture the PVs 
during pacing from the left atrium at 18 V and 1.5-ms pulse width and 
exit block was defined by failure to capture the left atrium during the 
pacing from the PVs. 
In hybrid patients endocardial recordings at the PVs were also employed 
to demonstrate entrance and exit block for each PV. Entrance block was 
defined as the absence of pulmonary veins potentials (PVPs). Exit block 
was defined by failure to capture when pacing from each dipole of the 
Lasso catheter with an output of 10 mA and 2.0 ms pulse width.  
In these patients, in case of sinus rhythm after PV ablation, induction of 
AF was attempted 5 times by pacing in the coronary sinus for 10 second 
at the shortest cycle length resulting in 1:1 atrial capture. AF was 
considered inducible if it lasted more than 1 minute. If AF was not 
inducible isoproterenol was infused at rates of 10-20 µg/min. If AF was 
still inducible (or was not terminated) linear lesions were carried out. We 
identified the conduction gaps from the endocardium and ablated those 
with a 3.5 mm tip-catheter (ThermoCool, Biosense Webster, Inc., 
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Diamond. Bar, CA, USA)  trough the sheath in the LA. The precise 
location of the linear lesions was visualized with the Coolrail probe 
(Atricure Inc, Westchester, Ohio, USA) in situ and using fluoroscopy. 
Gaps in linear lesions were defined as low amplitude and fragmented or 
narrowly split double atrial potentials.  
In case of persistence of AF, a left isthmus line was made in hybrid 
procedures starting from the ablation line on the antrum of the left 
inferior PV and crossing the CS, using the the Max 3 pen. (Atricure Inc, 
Westchester, Ohio, USA) on the epicardial side. This line was completed 
by the EP endocardially from the mitral annulus towards the CS with the 
ThermoCool  catether (ThermoCool, Biosense Webster, Inc., Diamond. 
Bar, CA, USA) 
The endpoint of ablation of the mitral isthmus was the bidirectional block 
which was achieved when the following criteria were met: 
1) proximal-to-distal activation sequence along the CS catheter after 
pacing lateral to the line in the LA appendage;  
2) Late activation on the opposite side after pacing on the septal side of 
the line through the CS; 3) widely separated local double potentials along 
the whole length of the ablation line. 
An inferior vena cava (IVC)-to-superior vena cava (SVC) and SVC 
circumferential lesions were added when patients with persistent and 
long-standing persistent AF had a right atrial volume ≥58 ml. IVC 
circumferential isolation was performed in patients with a small portion 
of intrapericardial IVC to be sure that the SVC-IVC line would stop at an 
area of no conduction. The isolation of the SVC and the IVC was 
confirmed by testing of conduction block across the ablation lines. 
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In hybrid patients, if the patient had a history of typical right atrial flutter 
or this arrhythmia became apparent during the procedure, we performed 
a cavo-tricuspid isthmus line (CTI) endocardially. The endpoint was 
bidirectional block and the presence of widely separated double 
potentials along the whole length of the ablation line.   
In patients with CHADS2 score ≥1, or in presence of a rapid firing 
coming from the left atrial appendage (LAA), and when the procedure 
was deemed safe, LAA exclusion/ closure was performed under 
transesophageal echocardiographic (TEE) guidance employing a stapler 
(Endo GIA, Covidien, Norwalk, CT) or a clip (Atricure, West Chester, 
OH). The absence of flow was confirmed by intraoperative 
transesophageal echocardiography.  
The lesion set in the two Groups is shown in Table 2. 
Median operative time were 268 minutes (IQR 186-477) in hybrid 
operations and 127 minutes (IQR 97-188) in standard minimally invasive 
procedures (p=0.001).   
Statistical Analysis 
Normal values were expressed as mean ± one standard deviation (SD), 
non-normal values as median and interquartile range (IQR) and 
categorical variables as percentages. T test, Wilcoxon and McNemar’s 
tests were employed where appropriate. 
We analyzed all of the intermittent data available in terms of time-related 
prevalence of atrial fibrillation with a multiphase hazard decomposition 
method
10, 15
. Time-related prevalences are presented as percentages with 
asymmetric 68% confidence limits (CLs), comparable to ± one standard 
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error. The CLs for AF prevalence were obtained with the bootstrap 
percentile method.  
Analyses of prevalence of AF do not account for anti-arrhythmic 
medications thus prevalence of anti-arrhythmic medication use was 
estimated by mixed modeling based on medication use at each follow-up 
assessment
16
.With the same method we estimated the prevalence of 
Warfarin use at time of each follow-up.  
Statistical analyses were performed using SPSS release 12.0 (SPSS, 
Chicago, IL, USA) and Curve Expert Professional release1.0.1 (D.G. 
Hyams, Chattanooga, TN, USA).P values less than 0.05 were considered 
significant. 
 
Results 
Clinical outcome and Recurrence of AF 
There was no pulmonary vein injury, mortality, stroke or reoperation for 
bleeding in the two groups. Furthermore, all the procedures could be 
completed as planned without any conversion to sternotomy and there 
were no requirements for blood transfusion. 
Median Intensive care unit (ICU) and median in-hospital length of stay 
were comparable in the two groups (6.2 hours [IQR 5.5-13.4] vs. 6.7 
hours [4.3 to 13.9] vs. p=0.9; 3.4 days [2.6-4.1 
vs. 3.8 days [2.9-4.4], p=0.87, in hybrid and no-hybrid procedures, 
respectively).No patient died during the follow up. There was a 
significant improvement in median EHRA (European Hear Rhythm 
Association) score in both groups (both, 1[1-2], p<0.001 vs. baseline).  
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Time-related prevalence of postoperative AF at 12 months (Figure 1 A-
B) in  patients undergoing  hybrid procedure or standard thoracoscopic 
approach were 5.2 % (4.2-6.7), and 6.0 % (3.2-9.6) , respectively 
(p=0.56). 
Figure 1 C-D shows estimated prevalence of postoperative atrial 
fibrillation by AF type. At 1 year it was 8.2% (5.1-11.6) and 14.9% 
(11.6-18.3) in long standing persistent (p=0.04), 3.8 % (1.4-6.9) and 0 % 
in persistent (p<0.001) and 3.2% (1.0-6.5) and 0% in paroxysmal AF 
(p<0.001) in hybrid and no hybrid and group, respectively 
At 12 months estimated prevalence of AAD (Figure 2 A-B) were 18.0% 
(15.5-21.7) and 16.7% ([13.9-21.5] p=0.65) in hybrid and no hybrid 
group, respectively (Figure 2 A-B). When comparing prevalence of AAD 
by AF type, it was significantly lower in hybrid patients in long-standing 
persistent AF (26.2 % [17.6-30.4] vs. 38.7% [32.9-42.7], p<0.001) 
whereas it was higher in this group in persistent (16.0 % [13.4-20.6] vs. 
6.1% [3.9-9.2], p<0.001) and paroxysmal AF (12.2 % [9.7-15.4] vs. 
4.7% [2.9-7.7], p<0.001). 
One-year prevalence of Warfarin use (Figure 2 C-D) were and 29.0% 
(26.2-33.1) and 13.4% (9.9-16.3) in hybrid and no hybrid group 
respectively (p<0.001). This difference was observed in long standing-
persistent (35.5 % [29.7-38.2] vs. 20.9% [16.9-20.6], p<0.001), persistent 
(22.7 % [16.1-24.8] vs. 13.0% [9.9-17.1], p<0.001) and paroxysmal AF 
(17.3 % [15.4-21.2] vs. 7.9 % [4.8-10.5], p<0.001).No thromboembolic 
event occurred during the follow-up in the two groups 
Finally, two patients in the hybrid group required electrical cardioversion 
(both 3 months after surgery). In contrast, none in the no-hybrid group 
underwent electrical cardioversion (p=0.57).  
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Echocardiographic Results 
At 3 month- LAVI was significantly reduced in both Groups (35±8 
mL/m
2
, p<0.001 vs. 3 months and 40±9 mL/m
2
, p=0.03 vs. 3 months, in 
hybrid and no-hybrid, respectively) with a further significant 
improvement at 12 months (30±7 mL/m
2
, p<0.001 and 35±3 mL/m
2
, 
p=0.03). However, biplane LAVI was significantly lower in the hybrid 
group at each control (p=0.03 and p=0.02 at 3 and 12 months, 
respectively). In long-standing persistent AF LAVI reduced significantly 
only in hybrid procedures at postoperative controls. In contrast it was 
reduced in both groups without statistical significance in long-standing 
persistent and paroxysmal patients (Figure 3 A-C). 
Based on the cut-off value (≥15% decrease in LAVI) LARR occurred in 
81.7% (n=30) of hybrid patients and 67.8% (n=19) of no-hybrid patients 
at 12-month control (p=0.02). In patients with long-standing LAF, LARR 
occurred in 81.8% (9/11) of patients in hybrid group and 0% (0/9) in no 
hybrid (p<0.001). The percentage of patients with persistent (87.5% [7/8] 
vs. 100% [5/5]) and paroxysmal LAF (87.5% [14/16] vs. 100% [14/14]) 
was comparable (p=0.3 and p=0.1, respectively). 
At 3 months LAEF raised only in no-hybrid patients (47±15%, p=0.002) 
whereas it reduced in hybrid without reaching statistical significance 
(35±9%, p=0.7, p<0.001 vs. no-hybrid). At 1 year LAEF   increased in 
both groups (50±14% [p<0.001 vs. 3 months] and 52±12% [p=0.004 vs. 
3 months], in hybrid and no-hybrid, respectively) without differences 
between groups (p=0.6). Figure 4 A-C shows LAEF by AF type: at one-
year control LAEF was significantly higher in the hybrid group in long-
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standing persistent patients and in the no-hybrid group in paroxysmal. In 
persistent AF data were comparable between groups..  
LA diameters decreased significantly at 3 months in hybrid (3.5 ± 0.3 
cm, p<0.001 vs. baseline) as well as in no hybrid patients (3.6 ± 0.4 cm, 
p=0.003). Both diameters further reduced at one year (hybrid, 3.3 ± 0.3 
cm; no-hybrid, 3.4 ± 0.3 cm) without reaching statistical significance 
(p=0.5 and p=0.4, respectively). Among long-standing persistent patients 
LA diameters reduced, in hybrid procedures, at 3 months (4.0 ± 0.4 cm, 
p<0.001 vs. baseline) and 12 months (3.6 ± 0.3 cm, p=0.01 vs. 3 months) 
whereas in no-hybrid did not vary from baseline (3 months, 4.4 ± 0.4 cm, 
p=0.08 vs. baseline; one year, 4.4 ± 0.4 cm, p=0.9 vs. 3 months). In 
persistent LA diameters decreased significantly at 3 months in hybrid 
(3.2 ± 0.3 cm, p<0.001) as well as in no hybrid patients (3.2± 0.3 cm, 
p=0.001; between groups p=0.9). Finally, in paroxysmal AF there was a 
significant reduction in both groups at 3 months (hybrid 3.0 ± 0.3 cm, 
p=0.01; no-hybrid, 2.9± 0.2 cm, p<0.001; between groups p=0.74) with 
values remaining stable at one year (hybrid 3.0 ± 0.3 cm, p=0.9; no-
hybrid, 2.9± 0.2 cm, p=0.09; between groups p=0.7). 
 
Discussion 
With the development of new tools and advanced techniques, the 
treatment of LAF moves toward a multidisciplinary approach involving 
cardiac surgeons and electrophysiologists
17
. Although catheter ablation is 
considered an effective treatment for AF
18
, its success rate without anti-
arrhythmic drugs resulted to be suboptimal
5
. Failures of percutaneous 
catheter ablation are most often due to recurrence of pulmonary vein 
conduction, due to a lack of transmural lesions
19
. In addition, recent data 
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A mes parents 
Vouloir c’est pouvoir 
 
suggests the importance of the left atrial appendage (LAA)
 20
, ligament of 
Marshall (LOM)
 21
, and epicardial ganglia
22
 which remain difficult to 
target endocardially. 
Surgical epicardial ablation, can isolate the superior vena cava (SVC) 
without phrenic nerve injury, eliminate the LOM, remove the LAA, 
target the ganglia and create transmural lesions around the PVs
,2, 
3,6,14
.Nonetheless, surgical ablation is limited by post-ablation flutters, 
often due to gaps in linear lesions made by unipolar devices
23
. In 
addition, typical right-sided atrial flutter complicates up to 12% of 
minimally invasive surgical ablation, and it could likely be prevented by 
a cavo-tricuspid isthmus (CTI) line, which is easily created by 
endocardial catheters
24
. 
Hybrid ablation is a dual approach in which an electrophysiologist 
ablates from inside the heart and a cardiac surgeon ablates on the outside 
of the heart in order to limit the shortcomings of both techniques and, at 
the same time, to combine their advantages. 
The concept of “hybrid procedure” was first published by Pak and co-
workers
25
  who combined percutaneous epicardial catheter ablation 
(PECA) and endocardial ablation in difficult cases of AF. More recently, 
Krul et al.
26
 presented their experience with thoracoscopic PV isolation 
and ganglionated plexus (GP) ablation guided by peri-procedural 
electrophysiological testing resulting in a single-procedure success rate 
of 86%. Mahapatra et al.
27 
have recently published their initial experience 
with surgical epicardial-catheter and endocardial ablation for ersistent 
and long-standing persistent atrial fibrillation carried out in two 
sequential steps. After a mean follow-up of 20.7±4.5 months, 86.7 % 
patients were free of any atrial arrhythmia and off of antyarrhythmic 
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drugs (AAD). This figure was 53.3% in patients undergoing catheter-
alone procedure (p =0.04).Nonetheless, no data have been published 
comparing the hybrid technique to standard thoracoscopic video-assisted 
surgery. The purpose of this study was, therefore, to investigate whether 
the combined approach has clear advantages over standard minimally 
invasive surgical AF ablation.  
The current literature is extremely difficult to interpret. This confusion is 
compounded by a lack of consensus on methods and timing of follow-up 
evaluation as well as the absence of strict definitions of success. The 
workforce on evidence-based surgery of the Society of Thoracic 
Surgeons 
10
 proposed an approach to report success/failure. They 
suggested analyzing all the intermittent data available in terms of time-
related prevalence (burden) of atrial fibrillation
10, 15, 16
. In the present 
study we report our results as time-related prevalence of postoperative 
AF, ADD use and Warfarin use. To the best of our knowledge, this is the 
first study which compares standard minimally invasive technique with 
the hybrid approach. 
The main findings of this study can be summarized as follows: 
First, although both techniques yielded satisfactory and comparable 
results in terms of 1-year related prevalence of postoperative AF (5.2 % 
and 6.0 % ) and  prevalence of AAD (18.0% vs.16.7% ), both these 
figures  (8.2% vs. 14.9% and 26.2 % vs.. 38.7%, respectively) were 
lower in hybrid patients in case of long-standing persistent AF. This may 
be explained with the fact that, unlike paroxysmal AF, which is caused 
by triggers that most often are inside the pulmonary veins, long-standing 
persistent AF is characterized by changes in the atrial tissue and muscle 
(substrate modification) that leads to chaotic electrical activity
28
. Thus, 
265
 
these patients might need more areas in the heart ablated than what is 
done in PV isolation. In contrast, the no-hybrid technique gained 
lower12-month related AF prevalence and prevalence of AAD in 
paroxysmal AF (0% vs. 3.2% and 4.7% vs. 12.2%) and, surprisingly, in 
persistent AF (0%vs.3.8% and 6.1% vs.16.0%, respectively). We might 
postulate that the smaller preoperative LA volume (54±12 ml/m
2
 vs. 
50±15 ml/m
2
) in patients with persistent AF in no-hybrid group reflects a 
lesser extent of substrate modifications and this could explain the better 
results obtained with the epicardial ablation in these patients.  
Second, we observed an higher  percentage of LA reverse remodeling 
after hybrid procedure in long-standing AF patients (81.8% vs.0%)  
whereas it was comparable in persistent ( 87.5% vs. 100%)  and 
paroxysmal LAF ( 87.5% vs. 100%). Atrial size and LAVI reduced in 
both groups in persistent and paroxysmal AF whereas, in long-standing 
persistent patients these values were reduced only in patients undergoing 
a hybrid procedure. Atrial structural remodeling, with LA enlargement is 
a hallmark of AF and reverse remodeling is considered an important 
target of any AF treatment. Indeed, LA volume showed a strong 
correlation with the extent of fibrosis at 3D delayed-enhancement and the 
stretching of the LA myocites increases the intercellular matrix, collagen 
production and fibrosis
29
. Longer duration of AF is known to cause 
progressive remodeling and increased LA volume and long-persistent AF 
is considered to be an advanced stage of the arrhythmia as compared to 
paroxysmal AF. Our findings demonstrate that these patients may benefit 
from the epicardial-endocardial approach which increases the likelihood 
that ablation lines are transmural. In contrast, epicardial PVs isolation 
was more effective, in terms of La remodeling, in patients with 
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paroxysmal AF. Minimally invasive epicardial ablation resulted in 
significant reverse remodeling also in patients with persistent AF with 
small atria in whom remodeling may be still reversible.  
Third, after a transient, even not significant, reduction presumably related 
to the scar tissue produced by radiofrequency endocardial catheter 
ablation, we observed, in the hybrid group, a significant increase in  atrial 
function, expressed as LA emptying fraction (LAEF). Atrial function was 
comparable in the two groups at one year. Nonetheless, when considering 
LAEF  by AF type, it improved at latest follow up much more in hybrid 
patiens when the AF was long-standing persistent while LAEF was 
significantly higher in the no-hybrid group in case of paroxysmal AF. In 
persistent AF data were comparable. The recovery of LA function after 
ablation is a complex phenomenon and currently there is no 
standardization in the measurement of LA function. Transmitral flow 
velocity with pulsed Doppler imaging shows the flow velocity due to 
atrial contraction. This can be used to measure atrial force, an indirect 
measure of atrial contraction. Unfortunately, the A wave is highly 
depending on loading condition (i.e. LA and LV pressures) and it is 
absent in AF. We employed the emptying fraction as measure of LA 
function. During the initial part of ventricular diastole, the LA has a 
passive conduit function, whereas it has an active pump or booster 
function during the later part of ventricular diastole, as the atrium 
contracts. In sinus rhythm atrial emptying comprises both passive and 
active phases whereas in AF there is only a passive phase, hence the term 
“emptying fraction” rather than “ejection fraction”. LAEF   mirrors the 
structural changes in LA and preoperative LAEF was shown to be a 
powerful predictor of successful MAZE procedure
30
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Fourth, one-year prevalence of Warfarin use was higher in hybrid 
patients independently of the type of atrial fibrillation and this can 
explained by an higher preoperative thrombo-embolic risk  in these 
patients, expressed by an higher CHADS2  score and larger LA volumes 
and diameters. However, although we recommend stopping Warfarin 
after 3 months if the patient has a  CHADS2  score<2 and she/he is in SR 
at the Holter recording, this is often at the discretion of referring 
cardiologists. 
 
Limitations of the Study 
Some limitations of the present study warrant consideration. The small 
number of patients and the short follow up does not allow to draw any 
conclusion about the effectiveness of these techniques. Furthermore, 
while data regarding postoperative AF prevalence were obtained from a 
high number of observations, some caution should be exercised before 
generalizing the results of left atrial remodeling by AF type due to the 
small number of patients in each group. In addition our study did not 
compare results of the hybrid approach to catheter ablation. However, 
this will be the subject of ongoing studies.  
Finally, atrial function was studied employing only the emptying fraction 
and neither pulsed-wave Doppler nor Tissue Doppler Imaging (TDI) and 
LA strain were employed which would have given more detailed 
information about LA function after AF surgical ablation. All these 
aspects deserve further investigations. 
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Conclusion 
Even with the above mentioned limitations we can conclude that both 
minimally invasive procedures resulted to be effective in the treatment of 
LAF. The hybrid procedure yielded better results in long-standing 
persistent AF and, in these patients it might represent a suitable option to 
treat LAF. Our findings need to be confirmed by further larger studies.  
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Normal data were presented as mean ±1 Standard deviation (SD), non parametric data as 
Median and [Interquartile Range]and discrete data as percentage (%).Abbreviations: M/F: 
Male/Female; BMI: Body mass index; AF: Atrial fibrillation; CI: Confidence Interval; EHRA: 
European Hear Rhythm Association; CHADS2 : cardiac failure, hypertension, age, diabetes, 
stroke (doubled)]; PTCA: Percutaneous transluminal coronary angioplasty; LA: Left Atrium; 
RA: Right Atrium LVEF: Left ventricular ejection fraction LAVI: (Biplane) Left atrial volume 
index; LAMax: Maximum left atrial volume; LAMin: minimum left atrial volume; LAEF : Left 
atrial emptying fraction. 
 
 
Table 1. Baseline Data (n=63) 
 Hybrid 
(n=35) 
No-Hybrid     
(n=28) 
p 
Age 57.1 ±9. 5 67.1 ± 9.1 0.06 
M/F 24/11 (68.5/31.4) 17/11(60.7/39.3) 0.1 
BMI 26.8±3.6 28.6±3.6 >0.9 
Diabetes 1(2.8) 0(0) 0.87 
Hypertension 15 (42.8) 14(50.0) 0.31 
TIA/CVA 0(0) 1 (3.5) 0.85 
Type of preoperative AF 
Paroxysmal 
Persistent 
Long-standing persistent 
 
16 (45.7) 
8 (22.8) 
11(31.5) 
 
14 (50.0) 
    5 (17.8) 
    9 (32.2) 
 
 
0.44 
Prevalence of AF 
Paroxysmal 
Persistent 
Long-standing persistent 
 
22.3 [19.2-257] 
32.6 [29.1-36.9] 
61.3 [57.4-65.0] 
 
21.9 [17.8-24.0] 
32.7 [28.9-36.2] 
68.4 [63.6-72.2] 
 
 
0.86 
EHRA Score 4 [3-4] 3 [3-4] 0.08 
CHADS2 Score 1.6 ±0.5 0.9±0.3 <0.001 
Duration of preoperative AF (yrs.) 5 [4.2-9.0] 7 [5.9-11.4] 0.06 
Antiarrhythmic Drugs 
Amiodaron 
Dysopiramide 
Flecainide 
Propaphenon 
Sotalol 
 
7 (20.0) 
2 (5.7) 
15 (42.8) 
2 (5.7) 
11 (31.4) 
 
7(25.0) 
2(7.1) 
16 (57.1) 
1 (3.5) 
11(39.2) 
 
 
 
0.12 
Electrical cardioversion 17 (48.5) 14 (50.0) 0.83 
Previous Catheter Ablation 21 (60.0) 21 (75.0) 0.06 
Preoperative Pace Maker 2 (10.5) 2 (7.1) 0.07 
Anticoagulant status 
Sodium Warfarin 
Aspirin 
 
30 (85.7) 
10 (28.5) 
 
25 (89.2) 
6 (21.4) 
 
0.67 
LAVI (mL/m
2
) 50±12 45±15 0.03 
LAEF (%) 38±11 36±10 0.66 
LA diameter (cm) 5.2±0.5 4.2±0.4 0.01 
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Discrete data were presented as number (percentage). Abbreviations. PVs: 
Pulmonary Veins; LA: Left atrium.  
 
 
 
 
 
 
Table 2 Lesion set (n=63) 
 
 Hybrid 
(n=35) 
No-Hybrid     
(n=28) 
Left atrium   
Right PVs Isolation 35 (100) 28 (100) 
Left PVs Isolation 35 (100) 28 (100) 
Inferior line 31 (88.5) 28 (100) 
Roof line 32 (91.4) 28 (100) 
Isthmus lesion 7 (20.0) - 
Endocardial gap closures 5 (14.2) - 
Excision of LA appendage 8 (22.8) 7 (25) 
Closure of LA Appendage with a clip 7 (20.0) 7 (25) 
Right atrium   
Superior vena cava to inferior vena cava lesion 10 (28.5) 8 (28.5) 
Superior vena cava circumferential isolation 8  (22.8) 3 (10.7) 
Inferior vena cava circumferential isolation 3 (8.5) 2 (7.1) 
Cavo-tricuspid isthmus line 3 (8.5) - 
Ablation of autonomic Ganglia 35 (100) 28(100) 
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Figure Legends 
 
 
 
 
 
 
Figure 1.  A.  Time-related prevalence of atrial fibrillation (solid line) and 68% confidence 
limits (broken lines) after minimally invasive hybrid procedure.  B. Time-related 
prevalence of atrial fibrillation (solid line) and 68% confidence limits (broken lines) after 
minimally invasive standard bilateral thoracoscopic procedure. C. Time-related prevalence 
of atrial fibrillation by AF type after minimally invasive hybrid procedure. D Time-related 
prevalence of atrial fibrillation by AF type after minimally invasive standard bilateral 
thoracoscopic procedure. 
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Figure 2. A. Time-related prevalence of class I/III anti-arrhythmic use after minimally 
invasive hybrid procedure B. Time-related prevalence of class I/III anti-arrhythmic use 
after minimally invasive standard bilateral thoracoscopic procedure. C Time-related 
prevalence of Warfarin use after minimally invasive hybrid  procedure. D  Time-related 
prevalence of Warfarin use after minimally invasive standard bilateral thoracoscopic 
procedure.  
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Figure 3.  A-C.  Left Atrial Volume Index (LAVI) and 95% Confidence interval (error 
bars) by atrial fibrillation type.*p<0.05 vs. baseline values. 
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Figure4. A-C. Left Atrial Emptying Fraction (LAEF) and 95% Confidence interval (error 
bars) by atrial fibrillation type.*p<0.05 vs. baseline values. 
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Abstract 
Objective. The present study was aimed at demonstrating the beneficial effect 
of minimally invasive radiofrequency surgical ablation on left atrial remodeling 
employing Two-dimensional speckle-tracking echocardiography 2D-STE. 
Methods. The study population consisted of 33 patients (mean age 64.6 ± 6.9, 
84.8% male) with paroxysmal lone atrial fibrillation undergoing minimally 
invasive radiofrequency surgical ablation at our Institution (Cardiothoracic 
Surgery, University Hospital, Maastricht, The Netherlands) between 2007 and 
2011.Twenty age- and gender-matched healthy adults represented the control 
group. LA peak systolic strain (εP), peak strain rate (SRP), peak early diastolic 
strain rate (SRE) and peak negative strain rate (SRA) were measured. Left atrial 
reverse remodeling (LARR) was defined as a reduction in Left atrial volume 
Index (LAVI) ≥15%. 
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Results. Peak systolic strain was lower in patients with AF compared with 
controls (p<0.001). It increased significantly at 3 months (p<0.001) and 1 
year (p=0.01). Similarly, SRP (p<0.001) and SRE (p<0.001) increased after 
surgery at 3 months (p=0.004) and 12 months (p=0.001). Finally, SRA was 
lower at baseline when compared with controls (p<0.001) but it increased 
significantly at follow-up (p= 0.02 and p= 0.01 at 3 and 12 months, 
respectively). LA reverse remodeling occurred in 60.6% of patients at 3 
months and 72.7% at 12 month-control. 
Conclusions. Minimally invasive radiofrequency ablation resulted in 
significant LARR as well as in a significant improvement of LA 
compliance and function after restoration of sinus rhythm as demonstrated 
by 2D-STE analysis. Our findings need to be confirmed by further larger 
prospective studies.  
 
Introduction 
Two-dimensional speckle-tracking echocardiography (2D-STE) is a non-
Doppler based technique that has been used recently to evaluate dynamic 
left atrial (LA) function
1
. It has been demonstrated that 2D-STE is an easy 
and reproducible tool for the assessment of atrial mechanics in atrial 
fibrillation (AF)
2
 and to be a predictor of stroke risk and cardiovascular 
outcomes in AF patients
3
.  
Electrical remodeling (shortening of atrial refractoriness), structural 
remodeling (alterations in atrial collagen content and atrial geometry) and 
contractile remodeling (loss of contractility) are  hallmarks of 
electrophysiological and cellular changes occurring in AF
4-6
. All these 
changes are partly reversible with a recovery of function, morphology, and 
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to some extent of electrophysiological properties of the LA tissue (left 
atrial reverse remodeling, LARR)
7
. Reverse remodeling has been shown 
after restoration of sinus rhythm after cardioversion
8
. In addition LARR has 
been demonstrated to occur in a significant number of patients after 
successful catheter ablation for AF
 
and it has been shown that baseline LA 
strain was an independent predictor of LARR after this procedure
9, 10
. 
Nonetheless, little information exists about LA function and LA strain after 
AF surgical ablation and, to the best of our knowledge, no data has been 
published on this topic regarding minimally invasive procedures. 
Therefore, the present study was aimed at demonstrating the beneficial 
effect of minimally invasive radiofrequency surgical ablation on left atrial 
function after restoration of sinus rhythm employing 2D-STE. 
 
Methods   
Study population 
The study followed the World Medical Association guidelines concerning 
ethical principles for medical research involving human subjects and was 
approved by the Institutional Ethics Board. All patients gave their informed 
consent. 
Patients were included in our study according to the following inclusion 
criteria: 1) Paroxysmal AF treated successfully by radiofrequency bipolar 
surgical ablation for lone atrial fibrillation (LAF) 2) Old history (>6 
months) of paroxysmal recurrent AF with symptoms but in stable sinus 
rhythm in the 48 h preceding the ablation therapy in order to perform a 
dedicated echocardiography. Exclusion criteria were: 1) Previous ablation 
procedures; 2) presence of intracardiac thrombi at transesophageal 
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echocardiography (TEE); 3) patent foramen ovale or atrial septal defect; 4) 
‘giant’ left atrium (diameter >65 mm); 5) coronary artery disease; 6) 
previous pulmonary or cardiac surgery. 
LAF was defined following American College of Cardiology/American 
Heart Association /European Society of Cardiology (ACC/AHA/ESC) 
guidelines
11
 and updated ESC Guidelines were employed to distinguish 
type of AF and to score the AF-related symptoms (European Heart Rhythm 
Association [EHRA] score)
12
. 
Among 72 patients undergoing minimally invasive radiofrequency surgical 
ablation at our Institution (Cardiothoracic Surgery, University Hospital, 
Maastricht, The Netherlands) between 2007 and 2011, 33 met the inclusion 
criteria and were, therefore, the subjects of this study. 
Patient characteristics are shown in Table 1 
Twenty age- and gender-matched healthy adults without cardiovascular 
disease and/or history or cardiovascular risk factors and who did not use 
cardiovascular medication, were selected as the control group as reference 
for the LA atrial function assessment by echocardiography. 
 
Surgery 
Indication for surgery was based on the HRS/EHRA/ECA Guidelines
13 
. 
All operations were performed by the same cardiac surgeon (M.L.M).The 
chest was entered in the second, fourth and sixth interspaces using 
respectively a 5-12-12mm port. Thoracoscopy of the right side was done 
first and was then followed by the left side. The pericardium was opened 
anterior to the phrenic nerve on the right and posterior to the phrenic nerve 
on the left. The technique was as originally described by Yilmaz et al
14
.The 
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rhythm was determined by placing a bipolar pen probe (Atricure Inc, 
Westchester, Ohio, USA) on the left atrium, and recordings were made 
with a physiological recorder
15
. Autonomic ganglia were identified by 
high-frequency stimulation to detect a vagal response at 20 predetermined 
epicardial sites around the pulmonary vein antra.  
Ablation of right and left PVs was performed using a bipolar 
radiofrequency clamp (Atricure, Westchester, OH, USA). With the clamp 
placed on the antrum of the pulmonary veins, 3 to 6 ablations were 
performed (mean 3.8± 0.9).The end point for pulmonary vein ablation was 
complete entrance and exit block into and from the pulmonary veins. 
Entrance block was defined as failure to capture the pulmonary veins 
during pacing from the left atrium at 7.5 V and 1.5-ms pulse width. Exit 
block was defined by failure to capture the left atrium when pacing from 
the pulmonary veins distal to the radiofrequency lesions at 7.5 V and 1.5-
ms pulse width. A proprietary algorithm terminated radiofrequency energy 
(maximum, 28 W) after impedance changes indicated transmural injury. In 
19 patients (57.5%) entrance and exit block were checked endocardially by 
the electrophysiologist through a catheter (Lasso catheter, Biosense 
Webster Inc, Diamond Bar, USA) placed at the ostium of the PVs to assess 
the presence of pulmonary vein potentials. 
Ganglionated plexi (GP) mapping was performed by placing the bipolar 
pen at each site and stimulating with an 18-mV, 1.5-ms pulse width 
impulse at 1000 pulses per minute from a temporary external pacemaker. A 
positive response to GP stimulation was defined as prolongation of RR 
interval ≥50%. Bipolar radiofrequency energy at 15 W was delivered 
through the bipolar pen .The end point for GP ablation was the elimination 
of a vagal response to stimulation. 
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Connecting lesions, the roof and inferior lines, were created using the 
Coolrail and/or the Max5 Pen (Coolrail, Atricure Inc, Westchester, Ohio, 
USA).The lesions were tested after completion of both lines by pacing 
inside the isolated posterior left atrium and confirming exit block. 
Left atrial appendage (LAA) exclusion/ closure was performed under TEE 
guidance in patients with CHADS2 score ≥116, in the presence of a rapid 
firing coming from the LAA and when it was deemed safe. Indeed, the left 
atrial appendage (LAA) was excised in 4 patients (12.1%) employing a 
stapler (Endo GIA, Covidien, Norwalk, CT) or, in 6 patients (18.1 %) it 
was closed by employing a clip (Atricure, West Chester, OH). The absence 
of flow was confirmed by intraoperative transesophageal 
echocardiography. 
  
Echocardiographic assessments 
Echocardiography was performed preoperatively, 3 months and 12 months 
postoperatively using a commercially available echocardiographic system 
(Philips iE33; Philips Medical Systems, Eindhoven, The Netherlands). All 
the parameters were analysed by two experienced echocardiographists 
(F.L. and C.M.R) using the Xcelera software (Philips Medical Systems 
Eindhoven, The Netherlands). Left ventricular ejection fraction (LVEF) 
was assessed by the bi-apical Simpson disk method
17
. 
In the parasternal long-axis views LA maximum antero-posterior (A-P) 
diameter was measured. 
LA superior-inferior (S-I) diameter was measured from the mitral annular 
plane to the posterior wall of the LA in the apical 4-chamber view. In the 
apical 4-chamber view, LA maximum volume (LA max), at the end of LV 
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systole, just before the opening of the mitral valve and LA minimum 
volume (LA min) at the end of LV diastole, just after the closure of the 
mitral valve, were measured
3
. LA emptying fraction (LA EF) was calculated 
as ([La max-LA min]/La max) x 100. LA maximum volume was also measured 
by biplane area-length method 
18
and indexed to body surface area (LAVI). 
LARR was defined as a reduction in LAVI ≥15%10.Responders were 
defined as patients who exhibited ≥15% reduction in LAVI, non responders 
the others.  
Pulsed-wave Doppler at the tips of mitral valve leaflets allowed us to 
measure early (E) and late (A) diastolic filling velocities, diastolic E/A 
ratio, and E deceleration time (DT). For The Tissue Doppler Imaging (TDI) 
peak early diastolic tissue velocity (E’) and peak late diastolic velocity (A’) 
were recorded from a four chamber view at the lateral and septal border of 
the mitral annulus. Septal and lateral measures were averaged according to 
Guidelines
19
. 
We used A’ as a reproducible measure of LA function
20
. Finally, E/E’ ratio 
was calculated and used as a reliable index of LV filling pressure
21
. 
 
Speckle Tracking    
Longitudinal LA strain was computed by speckle-tracking 
echocardiography (2D Cardiac Performance Analysis; TomTec Imaging 
Systems, Munich, Germany). Data from a total of 12 LA segments 
(annular, mid, and superior segments along the septal, lateral, anterior, and 
inferior LA walls using apical four-chamber and two-chamber images) 
were averaged to determine global LA peak systolic strain (εP) during LV 
ejection (LA reservoir phase). Peak strain rate (SRP) was measured during 
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LV ejection (LA reservoir phase) whereas peak early diastolic strain rate 
(SRE) was measured during LV early diastole (LA conduit phase) and peak 
negative strain rate (SRA) was measured during LV diastole occurring after 
the P-wave (active contraction phase).  
Assessment of LV strain was regarded as suboptimal when either (1) 
speckle tracking could not be obtained for at least four of the six 
myocardial segments in each view or (2) a theoretically unacceptable value 
or values were obtained. 
 
Primary Endpoint and Assessment of AF 
The primary efficacy endpoint was freedom from AF and atrial 
flutter/tachycardia off ADD  following the blanking period
13,22
.  
Patients underwent 7-day Holter monitoring (HM) at 3 months and 1 
year
23
. Monitoring was performed with an external loop recorder (Del Mar 
Reynolds, Spacelabs Healthcare, Issaquah, WA, USA) and analyzed with 
Lifescreen Software (Del Mar Reynolds, Spacelabs Healthcare, Issaquah, 
WA, USA). For analysis, three rhythms were considered postoperative AF: 
AF, atrial flutter or atrial tachycardia lasting more than 30 sec after a 3-
month blanking period. Anticoagulation and Anti-arrhythmic Therapy 
Anti-arrhythmic drugs were given postoperatively and were discontinued 3 
months after surgery if the patients appeared to be AF free. Electrical 
cardioversion was not attempted for patients who remained in AF after the 
surgical procedure and was reserved for patients who were still in AF after 
3 and 6 months. Warfarin was administered on postoperative day I with 
INR target of 2.5.and stopped after 3 months if two following Holter 
recordings showed SR or patients had a low thrombo-embolic risk and a 
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CHADS2 [cardiac failure, hypertension, age, diabetes, stroke (doubled)] 
score <2 
12
. 
 
Statistical analysis 
Parametric value was expressed as mean ± 1 standard deviation (SD), non 
parametric value as median and interquartile range (IQR) and categorical 
variables as percentages. Normally distributed variables were compared 
with paired-t test while Fisher’s and McNemar’s tests were employed to 
compare unpaired and paired categorical data, respectively.  
Echocardiographic variables over time were analyzed by means of 
ANOVA repeated measures followed by Tukey’s post hoc test to detect 
differences at different study points. 
Interobserver and intraobserver variability were examined using Pearson 
bivariate correlation. Intraobserver and interobserver correlations were: εP 
(r=0.90, p<0.001 and r=0.77, p=0.002), SRP (r=0.89, p<0.001 and r=0.80, 
p=0.001), SRE  (r=0.92, p<0.001 and r=0.70, p=0.01), SRA(r=0.88, p<0.001 
and r=0.75, p=0.006). 
Analyses were performed using SPSS release 12.0 (SPSS, Chicago, IL, 
USA). P values less than 0.05 were considered significant. 
 
Results 
Clinical Results 
No patient died within the first 30 days postoperatively. There was no 
pulmonary vein injury, mortality, stroke or reoperation for bleeding. All the 
procedures could be completed as planned without any conversion to 
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sternotomy. There were no requirement for blood transfusion. Median 
Intensive care unit (ICU) stay was 5.7 hours (IQR 3.7-11.6) and the median 
in-hospital length of stay was 6 days (IQR 5-7). 
No patient died during follow up. The EHRA score improved significantly 
from baseline (1 [IQR1-2], p<0.001). All patients were in sinus rhythm and 
off-AAD at 3 month- and 12 month follow-up .No major thromboembolic 
events were detected during the follow up period and no patient was taking 
Warfarin. Finally, no patient underwent electrical cardioversion. 
 
LA Reverse Remodeling  
Baseline morphological analysis (Table 2) revealed a significant LA 
enlargement in AF patients as compared with controls (LA A-P, p=0.006; 
LA S-I p=0.001). This enlargement was accompanied by an increase in 
LAMAX (p=0.001), LAMIN (p<0.001), and biplane LAVI (p=0.02). 
LA diameters decreased significantly at 3 months (LA A-P, p=0.04; LA S-I 
p=0.004) and 1 year (both, p=0.04). LAMAX (p=0.02 and p=0.03), LAMIN 
(p=0.02 and p=0.03), and biplane LAVI (p=0.03 and p=0.04) was 
significantly reduced at 3 months and 1 year, respectively. 
Based on the cut-off value (≥15% decrease in LAVI) LA reverse 
remodeling occurred in 60.6% of patients (n=20) at 3 months and 72.7% 
(n=24) at 12 month-control (p=0.31). At 3 months LAVI in non-responders 
was reduced by 10% or more in 7 patients (21.2%), less than 10% in 3 
(9.1%), and it was relatively stable (±1%) in 3 patients (9.1%). At 1 year 
LAVI in non-responders was reduced by 10% or more in 6 patients 
(18.2%), less than 10% in 2 (6.1%), and it was relatively stable (±1%) in 1 
(3.0%).  
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LA Function and Strain analysis 
Compared to controls, LA emptying fraction was significantly lower at 
baseline (p<0.001, Table 3). It increased significantly at 3 months (p=0.04) 
and 12 months (p=0.02).  
Of the total of 1,428 segments analyzed in 33 patients (baseline, 3-month 
and 12-month follow up) and 20 controls, analysis of regional strain was 
feasible in 1313 segments (91.9%). 
Global peak systolic strain εP was reduced in patients with AF compared 
with controls (Table 3, p<0.001). It increased significantly at 3 months 
(p<0.001) and 1 year (p=0.01). Similarly, peak systolic strain rate SRP 
(p<0.001) and early diastolic strain rate SRE (p<0.001) were lower in 
patients with AF but increased after surgery at 3 months (p=0.004) and 12 
months (p=0.001). Finally, late diastolic strain rate SRA was lower at 
baseline when compared with controls (p<0.001) but it increased 
significantly at follow-up controls (p= 0.02 and p= 0.01 at 3 and 12 
months, respectively). 
 
Pulsed-wave Doppler and Tissue Doppler Imaging (TDI) 
Peak E wave velocity, E wave deceleration time and E/A ratio (Table 4) in 
AF patients were not significantly different from controls at baseline and 
all these indices did not vary during the follow up. Contrastingly, A wave 
velocity was lower than in controls at baseline (p=0.03) and increased 
significantly at e 3 (p=0.03) and 12 months (p=0.04). 
Baseline TDI A' was lower compared with controls (p>0.001) and it 
increased at 3 months (p=0.01) and 1 year (p=0.008). Finally no difference 
was detected at baseline in E' wave and E/E' between controls and AF 
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patients. These indices did not show any significant modification during 
follow up. 
 
Discussion 
In recent years, due to the development of a variety of ablative energy 
sources as well as to an increasing knowledge about the pathophysiology of 
AF and the development of new ablation devices, minimally invasive 
surgical ablation of LAF has been performed with satisfactory results
24
. 
Atrial structural remodeling, with altered LA compliance, LA enlargement 
and impaired contractility, is a hallmark of AF, and reverse remodeling as 
well as recovery of atrial function are considered important targets of any 
AF treatment
10
. Left atrial reverse remodeling (LARR) has been 
demonstrated with drug therapy, after restoration of sinus rhythm with 
cardioversion and after successful catheter ablation for AF
10
. Nonetheless, 
reverse remodeling and atrial function in response to successful surgical 
AF ablation have been poorly investigated
25
 and little is known about 
morphological and functional changes following minimally invasive AF 
surgical ablation. It was for this reason that we conducted this study to 
evaluate left atrial function after restoration of sinus rhythm by minimally 
invasive methods 
Currently, there is no standardization in the measurement of LA function. 
Transmitral flow velocity with pulsed Doppler imaging shows the flow 
velocity due to atrial contraction. This can be used to measure the atrial 
force but, unfortunately, the A wave is highly dependent on loading 
conditions and diastolic function
3
. Tissue Doppler imaging (TDI) has the 
advantage of increased spatial resolution and the ability to evaluate 
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multiple segments in a single view and TDI A
’
 wave is a reproducible 
measure of LA function
21
. Another way of assessing atrial function is to 
measure the LA emptying fraction (LAEF). In sinus rhythm, atrial emptying 
comprises both passive and active phases. In AF there is only a passive 
phase, hence the term “emptying fraction” rather than “ejection 
fraction”
3
.Preoperative LAEF was shown to be a powerful predictor of 
successful MAZE procedure
26
. 
Myocardial mechanics by strain imaging, which is widely used to asses 
ventricular function, has been recently employed to evaluate atrial 
function
1
. Nonetheless, strain by Doppler techniques has inherent 
limitations caused by angle dependency and the influence of loading 
conditions.  
Two-dimensional speckle-tracking echocardiography (2D-STE) is a novel 
non-Doppler-based method for the angle-independent and objective 
quantification of myocardial deformation which has recently been 
introduced to evaluate LA function
1
 in order to overcome many of the 
limitations of Doppler-based methodologies
2,3
.  
To our knowledge, this is the first study that substantiates the changes in 
LA structure and function after minimally invasive surgery for lone atrial 
fibrillation employing 2D-STE. 
In our experience, patients showed preoperatively a significant impairment 
in LA compliance (reservoir function) estimated by global peak systolic 
strain εP and peak systolic strain rate SRP . 
Kuppahally et al
3
 found that LA fibrosis detected by 3D delayed-
enhancement MRI had significant correlation with systolic strain and strain 
rate and Tops and coworkers
10
 demonstrated that LA strain at baseline was 
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an independent predictor of LA reverse remodeling. Although the exact 
mechanism remains to be elucidated, the impairment in atrial compliance 
represented plays an important role in the ability to reverse LA enlargement 
and to maintain sinus rhythm during the follow up
10
. Both εP and SRP 
increased significantly after surgery and this suggests that this 
postoperative improvement in atrial compliance might be due to a still 
reversible LA functional changes in these patients. The improvement in 
atrial compliance is also demonstrated by a postoperative significant 
increase in LA EF. Furthermore, baseline LA conduit function (during LV 
passive filling) was also significantly altered, as shown by SRE values. We 
observed a significant improvement in the conduit phase as demonstrated 
by an increase in SRE, which was maintained also at the late control. 
Moreover, we showed an improvement in left atrial function after 
restoration of sinus rhythm reflected either by a mechanical reverse 
remodeling process or by enhancement in LA function. A traditional and 
widely used method of assessing structural remodeling is to measure LA A-
P diameter. Nonetheless, the utility of this approach is limited because the 
LA may enlarge in an asymmetrical way. Hence we examined the LA-S-I 
diameter which is more strongly correlated with LA strain than LA A-P
3
 
However, we found a significant reduction in both diameters at 3-month- 
and at 1 year- controls.  
The increment in LA volume is one of the most important structural 
pathological changes in AF. Indeed, the stretching of the LA myocites 
increases the intercellular matrix, collagen production and fibrosis. LA 
volume showed a strong correlation with the extent of fibrosis at 3D 
delayed-enhancement MRI
3,7
 and it was associated with higher mortality in 
patients with AF
2
. Thus reverse remodeling of the left atrium is considered 
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an important target of AF treatment. In our experience, based on the cut-off 
value (≥15% decrease in LAVI) LA reverse remodeling occurred in 60.6% 
of patients at 3 months and 72.7% at 12 month-control.  
Finally, an important finding in our study is, in our opinion, the 
postoperative significant improvement in LA pump function demonstrated 
by an increase, at 3 and 12 months, of SRA which was severely affected 
preoperatively and which  reflects the LA “active pump” or “booster” 
function during the later part of the ventricular diastole, as the atrium 
contracts. This atrial contraction phase depends on the LV filling pressure 
(LA afterload), and E/E’ ratio has been shown to represent a reliable index 
of LV filling pressure
21
. Interestingly, E/E’ did not change during the 
postoperative period and it was, at all times, comparable to controls. This 
demonstrates that the improvement in LA function is not secondary to a 
reduction in LV filling pressure but to a “true” improvement in LA 
contraction as is also confirmed by a parallel increase in A and A’ wave 
velocities and LAEF. 
LA mechanical function is an independent and powerful risk factor for 
thromboembolic stroke
27
. Therefore, strain-analysis of atrial function 
should be accounted for when considering anticoagulation  treatment for 
post minimally invasive ablation patients, especially with high CHADS 
score
11-13
. 
 
Limitations 
Our study presents some important limitations which have to be pointed 
out. First of all the small number of patients does not allow any definite 
conclusion about LA morphological and functional improvements 
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following minimally invasive surgery. Second, AF is also known to cause 
significant changes in the right atrium (RA). Unfortunately we were not 
able to carry out 2D-STE of the RA because of the small number of good-
quality images suitable for this analysis. Third, due to the small sample we 
did not compare LA reverse remodeling and LA function between patients 
who had LAA exclusion / closure and those who did not. This may have an 
incremental value on indicating LAA exclusion/ closure and deserves 
further investigations. Finally, we did not compare results of minimally 
invasive surgery with patients converted to SR on drugs and following 
catheter ablation. This will be object of an ongoing study. 
 
Conclusions 
Even with the above mentioned limitations, minimally invasive 
radiofrequency ablation resulted, in our experience, in significant LA 
reverse remodeling as well as in improvement in LA compliance and LA 
function after restoration of sinus rhythm as demonstrated by 2D-STE 
analysis. Our findings need to be confirmed by further larger prospective 
studies. 
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Data are presented as mean ± 1standard deviation or median [Interquartile ranges]. Discrete data 
are expressed as numbers (percentages). Abbreviations: M/F: Male/Female; BMI: Body Mass 
Index; AF: Atrial fibrillation; EHRA: European Heart Rhythm Association; LVEF: Left 
Ventricular Ejection Fraction.*Reported with 68% CI. 
 
 
Table 1. Preoperative Data (n=33) 
 
Age 64.6 ± 6.9 
M/F 28/5(84.8/15.2) 
BMI 27.9±3.3 
Hypertension 18(54.5) 
  
Prevalence of AF
* 
20.8 {16.5-23.6} 
EHRA Score 3 [3-4] 
Duration of preoperative AF (yrs.) 6.3 ± 2.1 
Antiarrhythmic Drugs 
Amiodaron 
Flecainide 
Propaphenon 
                                                                                      Ibutilide 
 
2 (6.0) 
20 (60.6) 
7  (21.2) 
1 (3.0) 
Electrical cardioversion 17 (51.5) 
Sodium Warfarin 33 (100) 
LVEF 
 
60.1±7.1 
304
 
  
 
Table 2. Left Atrial Remodeling and Reverse Remodeling (n=33) 
 
 Controls Baseline 3 months 12 months 
 
LAVI (mL/m
2
) 32±7 42±12
*
 37±10
*†
 34±9
*‡
 
LAMax(mL/m
2
) 35±14 52±25
*
 46±20
*†
 39±16
*‡
 
LAMin(mL/m
2
) 12±8 32±18
*
 26±10
*†
 21±11
*‡
 
LA A-P (cm) 3.1±0.4 4.2±0.5
*
 3.8±0.4
*†
 3.4±0.4
*‡
 
LA S-I (cm) 4.3±0.6 6.3±0.7
*
 5.7±0.5
*†
 5.3±0.5
*‡ 
 
Abbreviations: LAVI: (Biplane) Left atrial volume index; LAMax: Maximum left atrial volume; 
LAMin: minimum left atrial volume; LA A-P: Left atrial antero-posterior diameter; LA S-I: Left 
atrial antero-posterior diameter; 
*
Significance vs. controls; 
†
Significance vs. baseline
 ‡
 Significance 
vs. 3-months 
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Table 3. LA Function and Strain analysis 
 
 Controls 
 
Baseline 3 months 12 months 
LAEF (%) 65±13 38±14
* 
42±16
*†
 49±18
*‡
 
εP (%) 35.8±15 17.9±9.5
*
 23.6±9.8
*†
 28.7±15.7
*‡
 
SRP (s
-1
) 1.42±0.70 0.78±0.33
*
 0.96±0.46
*†
 1.23±0.55
*‡
 
SRE (s
-1
) 1.75±0.83 1.02±0.53
*
 1.23±0.66
*†
 1.47±0.66
*‡
 
SRA (s
-1
) 
 
-2.3±0.5 -1.41±0.67
*
 -1.63±0.76
*†
 -1.87±0.86
*‡
 
Abbreviations: LAEF
 
: Left atrial empting fraction; εP: Peak systolic strain; SRP: Peak systolic strain 
rate; SRE Peak early diastolic strain rate; SRA: peak late diastolic strain rate;  
*
Significance vs. controls; 
†
Significance vs. baseline
 ‡
 Significance vs. 3-months 
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Table 4. Pulsed-wave Doppler and Tissue Doppler Imaging (TDI) 
 Controls Baseline 3 months 
 
12 months 
E (cm/sec) 86.3±10.7 82.0±9.2 85.6±15.9 86.9±16.1 
A(cm/sec) 65.5±7.2 56.6±5.3
*
 60.8±8.9
*†
 63.7±12.1 
E/A 1.38±0.33 1.40±0.35 1.40±0.35 1.34±0.37 
DT (ms) 206±41 202±37 200 ±34 202 ±39 
E' 11.2±2.7 10.8±2.2 11.1±2.0 11.4±2.1 
E/E' 8.1±1.6 7.8±1.7 7.7±1.6 7.7±1.5 
A' 10.5±3.0 7.0±2.1
* 
 
8.2±2.9
*†
 9.4±2.0
*‡
 
Abbreviations: E: Early diastolic filling velocity; A: late diastolic filling velocity; DT: Deceleration 
time; E': (Tissue Doppler) early diastolic filling velocity; A': (Tissue Doppler) late diastolic filling 
velocity;
*
Significance vs. controls; 
†
Significance vs. baseline
 ‡
 Significance vs. 3-months 
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Chapter 9: General discussion 
 
A combined endocardial and epicardial procedure for the treatment of atrial 
fibrillation is an impartial way the cardiac surgeon and the electrophysiologist could 
explore as a team to reach a common goal, a high long-term cure rate achieved with a 
single-session procedure.  
The basic concepts of cardiac surgery and electrophysiology in AF treatment is 
obscured by different strategies, leading to conflicting trends and therefore 
misunderstanding. On the EP side isolation of the PVs with proof of an acute 
complete electrical isolation is the cornerstone of most ablation strategies. On the 
surgical side the classical idea of a successful AF procedure is still a Cox Maze 
procedure on the arrested heart with no electrophysiological confirmation of the effect 
and the quality of the lesion set. These distinctive characteristics of  different 
treatment platforms can only be changed if we are willing to accept our individual and 
technical limitations. If we are able to confront this, than the necessity of a direct link 
between the two disciplines will become clear. The energy that is needed to realize 
this multi-disciplinary approach is a reflection of the difficulty to define the 
parameters of energy delivery in the left and right atrium. The effect of this multi-
disciplinary approach will depend upon the power delivered, and the accuracy of the 
visualization and mapping of the ablated tissue in both atria. Fundamental questions 
like the necessity of a continuous and transmural lesion will no longer be unanswered  
if we can map triggers and substrate at the endocardium and epicardium, improve our 
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understanding of the mechanism of AF and confirm lesion transmurality at both sides  
with one single combined procedure.  
Recent EP literature shows that long-lasting endocardial catheter isolation of the PVs, 
whether it is achieved with RF energy or cryo, remains challenging 
1
. Because of this 
limitation it is not clear whether complete circumferential antral ablation is necessary 
for successful PV isolation in patients with PAF. Non-circumferential antral ablation 
could achieve similar success rates with shorter procedure and ablation times than 
circumferential ablation. Therefore, attention could be focused on producing 
permanent lesions rather than on completing antral encirclement after isolation is 
achieved 
2-4
.  
This basic philosophy was the rationale of our initial experience with the minimally 
invasive surgical treatment of lone AF. In 2005 we developed a technique of a 
monolateral right thoracoscopic approach. The procedure consisted of the creation of a 
box lesion with a catheter that used microwave energy to ablate left atrial tissue. At 
that time this catheter was the only commercially available thoracoscopic minimal 
invasive surgical ablation tool 
5-6
. The concept of the box lesion as a minimal lesion 
set was based on several factors, but most importantly, a consequence of  the absence 
of electrophysiological mapping during the surgical procedure. The rationale was to 
exclude a maximum of triggers, by isolating the four PVs, to try to obtain an 
important substrate modification by isolating the posterior wall of the left atrium, to 
reduce the critical mass, to denervate the four major ganlionated plexi and to ablate 
the ligament of Marshall. A potential major drawback for a monolateral right-sided 
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approach was the lack of opportunity to exclude or occlude the left atrial appendage 
safely. Since the LAA is largely responsible for thrombo-embolic events in patients 
with AF, and can be part of the substrate responsible for AF, it could be preferable to 
occlude the LAA in a sub-group of patients. We therefore developed a technique of a 
monolateral left-sided approach for patients when isolation of the LAA was deemed 
necessary. Freedom of AF at one year was 73% for the combined group of right and 
left-sided interventions. A complementary endocardial approach was performed at 6 
months in 18 patients 
7
. Since the success rate at two year follow-up was 
unsatisfactory 
8
 we changed the energy source from microwave to monopolar RF. 
Realizing that the concept of the epicardial box lesion was difficult to achieve 
epicardialy on the beating heart (epicardial fat, heat-sink effect, power delivery of a 
monopolar ablation device) we combined the surgical procedure with a simultaneous  
endocardial electrophysiology procedure. A single-session hybrid AF procedure was 
born. For the first time we could study the effect of an epicardial ablation on the 
endocardium in a human being during the same procedure and vice versa. Using this 
approach we could demonstrate that after epicardial creation of a box lesion with 
microwave or radiofrequency there was a conduction delay from the PVs and the 
posterior wall of the left atrium, but no exit or entrance block. The incomplete 
epicardial surgical ablation line necessitated a complementary endocardial isolation of 
one or more PVs, the roof and inferior line. 
The importance of these findings was twofold: first we proved the concept that 
combining a percutaneous endocardial approach with a thoracoscopic epicardial 
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approach was technically feasible and safe, secondly creation of a continuous 
transmural box lesion from the epicardium with a monopolar energy source was not 
possible. Even with satisfactory clinical results, transmurality and continuity of 
epicardial lesions could not be assumed. This could probably explain the low success 
rate at long-term follow-up. Again we had to change our strategy and decided to first 
focus on antral epicardial isolation of the PVs. In order to be an alternative for an 
endocardial ablation, it was mandatory to achieve a long-lasting antral isolation of the 
PVs. Since microwave and monopolar RF energy were inconsistent, we had to search 
for an alternative. Prasad et al. showed in an animal model the potential of a bipolar 
RF clamp to isolate PVs 
9
. Damiano et al. studied the results of a Cox Maze IV using a 
bipolar RF clamp and found that they where similar to the “cut and sew” Cox Maze III 
10
. Thus it was assumed that a bipolar RF clamp is able to isolate the PVs on the 
beating heart. However, endocardial redo procedures in patients with recurrence of AF 
who had had a thoracoscopic bipolar PV isolation showed that in 50% there was 
failure to isolate of one or more PVs 
11
. We demonstrated that clamping-induced 
ischemia could be responsible for these failures 
12
. Therefore, combining a bilateral 
thoracoscopic approach with antral isolation of the PVs followed by an endocardial 
mapping at least 30 minutes after the epicardial ablation should avoid incomplete 
isolation of the PVs. Building upon this antral isolation of the PVs we then could 
focus on the creation of linear lesions connecting the superior PVs and the inferior 
PVs using a bipolar unidirectional linear pen. 
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The group of Damiano demonstrated in an animal model the potential risk of 
incomplete lesions using these devices 
13
. Our clinical experience confirmed their 
findings, in 23% of patients the epicardial lines created with these linear ablation 
devices were not transmural and necessitated an endocardial touch-up, demonstrating 
the importance of power application and mapping during catheter treatment of AF 
14
. 
The possibility to perform such an endocardial touch-up to render epicardial lesions 
completely transmural, is one of the major advantages of this dual epicardial 
endocardial approach. 
It also appeared to be an advantage during a redo procedure by offering the possibility 
to first map the patient endocardialy. An important percentage of patients that will be 
send for an epicardial treatment of AF will have had a previous endocardial procedure, 
mostly PV isolation. Knowing which veins have been isolated, and which not, will 
have important consequences for the treatment strategy. If all PVs have been isolated, 
the epicardial procedure should be focused on linear lesions and (mostly) exclusion of 
the LAA. In these cases the thoracoscopic procedure can be limited to the left side. If 
the PVs have been isolated on one side, the thoracoscopic procedure will be limited to 
the other side. 
Starting from a single-sided thoracoscopic procedure with a monopolar energy source 
on the beating heart we were confronted with the surgical and technical limitations of 
the ablation devices. A simultaneous endocardial approach seemed mandatory to 
understand the limitations of our minimal approach. Setting up this collaboration with 
the EP was challenging. Trying to understand our common goals, organizing the 
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availability of the different teams, selection of the patients, deciding where the 
procedure should be performed, the sequences, where some of many challenges we 
had to confront. Evaluation of our findings acutely and over time made several 
changes of approach and choice of ablation technologies and devices necessary. This 
could only be achieved by a real open-minded team approach that stayed critical 
regarding the achieved progress and willing to look back and compare this new 
approach with other more standard procedures. 
 
Single-session hybrid procedure versus percutaneous catheter ablation 
 
The reported success rate of percutaneous catheter ablation of paroxysmal AF 
with a single procedure ranges between 50% to 80%, and is independent of operator 
experience. These results are even lower for patients with persistent AF (30% to 
50%). The differences in success rates could be explained by a variety of reasons 
including the experience of the centre, the ablation strategy, the technology, the 
follow-up and other variables. A major concern is a significant recurrence rate after 
initial complete PV isolation necessitating a repeat intervention to achieve long-term 
cure of AF (even in high volume centres). Recovered PV conduction after initial acute 
circumferential PV isolation is the dominant reason for recurrent AF and atrial 
tachyarrhythmias 
15
. The problem of durability of contiguous and transmural ablation 
lines in percutaneous transvenous endocardial procedures is related to different 
factors. The procedure is performed with the help of virtual imaging (fluoroscopy and 
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3-D mapping) limiting the anatomical accuracy, the permanent tissue effects will 
depend on adequate and stable catheter tip-tissue contact, and the  necessary 
parameters of energy delivery are difficult to define in an environment of circulating 
blood. These issues can be addressed by epicardial application of a bipolar RF 
clamping device and should therefore result in more persistent antral lesions of the 
PVs.  With an epicardial approach direct anatomical visualisation and stable catheter 
tip-tissue contact are obtained. Furthermore, clamping the tissue between two jaws 
excludes the effect of the circulating blood on delivery of power thereby eliminating 
the heat-sink effect. However, anatomical limitations and epicardial fat can still 
prevent transmurality. The epicardial approach which is anatomical and fast, which 
creates long contiguous lines, which partially eliminates the ganglionated plexi and 
through which the left atrial appendage can be more safely excluded is complementary 
to the endocardial approach which can confirm the quality of the lesion set, which can 
make a left and right isthmus line and which can eliminate CAFEs. This 
complementarities by itself also have the potential to reduce complications related to 
both individual procedures. On the epicardial side the combined approach avoids the 
necessity for a more invasive surgical procedure and the very limited endpoints of 
acute exit and entry block can be improved by a  more complete endocardial mapping. 
On the endocardial side the combined approach will avoid the risk for tamponade, 
oesophageal fistula, phrenic nerve injury and prolonged fluoroscopy. The risk of 
thrombo-embolic events with an epicardial approach is close to zero. By replacing a 
number of endocardial ablations to the epicardium, the total amount of thrombo-
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embolic events will be reduced 
16
. In short, the possibility to perform an endocardial 
mapping of the epicardial lesion set and the ability to touch-up endocardialy an 
incomplete lesion is what makes the hybrid procedure successful. 
 
Sequential hybrid procedure versus percutaneous catheter ablation 
 
Mahapatra et al. published their initial experience with surgical epicardial catheter and 
endocardial ablation for atrial fibrillation carried out in two sequential steps, but 
during the same hospitalization 
17
. Fifteen patients with persistent or long-standing 
persistent AF who failed at least one catheter ablation and one AAD were treated. 
This group was matched to 30 patients who had previously failed at least one catheter 
ablation and underwent a repeat catheter ablation. Five sequential hybrid patients had 
seven inducible flutters that were mapped and ablated. After a mean follow-up of 
20.7±4.5 months, 86.7% of patients of the sequential group were free of any atrial 
arrhythmia and off AAD, compared to 53.3% of the catheter-alone patients. The 
authors concluded that for patients with atrial fibrillation who have failed catheter 
ablation, sequential minimally invasive epicardial surgical ablation, followed by 
endocardial catheter-based ablation, has a higher early success rate than repeat 
catheter ablation alone. 
This staged approach may have logistical advantages over a combined, single-session 
hybrid procedure. A potential drawback could be oedema off the tissue post-ablation 
with difficulty to re-ablate the same area after a short waiting period. A second 
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problem could be the increase of complication rates since the two procedures are 
performed separately.  
 
Hybrid procedure versus surgical ablation 
 
By  replacing the incisions of the traditional Cox-maze III procedure with less 
invasive linear lesions of ablation using bipolar RF, Damiano et al. introduced the 
Cox-maze IV procedure.
 
This procedure requires cardiopulmonary bypass and at least 
one small right thoracotomy. The freedom of AF recurrence was 84% at 2 years for 
patients off AAD 
10
. These figures are comparable with our results although in the 
case of the hybrid procedure, no cardiopulmonary bypass is needed neither a 
thoracotomy. We know that none of the existing surgical ablation technologies (even 
bipolar RF) can guarantee complete transmurality 
11
. We solved this issue by 
endocardial mapping and in the case of incomplete lesions applying RF endocardialy. 
Another shortcoming of the surgical approach is the inability to precisely locate AF 
triggers and to map ATs or reentry arrhythmias known to occur during AF ablation.
 
In 
the setting of a hybrid procedure it is possible to perform extensive mapping in order 
to tailor the lesion set. Finally, if the surgical procedure is performed epicardialy on 
the beating heart, it is technically impossible to create a linear lesion across the left 
and right isthmus. Both these lesions can be performed with a hybrid approach. 
Nonetheless only a randomized study with a significant number of patients will be 
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able to demonstrate a preferred technique according to the classification of AF and its 
complication rate. 
 
Hybrid procedure versus surgical ablation with epicardial mapping 
 
Lockwood et al. described a technique for assessing conduction block across surgical 
lesions based on epicardial mapping 
18
. They identified gaps in linear lesions by 
pacing the atrium epicardialy on one side of the ablation line and mapping the 
direction of atrial activation on the opposite side. Transmurality of linear lesions was 
also assessed by reduction of atrial potential amplitude along the linear lesion and the 
development of double atrial potentials along the ablation line. Using RF devices, they 
achieved complete block across linear lesions by the first set of RF applications in 
only 21%. Several factors like epicardial fat and local myocardial thickness limited 
the depth of penetration of RF and thus the creation of transmural lesions. After 
identification and localisation of the gaps, epicardial ablation was repeated until 
complete bidirectional block across all the linear lesions. During a hybrid procedure 
pacing manoeuvres and mapping techniques are performed from the endocardial side. 
In our series, in 23% of patients we were not able to create a complete box lesion, 
even after identification of remaining gaps and repeating epicardial ablation. In these 
patients all PVs were isolated (bipolar bidirectional clamping) and the gaps were 
found in the connecting lesions at the roof or inferior line (bipolar unidirectional linear 
pen). To create contiguous transmural lesions in these areas, we had to apply 
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endocardial unipolar RF. Since the connecting lesions are created with a non-clamping 
device, epicardial fat, tissue thickness and the heat-sink effect are still a concern. 
Krul et al. described a series of 31 patients with AF which was treated with 
thoracoscopic PV isolation and ganglionated plexus (GP) ablation 
19
. In patients with 
non-paroxysmal AF, LA ablation lines were created and conduction block verified 
epicardialy with custom made catheters. After 1 year, they reported comparable 
success rates to our series (86% of patients had no recurrence of SVT off AAD), but 
had a significantly higher complication rate. Three patients had a sternotomy because 
of uncontrolled bleeding during thoracoscopic surgery. An important conceptual 
difference between both studies is that Krul et al. could only perform epicardial 
lesions without the possibility of add on endocardial lesions including endocardial 
touch-ups to improve transmurality, as well as performing CTI and left sided isthmus 
ablation. In addition, they could only check completeness of ablation lesions from the 
epicardium which may be insufficient to show complete electrical block. In these 
small patient groups it is difficult to make hard conclusions when comparing two 
studies. More than half of the patients in Krul’s study had PAF and all patients had a 
24-hour Holter monitoring after one year. In our series most patients had persistent or 
long-lasting persistent AF and had a 7-day Holter monitoring at 1 year.  
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What is the future of hybrid procedures in ablation of AF? 
 
Even with the best and most experienced hands stand-alone catheter ablations for the 
treatment of AF have a significant recurrence rate, even after initial complete PV 
isolation. The need for one or more repeat interventions to achieve long-term cure of 
AF is  cost ineffective and increases the potential complication rate unnecessarily. The 
majority of patients would prefer a single procedure if this can be achieved safely and 
with minimal invasiveness. There will not be one single standard approach for PV 
isolation, and the EP will have to choose among the available techniques and 
technologies.  
The lack of endpoints and of understanding which patients benefit most could be 
improved by a combined endocardial epicardial procedure. In the patient population 
where “AF begets AF” it seems that “catheter ablation begets catheter ablation”. A 
single-session hybrid procedure, although initially more complex and more costly, 
may lead to a higher cost-efficiency and lower complication rate because of a higher 
cure rate. Understanding that treatment of AF is mandatary because of the high costs 
associated with the persistence of AF despite medication, invasive therapies will 
become a serious economical burden. Reducing the surgical invasiveness and 
improving the quality of the endocardial ablation lines will increase success rates, the 
number of patients available for interventional procedures and the willingness of 
social security providers to accept the costs related to these invasive treatments. 
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Hybrid AF treatment will change the working relationship between 
electrophysiologist, cardiac surgeon and patient and could become a treatment option 
for symptomatic patients with persistent  or long-lasting persistent AF. With increased 
experience it could also become the treatment of choice for patients with PAF, after 
failed catheter ablation, or with increased LA size and important substrate 
modification. 
 
Conclusion 
 
The ideal approach for AF should be patient-tailored, employing a procedure which is 
adapted to the origin of the patient’s AF, and should take into consideration triggers 
and substrate. Therefore, the current classification of AF in four categories going from 
PAF to permanent AF is limiting when considering an ablation strategy. Defining  AF 
only within a time scale is insufficient to understand the complexity of the atrial 
pathology responsible. Our group has demonstrated in the lab that AF is not a disease 
coming from the endocardium or epicardium, but a disease involving the three 
dimensional structure of the atria. The study and treatment of the atria can only be 
complete if we have simultaneous access to the endocardium and epicardium of the 
beating heart. This can be achieved through a close collaboration between the surgeon 
and the electrophysiologist. 
The potential benefits of a hybrid procedure as a single-step or sequential ablation are 
important. The endocardial and epicardial approach gives us a perfect platform to 
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study the mechanisms of AF and thereby could improve our understanding of the 
difficulties to treat this disease. Two complementary techniques performed in 
conjunction could increase long-term success rate, reduce complication rate, 
morbidity and mortality related to AF. In a single-session procedure, the reduction of 
complication rates is not only because of the reduction in the number of procedures, 
but more importantly through the simultaneous access during the procedure. The 
robustness of the approach lies in its complimentary nature. In our experience almost a 
quarter of single-step hybrid AF procedures needed a touch-up with an endocardial 
catheter ablation to finish incomplete epicardial surgical lesions. In addition, the 
mitral isthmus line and CTI line can only be performed when combined with an 
endocardial approach. In redo procedures knowledge of the effect of the previous 
endocardial procedure(s) will guide the epicardial technique. 
The efficacy of this procedure as well as its superiority over catheter ablation or 
standard surgical techniques has to be proven by large comparative studies with long-
term follow-up. 
 
 
 
 
 
 
 
329
References 
 
1. Kottkamp H, Hindricks G. Beyond Pulmonary Vein Isolation: The Issue of 
Reconduction. J Cardiovasc Electrophysiol. 2009 Dec;20(12),1388-90. 
2. Sy RW, Gula LJ, Leong-Sit P, Klein GJ, Yee R, Krahn AD, Bentley C, Razak S, 
Skanes AC. Complete antral encirclement is not required for pulmonary vein 
isolation. Heart Rhythm. 2011 Jan;8(1):16-22. 
3. Stabile G, Turco P, Nocerino P, Stabile E and De Simone A. Is pulmonary vein 
isolation necessary for curing atrial fibrillation? Circ. 2003 ;108 ;657-660. 
4. van Brakel TJ, Bolotin G, Nifong LW, Dekker AL, Allessie MA, Chitwood WR Jr, 
Maessen JG. Robot-assisted epicardial ablation of the pulmonary veins: is a 
completed isolation necessary? Eur Heart J. 2005 Jul;26(13):1321-6. 
5. La Meir M, De Roy L, Blommaert D, Buche M. Treatment of lone atrial 
fibrillation with a right thoracoscopic approach. Ann. Thorac. Surg. 2007; 83,     
2244-2245. 
6. La Meir M. Unilateral approach for thoracoscopic AF ablation : technical   
considerations. Maessen J. Eds. Minerva Medica. Turin 2009. Pages: 25-32. 
7. La Meir M, De Roy L, Gourdin M. A Hybrid approach for treatment of    
patients with atrial fibrillation with radiofrequency catheters. In: Hybrid and    
minimally invasive cardiac intervention. Maessen J and Crijns H. Eds.   
Minerva Medica. Turin 2010. Pages: 9-13. 
8. Pruitt JC, Lazzara RR, Ebra G. Minimally invasive surgical ablation of atrial 
330
fibrillation: the thoracoscopic box lesion approach. J Interv Card Electrophysiol. 
2007;20(3):83-7. 
9. Prasad SM, Maniar HS, Schuessler RB, Damiano RJ Jr. Chronic transmural   
atrial ablation by using bipolar radiofrequency energy on the beating heart.    
J Thorac Cardiovasc Surg. 2002 Oct;124(4):708-13. 
10. Weimar T, Schena S, Bailey MS, Maniar HS, Schuessler RB, Cox JL,  
 Damiano RJ Jr. The cox-maze procedure for lone atrial fibrillation: a single-  
 center experience over 2 decades. Circ Arrhythm Electrophysiol. 2012 Feb  
 1;5(1). 
11. Kron J, Kasirajan V, Wood MA, Kowalski M, Han FT, Ellenbogen KA.       
Management of recurrent atrial arrhythmias after minimally invasive surgical  
pulmonary vein isolation and ganglionic plexi ablation for atrial fibrillation.      Heart 
Rhythm. 2010 Apr;7(4):445-51. 
12. Pison L, La Meir M, van Opstal J, Crijns HJ. Transient clamp-induced  
mechanical block of pulmonary vein potentials. J Thorac Cardiovasc Surg. 2011 
Feb;141(2):e15-6. 
13. Lee AM, Aziz A, Clark KL, Schuessler RB, Damiano RJ Jr. Chronic    
performance of a novel radiofrequency ablation device on the beating heart: 
Limitations of conduction delay to assess transmurality. J Thorac Cardiovasc Surg. 
2012 Feb 1. 
331
14. Pison L, La Meir M, van Opstal J, Blaauw Y, Maessen JG, Crijns HJ. Hybrid 
thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. J Am 
Coll Cardiol. 2012. “In press” 
15. Gerstenfeld EP, CallansDJ, Dixit S, Zado E, Marchlinski FE: Incidence 
and location of focal atrial fibrillation triggers in patients undergoing repeat 
pulmonary vein isolation: Implications for ablation strategies. J 
Cardiovasc Electrophysiol 2003;14:685-690. 
16. Sauren LD, la Meir M, de Roy L, Pison L, van der Veen FH, Mess WH, Crijns HJ, 
Maessen JG. Increased number of cerebral emboli during percutaneous endocardial 
pulmonary vein isolation versus a thoracoscopic epicardial approach. Eur J 
Cardiothorac Surg. 2009 Nov;36(5):833-7. 
17. Mahapatra S, LaPar DJ, Kamath S, Payne J, Bilchick KC, Mangrum , Ailawadi G. 
Initial Experience of Sequential Surgical Epicardial- Catheter Endocardial Ablation 
for Persistent and Long-Standing Persistent Atrial Fibrillation With Long-Term 
Follow-Up. Ann Thorac Surg 2011; 91: 1890–8. 
18. Lockwood D, Nakagawa H, Peyton MD, Edgerton JR, Scherlag BJ, Sivaram CA, 
Po SS, Beckman KJ, Abedin M, Jackman WM. Linear left atrial lesions in minimally 
invasive surgical ablation of persistent atrial fibrillation: Techniques for assessing 
conduction block across surgical lesions. Heart Rhythm 2009;6: S50-63. 
19. Krul SP, Driessen AH, van Boven WJ, Linnenbank AC, Geuzebroek GS, Jackman 
WM, Wilde AA, de Bakker JM, de Groot JR. Thoracoscopic video-assisted 
pulmonary vein antrum isolation, ganglionated plexus ablation, and periprocedural 
332
confirmation of ablation lesions: first results of a hybrid surgical-electrophysiological 
approach for atrial fibrillation. Circ Arrhythm Electrophysiol. 2011; 4: 262-70. 
 
333
334
Samenvatting voor niet medici 
 
De behandeling van hartritmestoornissen in de voorkamers blijft een uitdaging 
die vraagt naar nieuwe oplossingen. Toediening van medicatie om het hart te 
resinusaliseren, of de hartfrequentie te normaliseren, en medicatie om 
stolselvorming in de voorkamers te vermijden, heeft een aantal negatieve 
effecten, zeker bij een langdurige behandeling . Een alternatief bestaat uit het 
maken van een aantal littekens met catheters aan de binnenzijde of aan de 
buitenzijde van de beide voorkamers. De resultaten van deze technieken zijn 
bevredigend voor patiënten met boezemfibrilleren dat spontaan binnen de zeven 
dagen beëindigt, maar minder voor patiënten bij dewelke een elektrische shock 
of extra medicatie nodig is voor het stoppen van dit boezemfibrilleren. De 
doelstelling van dit proefwerk was om te bestuderen welke de mogelijkheden en 
mogelijke voordelen zijn indien we de beide voorkamers simultaan vanuit de 
buitenzijde en de binnenzijde benaderen. De buitenzijde van de voorkamers 
wordt benaderd via een kijkoperatie tussen de ribben waarbij met speciale 
catheters brandlijntjes worden gemaakt. Aan de andere kant wordt de 
binnenzijde van het hart benadert via een ader in de lies. Via deze weg kunnen 
signalen in het hart gemeten worden en een eventuele incomplete brandlijn aan 
de buitenzijde van de voorkamers vervolledigd worden. Deze gecombineerde 
ingreep noemen we een hybride thoracoscopische epicardiale en endoveneuze 
endocardiale behandeling van boezemfibrilleren. 
Hoofdstuk 1 is een algemene introductie. De geschiedenis, soorten, oorzaken en 
de mogelijke behandelingsopties worden beschreven. Hierop volgend geeft 
hoofdstuk 2 een overzicht van de huidige chirurgische minder invasieve 
mogelijkheden. In hoofdstuk 3 beschrijven we onze ervaring voor het 
behandelen van boezemfibrilleren met een kijkoperatie alleen. De resultaten van 
deze studie liggen aan de basis van onze hybride benadering. Hoofdstuk 4 is de 
beschrijving van een vereenvoudigde heelkundige techniek, waarbij de operatie 
335
gebeurt enkel via de rechterzijde van de ribbenkast, in combinatie met een 
procedure via een ader in de lies. Deze ervaring maakte duidelijk dat deze 
procedure doenbaar was en veilig kon gebeuren. Gezien de resultaten na 1 jaar 
suboptimaal waren, werd besloten om de catheters die tijdens de chirurgie 
werden gebruikt te veranderen door mogelijks efficiëntere catheters. Deze 
nieuwe catheters betekenden wel dat nu een benadering via zowel de rechter als 
de linker ribbenkast noodzakelijk was. Hoofdstuk 5 geeft onze resultaten met 
deze techniek. Hoofdstuk 6 vergelijkt de hybride techniek met een kijkoperatie 
via een zijde of via beide zijden van de ribbenkast. In hoofdstuk 7 vergelijken 
we de hybride techniek met een benadering via beide zijden met een niet 
hybride techniek. In hoofdstuk 8 bestuderen we de positieve effecten van de 
chirurgische benadering op de functie van de linkervoorkamer d.m.v. echografie 
van het hart. In hoofdstuk 9 worden tenslotte de bevindingen van al deze studies 
gekaderd binnen het onderzoek naar en de behandeling van boezemfibrilleren.   
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Dankwoord 
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